Clinical trial NCT03099096
Conditions: Asthma
Keywords: SB240563 Mepolizumab self-administration eosinophilic asthma autoinjector
Sponsor: GlaxoSmithKline
Start date: 2017-05-04; Completion date: 2017-11-30
Enrollment: 159 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This study is aimed to assess the correct real-world use of an autoinjector for the repeat self-administration of mepolizumab SC, so to improve subject / physician convenience and to enable repeat dose self injection themselves or via caregivers. This Phase III study will be an open-label, single-arm, repeat-dose, multi-centre study of mepolizumab liquid drug product in autoinjector (100 milligrams \[mg\]) administered subcutaneously (SC) every 4 weeks (3 doses) in subjects with severe eosinophilic asthma. Subjects will receive 100 mg mepolizumab SC as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (caregiver only). Each subject will participate in the study for up to 18 weeks including pre-screening visit, a screening visit and a 12-week treatment period which concludes with end of study assessments (Visit 5) 4 weeks after the last dose of mepolizumab. Approximately 158 subjects will be enrolled in the study.

Detailed description:

Arms: arm 1: Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
Interventions: intervention 1: Mepolizumab
Intervention descriptions: intervention 1: It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.

Protocol documents:
Prot_000.pdf: 
2016N275054_04
CONFIDENTIAL
The GlaxoSmithKline group of companies
204959
1
TITLE PAGE
Division: Worldwide Development
Information Type: Protocol Amendment
Title:
An open-label, single arm, repeat dose, multi-centre study to 
evaluate the use of an autoinjector for the subcutaneous 
administration of mepolizumab in subjects with severe 
eosinophilic asthma (Study 204959)
Compound Number:
SB-240563
Development Phase:
III
Effective Date:
15-FEB-2017
Protocol Amendment Number:  02
Author (s):
 
Copyright 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised copying or use of this information is prohibited.
PPD
PPD


2016N275054_04
CONFIDENTIAL
The GlaxoSmithKline group of companies
204959
2
Revision Chronology
GlaxoSmithKline
Document Number
Date
Version
2016N275054_00
2016-AUG-12
Original
2016N275054_01
2016-AUG-18
Republishing
To add serious systemic reactions including anaphylaxis to the risk assessment section. 
To remove GCSP as a contributory author as per GUI_264305 (3.0).
To clarify the wording around assessing eosinophilia from blood counts collected 
following a Liver Stopping Event
2016N275054_02
2016-OCT-06
Amendment No. 1
To refine the criteria for a successful injection following a use-related risk review
To amend Exclusion Criterion 7 to allow either Fridericia’s or Bazett’s to be used as the 
correction formula for heart rate when measuring the QT interval
To remove Exclusion Criterion 15 as the exclusion of pregnant or lactating females is 
covered in Inclusion Criterion 9
To correct minor typographical errors
2016N275054_03
2016-OCT-13
Amendment No. 1 
(Republish)
To include Appendix 9 detailing the changes to the original protocol
2016N275054_04
2017-FEB-15
Amendment No. 2
To include information regarding a change to the labelling of the autoinjector so that two 
different labelling formats will be used, depending on geographical region
To increase the subject numbers as a result of the introduction of two different label 
formats and to indicate that the results will be presented separately according to the label 
format
To amend inclusion criterion 5 to allow subjects to be enrolled who require high dose 
inhaled corticosteroids to prevent exacerbations but who may not have received 
continuous high dose inhaled corticosteroids due to financial or tolerance issues
To remove ‘incidence of asthma exacerbations’ as safety endpoint and reclassify as an
other endpoint
To change the wording to indicate that all used autoinjectors should to be returned to 
GSK rather than just faulty devices
To remove reference to a practice injection into a foam pad prior the first injection at


2016N275054_04
CONFIDENTIAL
The GlaxoSmithKline group of companies
204959
3
Visit 2
To add the assessment of asthma exacerbations during the study to the Time and Events 
table and under Section 7.7.8
To correct minor typographical errors


PP
D
PPD
PPD
PP
D


2016N275054_04
CONFIDENTIAL
204959
5
MEDICAL MONITOR/SPONSOR INFORMATION PAGE
Medical Monitor/SAE Contact Information: 
Role
Name
Day Time Phone Number and 
email address
After-hours 
Phone/Cell/
Pager 
Number
Fax 
Number
Site Address
Primary 
Medical 
Monitor 
Telephone: 
Cell:
Fax:
GlaxoSmithKline
Upper Merion
709 Swedeland 
Road, King of 
Prussia, PA –
19406
USA
Secondary 
Medical 
Monitor
Telephone:
Cell: 
Fax:
GlaxoSmithKline
Upper Merion
709 Swedeland 
Road, King of 
Prussia, PA –
19406
USA
SAE 
contact  
information 
Telephone:
Cell:
Fax:
GlaxoSmithKline
Upper Merion
709 Swedeland 
Road, King of 
Prussia, PA –
19406
USA
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
In some countries, the clinical trial sponsor may be the local GlaxoSmithKline Affiliate 
Company (or designee). If applicable, the details of the alternative Sponsor and contact 
person in the territory will be provided to the relevant regulatory authority as part of the 
clinical trial application.   
Regulatory Agency Identifying Number(s): IND No 006971, EudraCT No: 2016-001832-
36
PPD
PPD
PPD
PPD
PPD
PP
D
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD


2016N275054_04
CONFIDENTIAL
204959
6
INVESTIGATOR PROTOCOL AGREEMENT PAGE
For protocol number 204959
I confirm agreement to conduct the study in compliance with the protocol, as amended by 
this protocol amendment.
I acknowledge that I am responsible for overall study conduct. I agree to personally 
conduct or supervise the described study.
I agree to ensure that all associates, colleagues and employees assisting in the conduct of 
the study are informed about their obligations. Mechanisms are in place to ensure that site 
staff receives the appropriate information throughout the study. 
Investigator Name:
Investigator Address:
Investigator Phone Number:
Investigator Signature
Date


2016N275054_04
CONFIDENTIAL
204959
7
TABLE OF CONTENTS
PAGE
1.
PROTOCOL SYNOPSIS FOR STUDY 204959......................................................10
2.
INTRODUCTION....................................................................................................12
2.1.
Study Rationale ..........................................................................................12
2.2.
Brief Background ........................................................................................13
3.
OBJECTIVE(S) AND ENDPOINT(S) ......................................................................14
4.
STUDY DESIGN ....................................................................................................16
4.1.
Overall Design ............................................................................................16
4.2.
Treatment Arms and Duration.....................................................................18
4.3.
Type and Number of Subjects.....................................................................20
4.4.
Design Justification.....................................................................................20
4.5.
Dose Justification........................................................................................21
4.6.
Benefit:Risk Assessment ............................................................................21
4.6.1.
Risk Assessment .........................................................................22
4.6.2.
Benefit Assessment.....................................................................26
4.6.3.
Overall Benefit:Risk Conclusion...................................................26
5.
SELECTION OF STUDY POPULATION AND WITHDRAWAL CRITERIA .............26
5.1.
Inclusion Criteria.........................................................................................26
5.2.
Exclusion Criteria........................................................................................29
5.3.
Continuation to Treatment Criteria ..............................................................30
5.4.
Pre-Screening/Screening Failures ..............................................................31
5.5.
Withdrawal/Stopping Criteria.......................................................................32
5.5.1.
Withdrawal from the Study...........................................................32
5.5.2.
Liver Chemistry Stopping Criteria ................................................33
5.5.2.1.
Study Treatment Restart or Rechallenge....................34
5.5.3.
QTc Stopping Criteria ..................................................................34
5.6.
Subject and Study Completion....................................................................35
6.
STUDY TREATMENT ............................................................................................35
6.1.
Investigational Product and Other Study Treatment....................................35
6.2.
Medical Devices..........................................................................................36
6.3.
Treatment Assignment................................................................................37
6.4.
Blinding.......................................................................................................37
6.5.
Packaging and Labelling.............................................................................37
6.6.
Preparation/Handling/Storage/Accountability..............................................37
6.7.
Training Session.........................................................................................38
6.8.
Compliance with Study Treatment Administration.......................................38
6.8.1.
Self-Administration at the Clinic ...................................................38
6.8.2.
Self-Administration Outside the Clinic..........................................39
6.9.
Treatment of Study Treatment Overdose....................................................39
6.10.
Treatment after the End of the Study ..........................................................39
6.11.
Concomitant Medications and Non-Drug Therapies....................................40
6.11.1.
Permitted Medications and Non-Drug Therapies..........................40
6.11.2.
Prohibited Medications and Non-Drug Therapies.........................41


2016N275054_04
CONFIDENTIAL
204959
8
7.
STUDY ASSESSMENTS AND PROCEDURES .....................................................41
7.1.
Time and Events Table...............................................................................42
7.2.
Screening and Critical Baseline Assessments ............................................45
7.2.1.
Critical procedures performed at Screening (Visit 1)....................45
7.2.2.
Critical procedures performed at first treatment Visit 
(Baseline Visit 2)..........................................................................46
7.3.
Assessment of Autoinjector Use .................................................................46
7.4.
Pain Assessment........................................................................................47
7.5.
Device Usability/Functionality Question ......................................................47
7.6.
Exit Interviews ............................................................................................47
7.7.
Safety .........................................................................................................48
7.7.1.
Adverse Events (AE) and Serious Adverse Events (SAEs)..........48
7.7.1.1.
Time period and Frequency for collecting AE 
and SAE information...................................................48
7.7.1.2.
Method of Detecting AEs and SAEs ...........................49
7.7.1.3.
Follow-up of AEs and SAEs........................................49
7.7.1.4.
Cardiovascular and Death Events ..............................49
7.7.1.4.1.
Cardiovascular events ............................49
7.7.1.4.2.
Deaths....................................................49
7.7.1.5.
Regulatory Reporting Requirements for SAEs............49
7.7.2.
Pregnancy ...................................................................................50
7.7.3.
Medical Device Incidents (Including Malfunctions).......................50
7.7.3.1.
Time Period for Detecting Medical Device 
Incidents.....................................................................50
7.7.3.2.
Follow-up of Medical Device Incidents........................51
7.7.3.3.
Prompt Reporting of Medical Device Incidents 
to GSK........................................................................51
7.7.3.4.
Regulatory Reporting Requirements for 
Medical Device Incidents............................................51
7.7.4.
Physical Exams ...........................................................................51
7.7.5.
Vital Signs....................................................................................52
7.7.6.
Electrocardiogram (ECG).............................................................52
7.7.7.
Clinical Safety Laboratory Assessments ......................................52
7.8.
Asthma Exacerbations................................................................................53
7.9.
Pharmacodynamic Markers ........................................................................54
7.10.
Pharmacokinetics .......................................................................................54
7.11.
Immunogenicity...........................................................................................54
7.12.
Genetics .....................................................................................................54
8.
DATA MANAGEMENT ...........................................................................................55
9.
STATISTICAL CONSIDERATIONS AND DATA ANALYSES .................................55
9.1.
Hypotheses.................................................................................................55
9.2.
Sample Size Considerations.......................................................................55
9.2.1.
Sample Size Assumptions ...........................................................55
9.2.2.
Sample Size Sensitivity................................................................56
9.3.
Data Analysis Considerations .....................................................................56
9.3.1.
Analysis Populations....................................................................56
9.3.2.
Treatment Comparisons ..............................................................57
9.3.3.
Interim Analysis ...........................................................................57
9.4.
Key Elements of Analysis Plan ...................................................................57
9.4.1.
Analyses to Evaluate Autoinjector................................................57


2016N275054_04
CONFIDENTIAL
204959
9
9.4.2.
Safety Analyses...........................................................................58
9.4.3.
Pharmacodynamic Analyses........................................................58
9.4.4.
Pharmacokinetic Analyses...........................................................58
10. STUDY GOVERNANCE CONSIDERATIONS........................................................59
10.1.
Posting of Information on Publicly Available Clinical Trial Registers............59
10.2.
Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................59
10.3.
Quality Control (Study Monitoring) ..............................................................60
10.4.
Quality Assurance.......................................................................................60
10.5.
Study and Site Closure ...............................................................................60
10.6.
Records Retention......................................................................................61
10.7.
Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication .................61
11. REFERENCES.......................................................................................................63
12. APPENDICES........................................................................................................64
12.1.
Appendix 1: Abbreviations and Trademarks................................................64
12.2.
Appendix 2: Anaphylaxis Criteria ................................................................67
12.3.
Appendix 3: Modified List of Highly Effective Methods for Avoiding 
Pregnancy in FRP and Collection of Pregnancy Information.......................68
12.3.1.
Definition of post menopausal female ..........................................68
12.3.2.
Modified List of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) ..............68
12.3.3.
Collection of Pregnancy Information ............................................69
12.3.4.
References ..................................................................................70
12.4.
Appendix 4: Liver Safety Required Actions and Follow up 
Assessments ..............................................................................................71
12.4.1.
Liver chemistry stopping criteria and required follow up 
assessments................................................................................71
12.4.2.
Liver chemistry increased monitoring criteria with 
continued therapy ........................................................................73
12.5.
Appendix 5: Definition of and Procedures for Documenting Medical 
Device Incidents .........................................................................................74
12.5.1.
Definitions of a Medical Device Incident.......................................74
12.5.2.
Documenting Medical Device Incidents .......................................75
12.6.
Appendix 6: Definition of and Procedures for Recording, Evaluating, 
Follow-Up and Reporting of Adverse Events...............................................76
12.6.1.
Definition of Adverse Events........................................................76
12.6.2.
Definition of Serious Adverse Events...........................................77
12.6.3.
Definition of Cardiovascular Events .............................................78
12.6.4.
Recording of AEs and SAEs ........................................................79
12.6.5.
Evaluating AEs and SAEs............................................................79
12.6.6.
Reporting of SAEs to GSK...........................................................81
12.7.
Appendix 7: Genetic Research ...................................................................82
12.8.
Appendix 8 - Country Specific Requirements..............................................85
12.9.
Appendix 9: Protocol Changes....................................................................86
12.9.1.
Protocol Amendment 02 ..............................................................86
12.9.2.
Protocol Amendment 01 ..............................................................99


2016N275054_04
CONFIDENTIAL
204959
10
1.
PROTOCOL SYNOPSIS FOR STUDY 204959
Rationale
Mepolizumab (SB-240563) is a humanised monoclonal antibody (IgG1, kappa, mAb) 
that blocks human interleukin-5 (hIL-5) from binding to the IL-5 receptor complex 
expressed on the eosinophil cell surface and thus inhibits signalling; neutralisation of IL-
5 with mepolizumab reduces blood, sputum and tissue eosinophils.
Mepolizumab for Injection is supplied as a sterile, single-use, preservative-free, 
lyophilised powder formulation (herein referred to as lyophilised drug product). This is 
the form that was used in the clinical development programmes and is the current 
marketed presentation for asthma (NUCALATM). Before use, a healthcare provider must 
reconstitute each vial of lyophilised drug product with water for injection using aseptic 
techniques. As part of the life-cycle of mepolizumab, a liquid drug product provided as a 
ready-to-use pre-filled syringe assembled into either a safety syringe or an autoinjector, 
Mepolizumab Injection, has been developed.  Administration of Mepolizumab Injection 
(herein referred to as liquid drug product in autoinjector) will improve patient/physician 
convenience and enable home/self injection via caregivers and/or patients.
Objective(s)/Endpoint(s)
The aim of this study is to assess the correct real-world use of an autoinjector for the 
repeat self-administration of mepolizumab subcutaneously by determining the proportion 
of subjects with severe eosinophilic asthma who are successfully able to self-administer a 
dose of mepolizumab. For the purposes of this study, ‘self-administration’ is defined as 
either the administration of mepolizumab liquid drug product in autoinjector by the 
subject themselves or by their caregiver.
The primary and secondary objectives and associated endpoints are outlined below:
Objectives
Endpoints
Primary

To assess the use of the combination 
product, mepolizumab liquid drug 
product in autoinjector for the 
subcutaneous self-administration of 
mepolizumab by subjects with severe 
eosinophilic asthma

Proportion of subjects successfully able 
to self-administer their observed third 
dose at Week 8
Secondary

To assess the use of mepolizumab 
liquid drug product in autoinjector 
outside the clinic setting

Proportion of subjects successfully 
able to self-administer their 
unobserved second dose outside the 
clinic setting at Week 4


2016N275054_04
CONFIDENTIAL
204959
11
Overall Design
This Phase III study will be an open-label, single-arm, repeat-dose, multi-centre study of 
mepolizumab liquid drug product in autoinjector (100 mg) administered subcutaneously 
(SC) every 4 weeks in subjects with severe eosinophilic asthma.  Subjects will receive 
100 mg mepolizumab SC as a single injection that is self-administered in the thigh, 
abdomen or administered in the upper arm (caregiver only). The site of administration 
will be recorded.
Subjects (and/or their caregiver, if applicable) will self-administer mepolizumab liquid 
drug product in autoinjector for the first time immediately after being trained in its use at 
Visit 2 (i.e. the Start of Study Visit). The training is designed to be representative of the 
instruction and training materials that will be provided once the device is commercially 
available. 
Three doses of mepolizumab drug product in autoinjector will be self-administered by the 
subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in 
the clinic (at Visits 2 and 4).  The second in clinic administration (Visit 4) will not
include any onsite training or other support, other than the Instructions for Use, which 
could assist the subject.  One dose will be administered outside the clinic and without 
observation (within 24 hours after attending the clinic for Visit 3). Following each 
injection, subjects will complete a patient diary immediately following, 1- and 24-hours 
after administration indicating the pain experienced and, for the unobserved dose 
administered at home following Visit 3, subjects/caregivers will complete a checklist of 
the steps required to successfully administer the injection. At the End of Study Visit 
(Visit 5), subjects will be asked about their overall experience with the liquid drug 
product in autoinjector, including device performance and ease of use. 
Due to differences in the labelling requirements among regulatory authorities around the 
world, two different labelling approaches will be included in this global study:  labelling 
that includes a pictogram plus standard labelling elements, or a standard labelling without 
the pictogram.  The pictogram plus standard labelling elements is intended to satisfy 
requirements of the US Food and Drug Administration; while the standard labelling
(without pictogram) is intended to satisfy requirements of Regulatory Agencies outside of 
the United States.  English speaking subjects outside of the US can contribute to the 
cohort used to assess the US label.  All subjects at a given clinical trial site will utilise the 
same format of device label for all injections throughout the study.  The assessment of 
injection success will be reported separately according to the format of labelling used.
Treatment Arms and Duration
The study is single arm in which all subjects will receive mepolizumab 100 mg SC from 
the liquid drug product in autoinjector presentation.  Each subject will participate in the 
study for up to 18 weeks and will have a Pre-screening visit (Visit 0), a Screening visit 
(Visit 1) and a 12-week Treatment Period (Visits 2 through 4) which concludes with End 
of Study assessments (Visit 5) 4 weeks after the last dose of mepolizumab at Visit 4. 


2016N275054_04
CONFIDENTIAL
204959
12
Type and Number of Subjects
Male or female subjects aged 12 years or older with severe eosinophilic asthma. Subjects 
must either have been receiving mepolizumab administered SC for the treatment of 
severe eosinophilic asthma every 4 weeks for at least 12 weeks prior to Visit 1 or, if not 
previously using mepolizumab must be using, or have a requirement for, high dose 
inhaled corticosteroids plus an additional controller with a history of 1 or more 
exacerbations requiring systemic corticosteroids in the 12 months prior to Visit 1.
Approximately 225 subjects will be screened to achieve 158 enrolled subjects with the 
aim of achieving 150 completed/evaluable subjects. Approximately 100 subjects will use 
autoinjectors with labelling that includes a pictogram plus standard labelling elements 
and 50 subjects will use the standard labelling without the pictogram.
Sample Size Calculations and Statistical Analyses
No formal sample size calculations were performed. Assuming a 30% screen failure rate, 
approximately 225 subjects will be screened in order to enrol 158 subjects (attempting at 
least one self-administration of mepolizumab). Assuming a dropout rate of up to 5% 
during the study, 158 enrolled subjects should provide at least 150 subjects with complete 
study data.
The number and percentage of subjects successfully able to self-administer their doses 
will be reported separately for the group of subjects using labelling that includes a 
pictogram plus standard labelling elements or the group using the standard labelling 
without the pictogram, including 95% confidence intervals.  No hypothesis testing will be 
performed.
2.
INTRODUCTION
Mepolizumab (SB-240563) is a humanised monoclonal antibody (IgG1, kappa, mAb) 
that blocks human interleukin-5 (hIL-5) from binding to the IL-5 receptor complex 
expressed on the eosinophil cell surface and thus inhibits signalling; neutralisation of IL-
5 with mepolizumab reduces blood, sputum and eosinophils.
Mepolizumab has recently been approved in a number of markets including the United 
States (US), European Union (EU), Canada, Australia, Japan, South Korea, Switzerland 
and Taiwan for the treatment of severe eosinophilic asthma.  Mepolizumab is also under 
development for other indications, including the treatment of Chronic Obstructive 
Pulmonary Disease (COPD), FIP1L1/PDGFR-negative hypereosinophilic syndrome 
(HES) and eosinophilic granulomatosis with polyangiitis (EGPA) (i.e., Churg Strauss 
syndrome).
2.1.
Study Rationale
Mepolizumab for Injection is supplied as a sterile, single-use, preservative-free, 
lyophilised formulation (herein referred to as lyophilised drug product). This is the form 
that was used in the clinical development programmes and is the current marketed 
presentation for asthma (NUCALATM). Before use, a healthcare provider must 


2016N275054_04
CONFIDENTIAL
204959
13
reconstitute each vial of lyophilised drug product with water for injection (WFI) using 
aseptic techniques. As part of the life cycle of mepolizumab, a liquid drug product
(provided as a ready-to-use pre-filled syringe assembled into either a safety syringe or an 
autoinjector), Mepolizumab Injection, is being developed.  Administration of 
Mepolizumab Injection (herein referred to as liquid drug product in autoinjector) is 
intended to improve patient/physician convenience and enable home/self injection via 
caregivers and/or patients.
The changes to the liquid drug product site of manufacture, processing and formulation 
have been minimised. The liquid drug product has been assessed against the lyophilised 
drug product, prior to clinical evaluation, using comprehensive biochemical/biophysical 
comparability evaluations with comparability between the two products being 
demonstrated. The likelihood of clinically significant differences in the systemic 
exposure, efficacy, safety and/or immunogenicity of the liquid drug product in 
autoinjector or safety syringe as compared with the reconstituted lyophilised drug product 
is considered to be low.  To provide further assurance of comparable exposure from the 
liquid drug products and the lyophilised drug product, a single-dose pharmacokinetic 
(PK) comparability study in healthy subjects will be performed in parallel with this trial 
(Study 204958).   Thus, the primary objective of this study is to characterise the degree of 
appropriate use of the autoinjector by a group of subjects representative (i.e., similar age, 
dexterity and cognitive abilities, degree of training or experience with an autoinjector) of 
patients, likely to use the autoinjector as a self-injected medicine. A separate study (Study 
205667) will characterise the appropriate use of the safety syringe.
2.2.
Brief Background
Mepolizumab binds with high affinity to human IL-5 and blocks its binding to and the 
activation of the IL-5 receptor (CD125).
Randomised, multi-centre, placebo-controlled exacerbation studies (MEA112997, 
MEA115588) and an Oral Corticosteroid (OCS) Reduction Study (MEA115575) have 
demonstrated the efficacy of mepolizumab and support the use of mepolizumab 100 mg 
subcutaneous (SC) every 4 weeks as an add-on therapy for the treatment of severe 
eosinophilic asthma. Compared with placebo, mepolizumab has been shown to: 

Reduce the rate of clinically significant exacerbations by approximately 50%.  These 
results were replicated in studies MEA112997 and MEA115588.

Reduce the rate of exacerbations requiring hospitalisations and/or Emergency 
Department (ED) visits, with mean reductions ranging from 32% to 61%.

Produce statistically significant and/or clinically relevant improvements in lung 
function based on forced expiratory volume in one second (FEV1), asthma control 
based on Asthma Control Questionnaire (ACQ-5), quality of life based on St. 
George’s Respiratory Questionnaire (SGRQ) and clinician and subject-rated overall 
response to therapy in the target population.  

Produce consistent reductions in blood eosinophil levels detected at Week 4 which 
were sustained for the duration of treatment.


2016N275054_04
CONFIDENTIAL
204959
14
Additional details of the pharmacology, efficacy and safety can be found in the 
Investigator Brochure (IB) [GSK Document Number CM2003/00010/12].
3.
OBJECTIVE(S) AND ENDPOINT(S)
The aim of this study is to assess the correct real-world use of the mepolizumab liquid 
drug product in autoinjector for the repeat self-administration of mepolizumab 
subcutaneously by determining the proportion of subjects with severe eosinophilic 
asthma who are successfully able to self-administer a dose of mepolizumab. For the 
purposes of this study, ‘self-administration’ is defined as either the administration of 
mepolizumab liquid drug product in autoinjector by the subject themselves or by their 
caregiver.
The objectives and endpoints associated with these objectives are outlined below:
Objectives
Endpoints
Primary

To assess the use of the combination 
product, mepolizumab liquid drug 
product in autoinjector for the 
subcutaneous self-administration of 
mepolizumab by subjects with severe 
eosinophilic asthma

Proportion of subjects successfully able 
to self-administer their observed third 
dose at Week 8
Secondary

To assess the use of mepolizumab 
liquid drug product in autoinjector 
outside the clinic setting

Proportion of subjects successfully 
able to self-administer their 
unobserved second dose outside the 
clinic setting at Week 4


2016N275054_04
CONFIDENTIAL
204959
15
Objectives
Endpoints
Other

To assess the use of mepolizumab 
liquid drug product in autoinjector both 
inside and outside of the clinic setting

To evaluate autoinjector use & 
functionality

To evaluate any autoinjector injection 
errors/failures related to use or device 
performance

To characterise the subject experience 
of using the mepolizumab liquid drug 
product in autoinjector

To assess mepolizumab plasma trough 
concentrations following the SC 
administration of mepolizumab liquid 
drug product in autoinjector

To assess the pharmacodynamic effect 
following the SC administration of 
mepolizumab liquid drug product in 
autoinjector

To assess the frequency of asthma 
exacerbations

Proportion of subjects successfully able 
to self-administer their observed first 
dose at Week 0

Proportion of subjects successfully able 
to self-administer both their unobserved 
second dose and observed third dose at 
Weeks 4 and 8

Proportion of subjects successfully able 
to self-administer all three doses at 
Weeks 0, 4 and 8

Device usability/functionality
questionnaire completed at the End of 
Study/Early Withdrawal Visit

Evaluation of user/device errors

Root cause analysis of each 
unsuccessful injection

Subject Exit Interviews completed over 
the telephone after the End of 
Study/Early Withdrawal Visit

Mepolizumab plasma trough 
concentrations (Ctrough) at Weeks 4, 8 
and 12

Ratio to baseline of blood eosinophils 
at  Weeks 4, 8 and 12

Incidence of asthma exacerbations


2016N275054_04
CONFIDENTIAL
204959
16
Objectives
Endpoints
Safety
To evaluate the safety and tolerability of 
mepolizumab liquid drug product in 
autoinjector

Incidence and frequency of Adverse 
Events / Serious Adverse Events 
including systemic reactions and 
injection site reactions

Clinically significant change in 
haematological and/or clinical 
chemistry parameters

Vital signs

12-lead electrocardiogram (ECG)

Incidence of immunogenicity

Level of self-reported pain 
immediately following,1- and 24-
hours following each injection 
(patient diary)
4.
STUDY DESIGN
4.1.
Overall Design
This Phase III study will be an open-label, single arm, repeat-dose, multi-centre study of 
mepolizumab liquid drug product in autoinjector (100 mg) administered SC every 4 
weeks in subjects with severe eosinophilic asthma. The study is designed to evaluate the 
use of the autoinjector liquid drug product presentation by severe eosinophilic asthma 
subjects (or their caregivers) for the SC administration of mepolizumab (Figure 1).


2016N275054_04
CONFIDENTIAL
204959
17
Figure 1
Study Schematic
For the purposes of this study, ‘self-administration’ is defined as either the administration 
of mepolizumab liquid drug product in autoinjector by the subject themselves or by their 
caregiver. If applicable, only one caregiver per subject will be permitted.
Subjects will receive 100 mg mepolizumab SC as a single injection that is self-
administered in the thigh, abdomen or administered in the upper arm (caregiver only), 
using the liquid drug product in autoinjector presentation. The site of administration will 
be recorded.
Subjects (and/or their caregiver, if applicable) will self-administer mepolizumab liquid 
drug product in autoinjector for the first time immediately after being trained in its use at 
Visit 2 (i.e. the Start of Study Visit). The training is designed to be representative of the 
instruction and training materials, including the Instructions for Use (IFU) that will be 
provided once the device is commercially available [Note: the autoinjector is referred to 
as a ‘pre-filled pen’ in the IFU]. Each autoinjector will have labelling that includes a 
pictogram plus standard labelling elements, or a standard labelling without the pictogram 
dependant on the country in which it is being used.
Three doses of mepolizumab liquid drug product in autoinjector will be self-administered 
by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under 
observation in the clinic (at Visits 2 and 4).  The second in clinic administration (Visit 4) 
will not include any onsite training or support, other than the IFU, which could assist the 
subject.  One dose will be administered outside the clinic and without observation (within 
24 hours after attending the clinic for Visit 3). Following each injection, subjects will 
complete a patient diary, included in the Study Reference Manual (SRM), and report the 
pain experienced immediately following, 1- and 24-hours post injection. Observations 
about the injection will be recorded by the investigator or designee for the doses 
administered in the clinic using an observer checklist. For the unobserved dose 
administered at home, a similar checklist detailing the steps required to successfully 


2016N275054_04
CONFIDENTIAL
204959
18
administer the injection will be completed by the subject/caregiver. All injections will be 
assessed for success based on:

Direct observation of the self-administration using the Observer Checklist if the 
mepolizumab dose was administered in the clinic, and inspection of the 
autoinjector

Subject/caregiver completed checklist and inspection of the returned autoinjector 
if the mepolizumab dose was administered outside the clinic
A self-administered injection is considered successful if the following criteria are met: 

Use of a correct injection site (abdomen/thigh or upper arm [caregiver only])

Full dose administration: subject pushes the autoinjector all the way down and 
holds until either the second click, or the plunger stops moving and the inspection 
window is filled with the yellow indicator or pushes the autoinjector all the way 
down and holds for a total of 15 seconds

No observations are made with respect to the autoinjector, following inspection, 
which indicates the full dose has not been dispensed
If the above criteria are met, the investigator or designee will confirm the injection was 
successfully delivered. 
Any unsuccessful injection will undergo a root-cause investigation, following a scripted 
approach, and evaluation to assess whether the unsuccessful injection was associated with 
the instructions / use of the device or whether it was associated with a device failure 
using the Autoinjector (Pen) Error/Failure Reporting Form, further details of which can 
be found in the SRM. All devices will be evaluated by Device Engineering at 
GlaxoSmithKline (GSK), post-use, to assess overall performance and robustness of the 
device.
At the End of Study Visit, subjects will be asked to record their overall experience with 
the autoinjector including device performance.
In all subjects, blood samples for both PK, haematology assessment (which will include 
blood eosinophil count for the pharmacodynamic effect assessment) and clinical 
chemistry assessment will be collected at the time points indicated in the Time and 
Events Table (Section 7.1).
4.2.
Treatment Arms and Duration
This is a single arm study in which all subjects will receive mepolizumab 100 mg SC 
every 4 weeks, using the liquid drug product in autoinjector presentation, for 12 weeks. 
Each subject will participate in the study for up to 18 weeks (Visit 0 to the End of Study 
Visit (Visit 5) as described in Table 1.


2016N275054_04
CONFIDENTIAL
204959
19
Table 1
Study Phases
Phase
Phase Title
Duration
Description
1
Pre-screening
0 to 2 weeks
At the Pre-screening Visit (Visit 0), details 
about the study and procedures will be 
explained through the informed consent 
process. The Pre-screening Visit can occur 
on the same day as the Screening Visit 
(Visit 1) but must be completed prior to 
initiating any Visit 1 procedures. 
2
Screening
1 to 4 weeks
Subjects will be assessed for eligibility at 
the Screening Visit (Visit 1). Blood draws 
will be taken for assessments of liver 
function and to determine blood 
eosinophil levels in subjects not 
previously using mepolizumab and who 
do not meet the historical blood eosinophil 
criterion. 
3
Treatment
12 weeks
At Visit 2 (Week 0) those subjects who 
continue to meet the eligibility criteria and 
the continuation to treatment criteria (see 
Section 5.3) will receive mepolizumab 
100 mg SC every 4 weeks for a total of 3 
doses. 
The treatment period will conclude with 
subjects completing End of Study Visit 
(Visit 5) assessments approximately 4 
weeks after the subject was administered 
their last dose of study treatment at Visit 
4. 
A subject who adheres to the study treatment and assessment schedule (as detailed in 
Time and Events Table, Section 7.1) will be considered to have completed the study if 
they complete all of the assessments at the End of Study visit (Visit 5). A subject who 
permanently discontinues study treatment early will be withdrawn from the study after 
completing the Early Withdrawal visit (See Time and Events Table, Section 7.1).
Subjects receiving mepolizumab prior to the study will be advised to continue with their 
pre-study mepolizumab treatment following completion of the assessments at the End of 
Study/Early Withdrawal visit. Subjects not receiving mepolizumab prior to the start of 
the study will have mepolizumab treatment stopped at the End of Study/Early 
Withdrawal visit and will receive appropriate care and treatment as determined by their 
treating physician.


2016N275054_04
CONFIDENTIAL
204959
20
4.3.
Type and Number of Subjects
Approximately 225 subjects with severe eosinophilic asthma will be screened in order to 
achieve 158 enrolled subjects (attempting at least one self-administration of 
mepolizumab) and 150 subjects with complete study data. Approximately 100 subjects 
will use autoinjectors with labelling that includes a pictogram plus standard labelling 
elements and 50 subjects will use the standard labelling without the pictogram.
4.4.
Design Justification
An open-label, repeat-dose, single arm, multi-centre study design is deemed appropriate 
to evaluate self-administration of mepolizumab liquid drug product in autoinjector in 
subjects with severe eosinophilic asthma. The primary purpose, and resultant study
design is to assess the appropriate use of the autoinjector in a real world use setting.  
Participants are intended to be broadly representative of patients and caregivers (i.e., 
similar age, dexterity and cognitive abilities, degree of training or experience with an 
autoinjector) who may use the autoinjector, either for the treatment of severe eosinophilic 
asthma or, potentially, other approved indications. In addition, safety outcomes, 
immunogenicity, pharmacokinetics and pharmacodynamics will be also be characterised 
in this study.
A population of subjects with severe eosinophilic asthma either currently receiving or not 
currently receiving commercially available mepolizumab SC at study entry (Visit 1) was 
selected to reflect the intended population in “real world” use conditions. Subjects not 
currently receiving mepolizumab will have a history of ≥1 exacerbations requiring 
treatment with systemic corticosteroids in the previous 12 months while using, or having
a requirement for, high dose inhaled corticosteroids (ICS) plus a second controller.
Due to differences in the labelling requirements among regulatory authorities around the 
world, two different labelling approaches will be included in this global study:  labelling 
that includes a pictogram plus standard labelling elements, or a standard labelling without 
the pictogram.  The pictogram plus standard labelling elements is intended to satisfy 
requirements of the US Food and Drug Administration; while the standard labelling 
(without pictogram) is intended to satisfy requirements of Regulatory Agencies outside of 
the United States.  English speaking subjects outside of the US can contribute to the 
cohort used to assess the US label.  All subjects at a given clinical trial site will utilise the 
same format of device label for all injections throughout the study.  The assessment of 
injection success will be reported separately according to the format of labelling used.
The standardised training provided in this study will be representative of the instruction 
and training materials that will be given once the device is commercially available for 
use. Subjects will be observed self-administering liquid drug product from the 
autoinjector immediately after being trained in its use at Visit 2 (Week 0). Subjects will 
self-administer at 4-weekly intervals, either at the clinic or outside of the clinic (Time and 
Events Table, Section 7.1). The primary endpoint of the study will be assessed under 
observation at Visit 4, 8 weeks after the subject received training in the use of the 
autoinjector.


2016N275054_04
CONFIDENTIAL
204959
21
With regards to the pharmacokinetic and pharmacodynamic assessments, it is 
acknowledged that mepolizumab exposure will not be at steady-state after the first and 
second SC doses (administered at Visits 2 and at home following Visit 3, respectively) in 
those subjects not previously receiving mepolizumab treatment at Visit 1; however, 
mepolizumab plasma concentration at the end of the dosing interval (Ctrough) 
measurements can be compared with historical data. Likewise data from the Phase III 
study MEA115588 showed that in subjects previously not treated with mepolizumab, the 
reduction in blood eosinophil count at the end of the dosing interval following the first 
SC dose of mepolizumab (i.e. pre-steady-state) was close to the reduction observed at the 
end of the dosing interval following the eighth SC dose of mepolizumab (i.e. at steady-
state). Therefore, in those subjects not receiving mepolizumab treatment at Visit 1, 
assessing the pharmacodynamic effect of mepolizumab is still of interest. 
4.5.
Dose Justification
The 100 mg dose of mepolizumab liquid drug product in autoinjector will match the dose 
of reconstituted lyophilised drug product (the currently marketed form).
4.6.
Benefit:Risk Assessment
Summaries of findings from both clinical and non-clinical studies conducted with 
mepolizumab (SB-240563) lyophilised drug product can be found in the Investigator’s 
Brochure [GSK Document Number CM2003/00010/12].  The following section outlines
the key risks, risk assessment and mitigation strategy for this protocol based on 
mepolizumab lyophilised formulation.  The safety profile of the mepolizumab liquid 
formulation is anticipated to be similar to the lyophilised formulation.  


2016N275054_04
CONFIDENTIAL
204959
22
4.6.1.
Risk Assessment
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Investigational Product (IP)
Risk of Systemic Reactions including 
allergic reactions
Biopharmaceutical products administered 
subcutaneously may elicit systemic (e.g. 
hypersensitivity) and local site reactions.
In the placebo controlled severe asthma 
studies both acute and delayed systemic 
reactions including hypersensitivity have
been reported following administration of 
mepolizumab with incidence rates similar 
between mepolizumab and placebo-treated 
subjects:

54/915 subjects or 6% in the 
mepolizumab [all doses combined] 
group 

7/263 subjects or 3% in the 
mepolizumab 100 mg SC group

12/344 subjects or 3% in the 
mepolizumab  75 mg  intravenous (IV) 
group 

20/412 subjects or 5% in the placebo 
group. 
The most common symptoms reported with 
any systemic reaction included headache, 
rash, pruritus, fatigue, and dizziness. While 
Daily monitoring of serious adverse events 
(SAEs) by medical monitor; regular 
systematic review of adverse event 
(AE)/SAE data from ongoing studies by the 
GSK study team and/or safety review team. 
Customised AE and SAE case report form 
(CRF) utilised for targeted collection of 
information for systemic reaction adverse 
events.
Use of Joint National Institute of Allergy 
and Infectious Disease (NIAID)/Food 
Allergy and Anaphylaxis Network (FAAN) 
2nd Symposium on Anaphylaxis to collect 
data on reports of anaphylaxis (see 
Appendix 2 ).
Subjects are monitored in clinic for at least 
1 hour following self-administration of 
mepolizumab at the clinic. For 
administration at home, subjects will be 
instructed to call the investigator and/or go 
to an Emergency Department for any 
unusual symptoms (e.g. symptoms 


2016N275054_04
CONFIDENTIAL
204959
23
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
rare, serious systemic reactions including 
anaphylaxis have been reported.
Systemic reactions reported to date across 
the mepolizumab programme are 
summarized in the IB “Adverse Events of 
Special Interest” section; see also ‘Special 
Warnings and Special Precautions for Use’ 
section located in Section 6 titled ‘Summary 
of Data and Guidance for the Investigator’ 
[GSK Document 
Number CM2003/00010/12].
concerning for hypersensitivity include skin 
rash [hives] or redness, swelling of the face 
or mouth, becoming wheezy, coughing or 
having difficulty in breathing and/or feeling 
weak or light headed).
Injection site reactions
In the placebo controlled severe asthma 
(PCSA) studies the incidence of local site 
reactions with SC administration of 
mepolizumab was higher on mepolizumab 
100 mg SC group (21/263 or 8%) compared 
to mepolizumab 75mg IV (10/344 or 3%) or 
placebo (13/412 or 3%). Symptoms 
included pain, erythema, swelling, itching, 
and burning sensation. 
Local injection site reactions reported to 
date across the mepolizumab program are 
summarized in the IB “Adverse Events of 
Special Interest” section; see also Section 6 
titled ‘Summary of Data and Guidance for 
the Investigator’ [GSK Document 
Daily monitoring of serious adverse events 
(SAEs) by medical monitor; regular 
systematic review of adverse event 
(AE)/SAE data from ongoing studies by 
GSK study team and/or safety review team. 
Customised AE and SAE case report form 
(CRF) utilised for targeted collection of 
information for local injection site reaction 
adverse events.
Pain assessment will also be done utilizing 
visual analog scale, in the patient diary, 
immediately after injection, 1 hour after 
injection and 24 hours (4 hours) after 
injection.


2016N275054_04
CONFIDENTIAL
204959
24
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Number CM2003/00010/12].
Potential risk of immunogenicity
Biopharmaceutical products may elicit anti-
drug antibody (ADA) and neutralising 
antibody (NAb), which have the potential to 
modulate pharmacokinetic (PK), 
pharmacodynamic (PD) or produce adverse 
reactions. 
Mepolizumab has low immunogenic 
potential. Both incidence and titer data from 
completed studies demonstrate a low risk 
for loss of efficacy associated with AEs 
and/or altered PK/PD. Immunogenicity data 
reported to date across the mepolizumab 
development program are summarized in 
the IB; See Section 5.4 ‘Clinical 
Immunogenicity’ and a summary of 
immunogenicity findings in Section 6 
‘Other Potentially Clinically Relevant 
Information for the Investigator’ [GSK 
Document Number CM2003/00010/12].
Blood samples will be collected for 
detection of both ADA and NAb.
Study Procedures
Injuries due to accidental needle sticks
The autoinjector has been designed and 
verified to comply with ISO23908  ‘Sharps 
injury protection – Requirements and test 
methods – Sharps protection features for 
single-use hypodermic needles, introducers 
for catheters and needles used for blood 
The subject will be educated by the staff 
prior to self-administration and their first 
scheduled dose will be supervised in the 
clinic by the staff. Additionally, the IFU 
will instruct the subject on the safe use of 


2016N275054_04
CONFIDENTIAL
204959
25
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
sampling’
the device.
A plastic needle cover shields the needle 
before and after injection to minimise the 
potential for needle stick injuries.
The needle is protected by a guard, which 
following injection, re-extends and locks in 
place to cover the needle.


2016N275054_04
CONFIDENTIAL
204959
26
4.6.2.
Benefit Assessment
The primary purpose of this study is to assess the appropriate use of the autoinjector in a 
real world use setting.  Participants are intended to be broadly representative of patients 
and caregivers (i.e., similar age, dexterity and cognitive abilities, degree of training or 
experience with an autoinjector) who may use the autoinjector, either for the treatment of 
severe eosinophilic asthma or, potentially, other approved indications. Efficacy is not 
being assessed in this study as the efficacy of mepolizumab in severe eosinophilic asthma 
has previously been demonstrated in prior studies [Haldar, 2009; Nair, 2009; Pavord, 
2012; Bel, 2014; Ortega, 2014].  The autoinjector is intended to provide a more 
convenient mode of delivery from previous mepolizumab administration and potentially 
gives patients an option to self-administer mepolizumab at home.
4.6.3.
Overall Benefit:Risk Conclusion
Current data from mepolizumab preclinical and clinical development indicate the ability 
of mepolizumab to inhibit IL-5 leading to consistent reduction in blood eosinophils, with 
demonstration of clinical benefit in the treatment of conditions associated with 
eosinophilic inflammation, such as asthma. Data from the Phase III asthma programme 
with mepolizumab demonstrates, compared to placebo, a reduction in asthma 
exacerbations, improvements in asthma control and quality of life (as measured by the 
ACQ and SGRQ, respectively), improvements in lung function and a reduction in oral 
corticosteroid use in those subjects on chronic OCS treatment. To date, the safety profile 
of mepolizumab has been favourable and the benefit/risk profile remains positive in 
patients with severe asthma. The change in drug product presentation from a lyophilised 
drug product to a liquid drug product in an autoinjector is not anticipated to alter the 
overall benefit:risk. The ability of subjects to self-administer treatment will be closely 
observed in the clinic and subjects will be instructed to seek medical attention if they 
experience any abnormal symptoms following administration at home, away from the 
clinic. 
5.
SELECTION OF STUDY POPULATION AND 
WITHDRAWAL CRITERIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the GSK investigational product or other study 
treatment that may impact subject eligibility is provided in the IB/IB supplement(s).
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially jeopardise the scientific integrity of the study, regulatory acceptability or 
subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.
5.1.
Inclusion Criteria
A subject will be eligible for inclusion in this study only if all of the following criteria 
apply:


2016N275054_04
CONFIDENTIAL
204959
27
AGE
1. Age: At least 12 years of age inclusive, at the time of signing the informed consent.
[For those countries where local regulations permit enrolment of adults only, subject 
recruitment will be restricted to those who are 18 years of age]
TYPE OF SUBJECT AND DIAGNOSIS INCLUDING DISEASE SEVERITY 
2. Asthma: A physician diagnosis of asthma for ≥2 years that meets the National Heart, 
Lung and Blood Institute guidelines [National heart, lung and blood institute (NIH),
2007] or Global Initiative for Asthma (GINA) guidelines [GINA, 2015]
3. Mepolizumab treatment:
a.
Not receiving mepolizumab treatment at Visit 1
(NB: these subjects must also meet inclusion criteria 4, 5, 6 and 7).
OR
b. Receiving 100 mg SC mepolizumab administered for the treatment of 
severe eosinophilic asthma every 4 weeks for at least 12 weeks prior to 
Visit 1.
The following inclusion criteria are only applicable to those subjects NOT receiving 
mepolizumab treatment at Visit 1:
4. Eosinophilic asthma: A high likelihood of eosinophilic asthma as per the required 
‘Continuation to Treatment’ - Criterion 2.
5. Inhaled Corticosteroid: A well-documented requirement for regular treatment with
high dose inhaled corticosteroid (ICS) in the 12 months prior to Visit 1 with or 
without maintenance oral corticosteroids (OCS).

For subjects 18 years old:

ICS dose must be ≥880 mcg/day fluticasone propionate (FP) (ex-
actuator) or equivalent daily.

For ICS/long-acting-beta-2-agonist (LABA) combination 
preparations, the highest strength approved maintenance dose in the 
local country will meet this ICS criterion.
For subjects 12 to 17 years old:

ICS dose must be ≥440 mcg/day FP (ex-actuator) or equivalent daily.

For ICS/LABA combination preparations, the mid-strength approved 
maintenance dose in the local country will meet this ICS criterion.
( Subjects will be permitted to be enrolled without continuous high dose ICS 
providing the subject was receiving continuous ICS and the Investigator attests that 
the subject should have been treated with high dose ICS to mitigate the risk of 
exacerbations but financial or tolerance issues prevented the use of high-dose ICS.
Such subjects should be discussed with GSK Medical Monitor prior to enrolment)


2016N275054_04
CONFIDENTIAL
204959
28
6. Controller Medication: Current treatment with an additional controller medication, 
besides ICS, for at least 3 months or a documented failure in the past 12 months of an 
additional controller medication [e.g., long-acting beta-2-agonist (LABA), 
leukotriene receptor antagonist (LTRA), or theophylline] for at least 3 successive 
months.  
7. Exacerbation history: Previously confirmed history of one or more exacerbations 
requiring treatment with systemic corticosteroid (CS) [intramuscular (IM), 
intravenous, or oral] in the 12 months prior to Visit 1, despite the use of high-dose 
ICS.  For subjects receiving maintenance CS, the CS treatment for an exacerbation 
must have been a two-fold dose increase or greater. 
WEIGHT
8. Body weight: A minimum 40 kg at Visit 1
SEX
9. Gender: Male or Female
Females: 
A female subject is eligible to participate if she is not pregnant (as confirmed by a 
negative urine human chorionic gonadotrophin (hCG) test), not planning to become 
pregnant during the time of study participation (and up to 16 weeks after the last dose), 
not lactating, and at least one of the following conditions applies:
a.
Non-reproductive potential defined as:
Pre-menopausal females with one of the following:

Documented tubal ligation

Documented hysteroscopic tubal occlusion procedure with follow-up 
confirmation of bilateral tubal occlusion 

Hysterectomy

Documented Bilateral Oophorectomy
Postmenopausal female (see Appendix 3 for specific criteria).
b.
Reproductive potential and agrees to follow one of the options listed in the Modified 
List of Highly Effective Methods for Avoiding Pregnancy in Females of 
Reproductive Potential (FRP) (see Appendix 3) from 30 days prior to the first dose of 
study medication and until 16 weeks after the last dose of study medication and 
completion of the End of Study/Early Withdrawal visit.
The investigator is responsible for ensuring that subjects understand how to properly use 
these methods of contraception.


2016N275054_04
CONFIDENTIAL
204959
29
INFORMED CONSENT
10. Informed Consent: Capable of giving signed informed consent which includes 
compliance with the requirements and restrictions listed in the consent form and in 
this protocol.
5.2.
Exclusion Criteria
A subject will not be eligible for inclusion in this study if any of the following criteria 
apply:
CONCURRENT CONDITIONS/MEDICAL HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1.
Concurrent Respiratory Disease: Presence of a known pre-existing, clinically 
important lung condition other than asthma.  This includes current infection, 
bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of 
emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than 
asthma) or a history of lung cancer.
2.
Eosinophilic Diseases: Subjects with other conditions that could lead to elevated 
eosinophils such as Hypereosinophilic Syndromes, including Churg-Strauss 
Syndrome, or Eosinophilic Esophagitis.  Subjects with a known, pre-existing 
parasitic infestation within 6 months prior to Visit 1 are also to be excluded.
3.
Malignancy: A current malignancy or previous history of cancer in remission for 
less than 12 months prior to screening (Subjects that had localized carcinoma of the 
skin which was resected for cure will not be excluded). 
4.
Immunodeficiency: A known immunodeficiency (e.g. human immunodeficiency 
virus – HIV), other than that explained by the use of corticosteroids taken as therapy 
for asthma.
5.
Other Concurrent Medical Conditions: Subjects who have known, pre-existing, 
clinically significant cardiovascular, endocrine, autoimmune, metabolic, 
neurological, renal, gastrointestinal, hepatic, haematological or any other system 
abnormalities that are uncontrolled with standard treatment.
6.
Liver Disease: Known, pre-existing, unstable liver disease (as defined by the 
presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal 
or gastric varices or persistent jaundice), cirrhosis, and known biliary abnormalities 
(with the exception of Gilbert’s syndrome or asymptomatic gallstones).
7.
ECG Assessment: QT interval corrected for heart rate by either Fridericia’s or 
Bazett’s formula QTc(F)/QTc(B) ≥450msec or QTc(F)/QTc(B) ≥480 msec for 
subjects with Bundle Branch Block at Visit 1.
CONCOMITANT MEDICATIONS
8.
Xolair: Subjects who have received omalizumab within 130 days of Visit 1.


2016N275054_04
CONFIDENTIAL
204959
30
9.
Other Monoclonal Antibodies not including mepolizumab: Subjects who have 
received any monoclonal antibody (other than Xolair) to treat inflammatory disease 
within 5 half-lives of Visit 1.
10. Investigational Medications: Subjects who have received treatment with an 
investigational drug, other than mepolizumab within the past 30 days or five terminal 
phase half-lives of the drug whichever is longer, prior to visit 1 (this also includes 
investigational formulations of marketed products) or experimental anti-
inflammatory drugs (non biologicals) in the past 3 months.
11. Chemotherapy: Subjects who have received chemotherapy within 12 months prior 
to Visit 1.
RELEVANT HABITS
12. Alcohol/Substance Abuse: A history (or suspected history) of alcohol misuse or 
substance abuse within 2 years prior to Visit 1.
CONTRAINDICATIONS 
13. Hypersensitivity: Subjects with hypersensitivity to mepolizumab or to any of the 
excipients (sodium phosphate, citric acid, sucrose, EDTA, polysorbate 80).
DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
14. Adherence: Subjects who have known evidence of lack of adherence to controller 
medications and/or ability to follow physician’s recommendations.
5.3.
Continuation to Treatment Criteria
At Visit 2, those subjects who continue to meet the inclusion/exclusion criteria and who 
meet the continuation to treatment criteria will commence the study treatment phase until 
the target of approximately 158 enrolled subjects is reached.  
In order to receive study treatment subjects must have fulfilled all inclusion and 
exclusion criteria described in Section 5.1 and Section 5.2. In addition to the following:
REQUIRED CRITERIA TO START TREATMENT
1. Liver Function: At Visit 2, ALL study subjects must fulfil the following additional 
criteria in order to be eligible for study treatment:

Liver Function Tests: obtained at Visit 1:
o
Alanine aminotransferase (ALT)≤2x ULN (upper limit of normal)
o
Bilirubin ≤1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if 
bilirubin is fractionated and direct bilirubin <35%)
2. Eosinophilic Phenotype: At Visit 2, study subjects that were NOT receiving 
mepolizumab treatment at Visit 1 must fulfil the following additional criteria in order 


2016N275054_04
CONFIDENTIAL
204959
31
to be eligible for study treatment:

Airway inflammation characterised as eosinophilic in nature as indicated by 
one of the following:
a) A peripheral blood eosinophil count of 300 cells/L that is related to 
asthma demonstrated in the past 12 months prior to Visit 1.
OR
b) A peripheral blood eosinophil count of 150 cells/L at Visit 1 that is    
related to asthma.
5.4.
Pre-Screening/Screening Failures
A subject will be assigned a subject number at the time the informed consent is signed.
A subject who is assigned a subject number at Visit 0 but does not have any screening 
Visit 1 procedures will be considered a pre-screen failure.
Screen failures will be defined as those subjects who complete at least one Visit 1 
(Screening) procedure but do not attempt to self-administer a dose of mepolizumab.
The following information will be collected in the electronic case report (eCRF) for 
subjects who are pre-screen, and screen failures:

Date of Informed Consent Form (ICF) signature

Demographic information including race, age and gender

Child bearing status assessment for all female subjects of reproductive potential 

Subject number

Details of asthma medications within 3 months of the pre-screening Visit 0

Details of asthma exacerbations during the pre-screening period

Serious Adverse Event information only for any SAE considered as related to 
study participation (e.g. protocol mandated procedures, invasive tests or change 
in existing therapy) or related to a GSK concomitant medication

Investigator signature page
In order to ensure transparent reporting of screen failure subjects, meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements, and respond to 
queries from Regulatory authorities, a minimal set of screen failure information is 
required including Demography, Screen Failure details, Eligibility Criteria, and Serious 
Adverse Events (see Section 7.7.1).


2016N275054_04
CONFIDENTIAL
204959
32
5.5.
Withdrawal/Stopping Criteria
A subject may withdraw from study treatment at any time at his/her own request, or may 
be withdrawn at any time at the discretion of the investigator for safety, behavioural, or 
administrative reasons. If a subject withdraws from the study, he/she may request 
destruction of any samples taken, and the investigator must document this in the site 
study records. As the aim of this study is to evaluate the use of the mepolizumab liquid 
drug product, in autoinjector presentation, for delivery of mepolizumab, subjects who 
permanently withdraw from study treatment will also be withdrawn from the study (see 
Section 5.5.1). Reasons for premature discontinuation of study treatment will be captured 
in the CRF.
5.5.1.
Withdrawal from the Study
Subjects who have withdrawn from the study should complete assessments for the Early 
Withdrawal Visit, 4 weeks after the last dose of mepolizumab (see Time and Events 
Table, Section 7.1).
A reason for the withdrawal from the study must be captured in the eCRF.
A subject must be discontinued if any of the following criteria are met:

Withdrawal of consent

Lost to follow-up
A subject will also be withdrawn from the study, in consultation with the medical 
monitor and principal investigator, if any of the following stopping criteria are met:

Laboratory parameters: Clinically important changes in laboratory parameters 
identified

ECG: Clinically significant abnormality identified during the study that meet the 
QTc stopping criteria described in Section 5.5.3

Liver Chemistry: Meets any of the Liver chemistry stopping criteria (see Section 
5.5.2 and Appendix 4

Pregnancy: Positive pregnancy test (see Appendix 3). Pregnancy and pregnancy 
outcomes of subjects exposed to mepolizumab will be followed
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required study visit:

The site must attempt to contact the subject and re-schedule the missed visit as 
soon as possible. 

The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study. 


2016N275054_04
CONFIDENTIAL
204959
33

In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact with the subject (where 
possible, 3 telephone calls and if necessary a certified letter to the subject’s last 
known mailing address or local equivalent methods). These contact attempts 
should be documented in the subject’s medical record. 

Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study with a primary reason of “Lost to Follow-up”. 
5.5.2.
Liver Chemistry Stopping Criteria
Liver chemistry stopping and increased monitoring criteria have been designed to 
assure subject safety and evaluate liver event etiology (in alignment with the Food and 
Drug Administration [FDA] premarketing clinical liver safety guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Liver Chemistry Stopping and Increased Monitoring Algorithm
Continue Study Treatment 
Discontinue Study Treatment 
Plus 
Bilirubin≥2x
ULN (>35% 
direct) or plus
INR>1.5, if 
measured*
Possible  
Hy’s Law
ALT≥3xULN
ALT
≥8xULN
Plus
Symptoms of 
liver injury
or 
hypersensitivity
No
Yes
Yes
Yes
No
No
No
See algorithm 
for continued 
therapy with 
increased liver 
chemistry 
monitoring
Yes
*INR value not applicable to subjects on anticoagulants 
ALT 
≥3xULN 
but 
<8xULN
Yes
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*


2016N275054_04
CONFIDENTIAL
204959
34
Liver Chemistry Increased Monitoring Algorithm with Continued Therapy for ALT 
3xULN but <8xULN
Required actions and follow-up assessment for all subjects who meet liver chemistry 
stopping or monitoring criteria are defined in Appendix 4.
5.5.2.1.
Study Treatment Restart or Rechallenge
Study treatment restart or rechallenge after liver chemistry stopping criteria are met, by 
any subject participating in this study, is not allowed.
5.5.3.
QTc Stopping Criteria

The same QT correction formula must be used for each individual subject to 
determine eligibility for and discontinuation from the study.  This formula may 
not be changed or substituted once the subject has been enrolled.  For example, if 
a subject is eligible for the protocol based on on QT interval corrected for heart 
rate by Bazett’s formula (QTcB), then QTcB must be used for discontinuation of 
this individual subject as well.

Once the QT correction formula has been chosen for a subject’s eligibility, the 
same formula must continue to be used for that subject for all QTc data being 
collected for data analysis.  Safety ECGs and other non-protocol specified 
ECGs are an exception.  

The QTc should be based on single or averaged QTc values of triplicate 
electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period. 
For example if a routine ECG demonstrates a prolonged QT, obtain 2 more 
Continue Study Treatment   and   Monitor Liver Chemistry
Discontinue Study Treatment 
ALT≥5xULN 
but <8xULN
+ bili <2xULN +
no symptoms
No
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Yes
ALT ≥3xULN 
but <5xULN
+ bili <2xULN  +
no symptoms
Able to 
monitor  
weekly 
for  ≥2 
weeks
Persists for 
≥2 weeks  
or other 
stopping 
criteria  
met
No
Yes
Yes
Yes
No
No
Able to 
monitor  
weekly 
for  ≥4 
weeks
Persists for 
≥4 weeks  
or other 
stopping 
criteria  
met
No
Yes
Yes
Yes
Yes
ALT ≥5xULN 
ALT <5xULN 
Yes
Yes
*INR value not applicable to subjects on anticoagulants 
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*


2016N275054_04
CONFIDENTIAL
204959
35
ECGs over a brief period and then use the averaged QTc values of the 3 ECGs 
to determine whether patient should be withdrawn from the study.
A subject who meets either of the bulleted criteria below will be withdrawn from the 
study:

QTc >500 msec OR Uncorrected QT >600 msec

Change from baseline (Visit 2) of QTc >60 msec
For patients with underlying bundle branch block, follow the discontinuation criteria 
listed below:
Baseline (Visit 2) QTc with Bundle 
Branch Block
Discontinuation QTc with Bundle 
Branch Block
<450 msec
>500 msec
450 – 480 msec
≥530 msec
5.6.
Subject and Study Completion
A completed subject is one who has completed the End of Study (Week 12) visit.
The end of the study is defined as the last subject’s last visit.
6.
STUDY TREATMENT
6.1.
Investigational Product and Other Study Treatment
The term ‘study treatment’ is used throughout the protocol to describe the mepolizumab 
drug product in autoinjector received by the subject as per the protocol design. 
Mepolizumab liquid drug product will be supplied by GSK in Type I glass syringes with 
staked needles (1/2 inch x 29 gauge thin wall), sealed with latex-free rubber plungers.  
These will be assembled in single use, disposable autoinjectors to enable automatic 
delivery of the drug product. Each device will deliver 100mg mepolizumab in 1.0mL.  
The formulation contains sodium phosphate, citric acid, sucrose, EDTA and polysorbate 
80.


2016N275054_04
CONFIDENTIAL
204959
36
Study Treatment
Product name:
Mepolizumab (NUCALA) (SB240563)
Device:
Prefilled syringe contained within an autoinjector
Formulation description:
100 mg/mL mepolizumab with sodium phosphate, citric acid, 
sucrose EDTA and polysorbate 80
Dosage form:
Sterile, liquid formulation
Unit dose 
strength(s)/Dosage level(s):
100 mg/mL; 1.0mL (deliverable)
Route of Administration
SC injection
Dosing instructions:
SC dose in thigh, abdomen or upper arm every 4 weeks
Physical description: 
mepolizumab
Clear to opalescent, colourless to pale yellow sterile solution for 
SC injection in a single-use, prefilled syringe contained within an 
autoinjector
Physical description of 
injection device:
Single use, disposable autoinjector assembled with the prefilled 
syringe containing the drug product. The autoinjector enables 
automatic delivery of the drug product under the power of a 
spring mechanism following activation of the device. Start and 
end of injection clicks inform the user of correct use. A plastic 
needle cover shields the needle before and after injection to 
minimise the potential for needle stick injuries.
Manufacturer/source of 
procurement:
Prefilled syringe: Prefilled syringe components are procured 
from Becton Dickinson.  Prefilled syringe is filled with drug 
product and assembled at GSK, Barnard Castle, UK.
Autoinjector: The autoinjector components are manufactured by 
Ypsomed AG and assembled with the prefilled syringe at GSK, 
Barnard Castle, UK.
6.2.
Medical Devices
The GSK manufactured medical devices (or devices manufactured for GSK by a third 
party) provided for use in this study are injection devices: a prefilled syringe contained 
within an autoinjector. The devices used in the study are representative of the devices and 
regionally appropriate device product labeling planned to be marketed for the product.
The components that comprise the prefilled syringe, including glass barrel with prestaked 
needle and plunger are sourced from Becton Dickinson.  The prefilled syringe is filled 
and assembled at GSK, Barnard Castle.  
The autoinjector components are manufactured by Ypsomed AG.  The autoinjector 
components are assembled with the prefilled syringe at GSK, Barnard Castle.
The IFU of these injection devices are provided in the SRM. The instructions were 
developed and optimised as a result of formative human factors studies and are 
representative of those that are planned for the product.


2016N275054_04
CONFIDENTIAL
204959
37
GSK medical device incidents, including those resulting from malfunctions of the device, 
must be detected, documented, and reported by the investigator throughout the study –
see Section 7.7.3.
6.3.
Treatment Assignment
All subjects will be assigned to the same treatment at Visit 2 (Week 0).
6.4.
Blinding
This will be an open-label, single arm study. 
6.5.
Packaging and Labelling
The contents of the label will be in accordance with all applicable regulatory 
requirements. The autoinjector will either be labelled with a pictogram plus standard 
labelling elements or standard labelling without the pictogram.
6.6.
Preparation/Handling/Storage/Accountability
No special preparation of study treatment is required.
Study treatment must be dispensed or administered according to procedures described 
herein.  Only subjects enrolled in the study may receive study treatment.  Only authorised 
site staff may supply study treatment.  All study treatment must be stored in a secure area 
with access limited to the investigator and authorised site staff.  
Mepolizumab will be supplied in a single use prefilled syringe contained within an 
autoinjector and should be stored in a refrigerator at 2 to 8°C with protection from light. 
Each injection device will contain 100 mg mepolizumab as a single 1.0 mL injection of 
the liquid drug product (100 mg/mL).  Maintenance of a temperature log at the clinical 
dispensing sites (manual or automated) is required.

The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study treatment received and any 
discrepancies are reported and resolved before use of the study treatment.

Only the subject or previously identified caregiver may administer the study 
treatment.  Whilst on site, all study treatments must be stored in a secure 
environmentally controlled and monitored (manual or automated) area in 
accordance with the labelled storage conditions with access limited to the 
investigator and authorised site staff. 

The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study treatment accountability, reconciliation, and 
record maintenance (i.e. receipt, reconciliation and final disposition records).  

Further guidance and information for final disposition of unused study treatment 
are provided in the SRM. 


2016N275054_04
CONFIDENTIAL
204959
38

Under normal conditions of handling and administration, study treatment is not 
expected to pose significant safety risks to site staff.  

A Material Safety Data Sheet (MSDS)/equivalent document describing 
occupational hazards and recommended handling precautions either will be 
provided to the investigator, where this is required by local laws, or is available 
upon request from GSK.

Subjects will be provided an autoinjector for home use at Visit 3 and asked to 
follow the information on the IFU with regards to the storage and use of the 
device. Cool bags and cold packs will be provided to transport the autoinjector 
from site to home. Subjects will be asked to return the used autoinjector at Visit 4. 
A record of the dispensing of the autoinjector given to the subject at Visit 3 and 
collection of the autoinjector returned at Visit 4 will be maintained by the 
Investigator or designee. The Investigator or designee will also inspect the 
returned autoinjector to determine if the dose has been dispensed correctly.
6.7.
Training Session
Training of study treatment, handling and administration techniques by qualified study 
site personnel will be provided to the study participants at Visit 2, prior to self-
administration.  The training is designed to be representative of the instruction and 
training materials that will be used in the post-marketing setting.  The training will 
consist of a walk-through of the IFU for the injection devices by the site personnel.  The 
first injection will then be observed by site personnel and may include feedback to the 
subject as needed.
6.8.
Compliance with Study Treatment Administration
A record of the number of autoinjectors dispensed and returned by each subject must be 
maintained and reconciled with study treatment and compliance records.  
6.8.1.
Self-Administration at the Clinic
Following the training (see Section 6.7) at Visit 2 (Week 0), the subject (and/or caregiver, 
if applicable) will self-administer the first dose of study treatment by SC injection under 
medical supervision of the investigator or designee at the study site. The 
subject/caregiver will also administer the dose of study treatment at the clinic under 
medical supervision, but without further training, at Visit 4 (Week 8). Observations about 
the injection will be recorded by the investigator or designee using a checklist for the 
doses administered in the clinic. Details of the Observer Checklist can be found in the 
SRM. The subject will complete a patient diary with a visual analogue scale (VAS) 
indicating the pain experience immediately following, 1- and 24-hours after the dose.
The date, time of the dose, person administering the dose (subject/caregiver) and site of 
administration (thigh, abdomen or upper arm [caregiver only]) of each dose administered 
in the clinic will be recorded on the observer checklist and in the source documents.  
Subjects will be monitored for 1 hour after mepolizumab self-administrations in the clinic 
at Visit 2 and Visit 4.  In the event of an acute severe reaction (e.g., anaphylaxis) 


2016N275054_04
CONFIDENTIAL
204959
39
following administration of study treatment, there are personnel/staff onsite at the 
treatment facility who are appropriately trained in basic life support to manage the 
subject including administration of medications (e.g., epinephrine), and have access to a 
system that can promptly transport the patient to another facility for additional care if 
appropriate.
6.8.2.
Self-Administration Outside the Clinic
The subject (or caregiver) will self-administer the dose of study treatment outside the 
clinic and without observation during Week 4, up to 24 hours after attending clinic Visit 
3. The subject/caregiver will complete a checklist of the steps required to use the 
autoinjector, which will also include the date and time of dose, site of injection, person 
administering the dose (subject/caregiver) and the ease with which the subject/caregiver 
was able to complete each of the critical steps required to administer the dose from the 
autoinjector. In addition, the subject will complete the patient diary capturing the pain 
experienced by the subject immediately following, 1- and 24-hours after the dose. 
Subjects will be instructed to contact clinical study staff if they have concerns or 
questions regarding self-administration. They will have the option of returning to the 
clinical site for further training or assistance with self-administration.  Requirement for 
additional training will be documented.
Compliance with the autoinjector will be assessed through reviewing the subject 
completed checklist, inspection of the returned autoinjector and querying the subject 
during the next site visit (Visit 4) and documented in the source documents.  
For self-administration of mepolizumab outside of the clinic (at home), subjects should 
be instructed to call the investigator and/or go to an Emergency Department for any 
unusual symptoms (e.g. skin rash [hives] or redness, swelling of the face or mouth, 
becoming wheezy, coughing or having difficulty in breathing and/or feeling weak or light 
headed).
6.9.
Treatment of Study Treatment Overdose
The dose of mepolizumab considered to be an overdose has not been defined. There are 
no known antidotes and GSK does not recommend a specific treatment in the event of a 
suspected overdose. The investigator will use clinical judgment in treating the symptoms 
of a suspected overdose.
6.10.
Treatment after the End of the Study
The investigator is responsible for ensuring that consideration has been given to the post-
study care of the subject’s medical condition, whether or not GSK is providing specific 
post-study treatment.
There are no plans to provide mepolizumab following study completion.


2016N275054_04
CONFIDENTIAL
204959
40
6.11.
Concomitant Medications and Non-Drug Therapies
6.11.1.
Permitted Medications and Non-Drug Therapies
Throughout the study, subjects are to be maintained on their baseline standard of care 
asthma treatment.
For subjects previously receiving mepolizumab, additional asthma medications such as 
theophyllines or anti-leukotrienes will be permitted provided that they have been taken 
regularly in the 3 months prior to first dose of mepolizumab treatment (Visit 2, Week 0).
For subjects who have not previously received mepolizumab, subjects must have a 
well-documented requirement for regular treatment with high dose inhaled corticosteroid 
(ICS) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids 
(OCS).

Subjects 18 years old:

ICS dose must be ≥880 mcg/day fluticasone propionate (FP) (ex-
actuator) or equivalent daily.

For ICS/LABA combination preparations, the highest strength
approved maintenance dose in the local country will meet this ICS 
criterion.
Subjects 12 to 17 years old:

ICS dose must be ≥440 mcg/day FP (ex-actuator) or equivalent daily.

For ICS/LABA combination preparations, the mid-strength approved 
maintenance dose in the local country will meet this ICS criterion.
(Subjects will be permitted to be enrolled without continuous high dose ICS providing the 
subject was receiving continuous ICS and the Investigator attests that the subject should 
have been treated with high dose ICS to mitigate the risk of exacerbations but financial 
or tolerance issues prevented the use of high-dose ICS. Such subjects should be discussed 
with GSK Medical Monitor prior to enrolment)
Subject not previously receiving mepolizumab must also be receiving current 
treatment with an additional controller medication, besides ICS, for at least 3 
months or a documented failure in the past 12 months of an additional controller 
medication [e.g., LABA, LTRA, or theophylline] for at least 3 successive months.  
All concomitant medications taken during the study will be recorded in the eCRF. In 
addition, all medications taken by the patient for the treatment of asthma including 
asthma exacerbations in the 12 months prior to Visit 1 must also be recorded in the 
eCRF. The minimum requirement is that the drug name and the dates of administration 
are recorded.


2016N275054_04
CONFIDENTIAL
204959
41
6.11.2.
Prohibited Medications and Non-Drug Therapies
The following medications (Table 2) are not allowed prior to screening (Visit 1) 
according to the following schedule, or during the study:
Table 2
Medications not allowed prior to the Screening Visit 1 and 
throughout the study
Medication
Washout Time
Prior to Screening Visit 1
Omalizumab (Xolair)
Within 130 days
Other monoclonal antibodies (other than Xolair or 
mepolizumab) to treat inflammatory disease
5 half-lives
Investigational drugs (excluding mepolizumab)
30 days or 5 half-lives whichever is 
longer
Chemotherapy
12 months
Recreational drug use is not allowed during the study.
7.
STUDY ASSESSMENTS AND PROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety 
concerns. Therefore, adherence to the study design requirements, including those 
specified in the Time and Events Table, are essential and required for study conduct.
This section lists the procedures and parameters of each planned study assessment.  The 
exact timing of each assessment is listed in the Time and Events Table Section 7.1


2016N275054_04
CONFIDENTIAL
204959
42
7.1.
Time and Events Table
Pre-screening
Week -6 to Week -
5a
Screening
Week -4 to Week -
1
Week 0 (Day 
1)
Week 4 
(±7 days)
Week 8
(±7 days)
Week 12
(±7 days)
End of Study/
Early Withdrawalb
Procedures                                           Visit number
V0
V1
V2
V3
V4
V5
Informed consent
X
Demography/child bearing status assessment
X
Medical history
X
Asthma and Exacerbation history
X
Asthma Therapy history
X
Smoking history
X
Parasitic screeningc
X
Prior needle use / self-administration assessment
X
Inclusion/Exclusion criteria
X
Training session 
Xd
Autoinjector self-administration in clinic
X
X
Autoinjector self-administration outside of clinic
Xe, f
Laboratory:
Urine pregnancy test
X
Xd
Xd
Xd
X
Hematology (including eosinophils)g / Clinical Chemistry
X
Xd
Xd
Xd
Xd
Urinalysis
X
Immunogenicity
Xd
Xd
PK
Xd
Xd
Xd
Xd
Pharmacogeneticsh
X
Physical/Clinical:
Vital signsi
X
Xd
Xd
Xd
X
12-lead ECG
X
X
Physical examination
X
X
Weight
X
Concomitant Medication
X
X
X
X
X
X
Asthma Exacerbations
X
X
X
X
X
Serious Adverse Eventsj,k,l
X
X
X
X
X
X
Adverse Eventsj,k,l
X
X
X
X


2016N275054_04
CONFIDENTIAL
204959
43
Pre-screening
Week -6 to Week -
5
Screening
Week -4 to Week -
1
Week 0 (Day 
1)
Week 4
(±7 days)
Week 8
(±7 days)
Week 12
(±7 days)
End of Study/
Early Withdrawalb
Procedures                                           Visit number
V0
V1
V2
V3
V4
V5
Dispense patient diary
Xm
X
X
Return/review patient diary
X
X
Xn
Dispense autoinjector for self-administration outside of clinic
X
Return/ inspect autoinjector following self-administration 
outside of clinic
X
Xn,o
Subject completed pain assessment diary (0, 1- and 24-
hours post dose)
X
Xf
X
Autoinjector observer assessment checklist
X
X
Subject/caregiver completed autoinjector checklist
Xf
Assessment of injection success
X
Xp
Device usability/functionality questionnaire
X
Exit InterviewQ
(X)
a.
Pre-screening Visit can occur on the same day as the Screening Visit but must be completed prior to initiating any Visit 1 procedures; The Pre-screening Visit can be conducted 
up to a maximum of 2 weeks prior to the Screening Visit.
b.
The Early Withdrawal Visit will occur 4 weeks (7 days) after last dose of mepolizumab for any subject who withdraws prior to Week 12
c.
Parasitic screening is only required in countries with high-risk or for subjects who have visited high-risk countries in the past 6 months. Sites should use local laboratories.
d.
Perform prior to mepolizumab administration during the study and prior to restarting pre-study mepolizumab treatment on study completion/early withdrawal.
e.
Subjects will be instructed to contact clinical study staff at any time if they have concerns or questions regarding self-administration.  They will have the option of returning to the 
clinical site for further training or assistance with self-administration.  Requirement for additional training or assistance will be documented.
f.
Self-administration of mepolizumab using the autoinjector should occur within 24 hours following the clinic visit.
g.
Includes measurement of eosinophil levels for pharmacodynamic analysis at Visits 2, 3, 4 and 5
h.
Pharmacogenetic sample may be drawn any time after the respective informed consent form is signed and the subject is enrolled.
i.
Vital signs include temperature, sitting blood pressure, respiratory rate and pulse.
j.
Any SAEs assessed as related to study participation (e.g., study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK 
concomitant medication, will be recorded from the time a subject consents to participate in the study up to and including any follow up contact. All other AEs/SAEs are recorded 
from the start of study treatment until the End of Study / Early Withdrawal visit.
k.
Injection site reactions (e.g., induration, erythema, edema, rash, pruritus, pain) are to be recorded on both AE and SAE CRF forms.
l.
Information on systemic reactions  and events that meet the anaphylaxis criteria is collected on both AE and SAECRF  forms
m.
Patient diary should be dispensed prior to administration of injection
n.
For any subject who withdraws prior to Week 12, patient diary and study drug for self-administration outside of clinic will be returned at the Early Withdrawal visit (if applicable).


2016N275054_04
CONFIDENTIAL
204959
44
o.
Assessment to be completed at the Early Withdrawal visit only if the dose of mepolizumab immediately prior to withdrawal was administered outside of the clinic.
p.
Includes both the injection outside the clinic from Week 4 and the injection in clinic at Week 8
q.
In a subset of subjects only. Completed over the telephone after the End of Study/Early Withdrawal Visit


2016N275054_04
CONFIDENTIAL
204959
45
7.2.
Screening and Critical Baseline Assessments
Subjects can perform the Pre-screening Visit (Visit 0) up to 2 weeks prior to or on the 
same day as the Screening Visit (Visit 1).  A subject number will be assigned at the time 
the informed consent form (ICF) is signed.  During the Pre-screening Visit, study 
designated personnel must provide informed consent (including informed consent for the 
optional pharmacogenetics part of the study, as applicable) to study participants.
Once the informed consent document has been signed, pre-screening assessments can be 
conducted. The following demographic parameters will be captured: year of birth, sex, 
race and ethnicity. In addition, Asthma Therapy, Asthma and Exacerbation history and 
concomitant medications will be assessed. From the pre-screening visit onwards 
concomitant medications, exacerbations and SAEs (considered as related to study 
participation) must be reported.
7.2.1.
Critical procedures performed at Screening (Visit 1)

Medical history including smoking status, history of sinusitis, nasal polyposis, 
aspirin sensitivity, current treatment, duration of asthma, courses of rescue 
corticosteroids in the past 12 months, history of previous intubations, asthma 
exacerbation history in the previous 12 months, asthma triggers and smoking history

Prior experience of needle use including any history of self-administration using an 
autoinjector device

Therapy history, including use of mepolizumab, omalizumab or previous biologics in 
the past 12 months (see Section 6.11.2). For subjects currently receiving 
mepolizumab, data will be collected on whether mepolizumab treatment was 
initiated based on an eosinophil count within 6 weeks of starting treatment or a 
historical measurement collected in the 12 months prior to initiating mepolizumab. 
The blood eosinophil count closest to the initiation of mepolizumab treatment, if 
available, should be recorded.

Cardiovascular medical history/risk factors (as detailed in the eCRF). This 
assessment must include a review of the subject responses to the cardiovascular 
assessment questions and height, weight, blood pressure, smoking history, medical 
conditions, and family history of premature cardiovascular disease

Physical exam (see Section 7.7.4)

Vital signs (see Section 7.7.5)

Resting 12-lead ECG (see Section 7.7.6)

Laboratory tests (see Section 7.7.7). This should include:

Chemistry

Haematology with differential count

Urinalysis

Urine pregnancy test- for all women of child bearing potential


2016N275054_04
CONFIDENTIAL
204959
46

Follicle stimulating hormone (FSH) will be assessed to confirm child-bearing 
status (if applicable)

Parasitic screening (only in countries with a high-risk or in subjects who have 
visited a high-risk country)

Review of Inclusion/Exclusion criteria

Review of exacerbations, SAEs
Procedures conducted as part of the subject’s routine clinical management [e.g. blood 
eosinophil counts] and obtained prior to signing of informed consent may be utilised for 
Screening or baseline purposes provided the procedure meets the protocol-defined criteria 
and has been performed within the timeframe defined in the Time and Events Schedule.
7.2.2.
Critical procedures performed at first treatment Visit (Baseline 
Visit 2)

Vital signs (see Section 7.7.5)

Laboratory tests (see Section 7.7.7). This should include

Clinical Chemistry

Haematology with differential

Blood for baseline immunogenicity

Blood for PK assessment

Urine pregnancy test for all females of childbearing potential

Review of exacerbations, concomitant medications, AEs, SAEs

Review of Continuation to Treatment criteria (see Section 5.3).

Training of the subject or caregiver as to the correct use of the autoinjector
7.3.
Assessment of Autoinjector Use
At Visit 2 (Week 0), and at Visit 4 (Week 8), the investigator or designee will observe, 
using a checklist based on the autoinjector IFU, the ability of the subject/caregiver to 
(self)-administer the injection. The Observer Checklist (see SRM) will be used to 
determine if each step, according to the IFU, was completed easily, with some difficulty 
or not completed/intervention required. Failure to perform one of the critical steps, i.e., 
correct choice of injection site and a full dose administered (determined by the subject 
pushing the autoinjector all the way down and holding until either the second click, or the 
plunger stops moving and the inspection window is filled with the yellow indicator or by 
the autoinjector being pushed all the way down and held for a total of 15 seconds) will be 
deemed to be a failure to successfully administer the injection. In addition, the 
investigator or designee will be asked to inspect the autoinjector, following each 
injection, to confirm that the yellow indicator fills the inspection window and the needle 
guard has locked into place (checked by pressing the needle guard against a firm surface), 


2016N275054_04
CONFIDENTIAL
204959
47
as well as noting any additional observations which indicate the full dose has not been 
dispensed.
Any user errors or device malfunctions will be recorded and reported using the 
Autoinjector (Pen) Error/Failure Reporting Form (see SRM).  Malfunction or failure of 
the autoinjector meeting the definition of a Medical Device Incident (see Appendix 5), 
will also require a Medical Device Incident form to be completed and must be reported as 
described in Section 7.7.3.
Subjects will complete a patient diary at Week 0, 4 and 8 recording the pain experienced 
immediately following, 1- and 24-hour after the injection (see SRM). At Week 4, when 
self-administration is performed outside the clinic (within 24-hours of attending the Visit 
3 clinic visit), the subject/caregiver will also record the date and time of injection, site of 
injection, who administered the injection (subject or caregiver) and complete a checklist 
similar to the Observer Checklist outlining the various steps in the IFU and whether each 
step was completed easily, with some difficulty, or not completed (see SRM). The 
responses on the checklist will be checked by the Investigator or designee at the next 
clinic visit (Visit 4). Failure to perform one of the critical steps will deemed to be a 
failure to successfully administer the injection.
All devices utilised as part of the study will be returned to the clinic where they will be 
assessed to confirm that the device has been successfully actuated.  Any unsuccessful 
injection will undergo a root-cause investigation, following a scripted approach, and 
evaluation to assess whether the unsuccessful injection was associated with the 
instructions / use of the device or whether it was associated with a device failure using 
the Autoinjector (Pen) Error/Failure Reporting Form, further details of which can be 
found in the SRM. All devices, will be evaluated by Device Engineering, post-use, to 
assess overall performance and robustness of the device.
7.4.
Pain Assessment
Following each injection, any pain at the injection site will be assessed by the subject 
using a visual analog scale, in the patient diary, immediately after injection, 1 hour after 
injection and 24 hours (4 hours) after injection. The results will be recorded in the 
patient diary. All measurement timings are detailed in the Time and Events Table 
(Section 7.1) and further details regarding the pain assessment are found in the SRM.
7.5.
Device Usability/Functionality Question
A short survey will be administered to all subjects at the End of Study/Early Withdrawal 
Visit. This survey (see SRM) will collect quantitative data on patient views of treatment 
and the use of the autoinjector. 
7.6.
Exit Interviews
Exit interviews will be conducted after the End of Study/Early Withdrawal Visit over the 
telephone, in a subset of subjects only, to explore subjects’ experience with study 
treatment and device usage. Exit interviews are qualitative interviews conducted with 
study subjects to capture subject experiences in drug development on completion of 


2016N275054_04
CONFIDENTIAL
204959
48
participation in a clinical study. Interview questions are designed to fully assess a 
subject’s experience with a study medication and autoinjector and are administered in a 
semi-structured format over the telephone by a trained interviewer. Subject feedback will 
be captured in a data collection sheet as well as being audio-taped for subsequent 
transcription and qualitative analysis. The Exit interview technique and questions will be 
described in the SRM.
7.7.
Safety
Planned time points for all safety assessments are listed in the Time and Events Table 
(Section 7.1).  
7.7.1.
Adverse Events (AE) and Serious Adverse Events (SAEs)
The definitions of an AE or SAE can be found in Appendix 6.
The following adverse events of special interest will have customized AE and SAE pages 
in the eCRF:

Local injection site reactions

Systemic reactions
In addition, the information whether an event met the diagnostic criteria for anaphylaxis 
as outlined by the Second Symposium on Anaphylaxis [Sampson, 2006] and in Appendix 
2 will be collected on the AE and SAE CRF pages.
The investigator and their designees are responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE. 
7.7.1.1.
Time period and Frequency for collecting AE and SAE information

Any SAEs assessed as related to study participation (e.g., protocol-mandated 
procedures, invasive tests, or change in existing therapy) or related to a GSK 
product will be recorded from the time a subject consents to participate in the 
study up to and including any follow-up contact. 

AEs will be collected from the start of Study Treatment (Visit 2) until the End of 
Study/Early Withdrawal Visit at the timepoints specified in the Time and Events 
Table (Section 7.1).

Medical occurrences that begin prior to the start of study treatment but after 
obtaining informed consent may be recorded on the Medical History/Current 
Medical Conditions section of the CRF.

All SAEs will be recorded and reported to GSK within 24 hours, as indicated in 
Appendix 6.

Investigators are not obligated to actively seek AEs or SAEs in former study 
subjects. However, if the investigator learns of any SAE, including a death, at any 
time after a subject has been discharged from the study, and he/she considers the 
event reasonably related to the study treatment or study participation, the 
investigator must promptly notify GSK.


2016N275054_04
CONFIDENTIAL
204959
49
NOTE: The method of recording, evaluating and assessing causality of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to GSK are provided in 
Appendix 6
7.7.1.2.
Method of Detecting AEs and SAEs
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:

“How are you feeling?” 

“Have you had any (other) medical problems since your last visit/contact?” 

“Have you taken any new medicines, other than those provided in this study, since 
your last visit/contact?” 
7.7.1.3.
Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each 
subject at subsequent visits/contacts.  All SAEs, and non-serious AEs of special interest 
(as defined in Section 4.6.1) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up 
(as defined in Section 5.5). Further information on follow-up procedures is given in 
Appendix 6.
7.7.1.4.
Cardiovascular and Death Events
7.7.1.4.1.
Cardiovascular events
Cardiovascular-related AEs and SAEs that will require the investigator to complete event 
specific pages in the eCRF are listed in Section 12.6.3, Appendix 6.
Cardiovascular events information should be recorded on the corresponding eCRF pages 
within one week of when the AE/SAE(s) are first reported.  Please refer to Appendix 6
for timelines for reporting AE/SAEs.
7.7.1.4.2.
Deaths
In addition, all deaths will require completion of a specific death data collection page in 
the eCRF.  The death data collection page in the eCRF includes questions regarding 
cardiovascular (including sudden cardiac death) and non-cardiovascular death.
Death information should be recorded on the death eCRF page within one week of when 
the death is first reported.
Please refer to Section 12.6.6, Appendix 6 for timelines for reporting SAEs.
7.7.1.5.
Regulatory Reporting Requirements for SAEs
Prompt notification by the investigator to GSK of SAEs related to study treatment (even 
for non- interventional post-marketing studies) is essential so that legal obligations and 


2016N275054_04
CONFIDENTIAL
204959
50
ethical responsibilities towards the safety of subjects and the safety of a product under 
clinical investigation are met. 
GSK has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a product under clinical investigation.  GSK will 
comply with country specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory requirements and GSK policy and are forwarded 
to investigators as necessary.
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safety information (e.g., summary or listing of SAEs) from GSK will file it with 
the IB and will notify the IRB/IEC, if appropriate according to local requirements.
7.7.2.
Pregnancy

Details of all pregnancies in female subjects will be collected after the start of 
dosing (Visit 2) and until 16 weeks post-last dose.

If a pregnancy is reported then the investigator should inform GSK within 2 
weeks of learning of the pregnancy and should follow the procedures outlined in 
Appendix 3.
7.7.3.
Medical Device Incidents (Including Malfunctions)
GSK medical devices are being provided for use in this study.  In order to fulfil 
regulatory reporting obligations worldwide, the investigator is responsible for the 
detection and documentation of events meeting the definitions of incident or malfunction 
that occur during the study with such devices. 
The definition of a Medical Device Incident can be found in Appendix 5. 
NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Section 12.6 and Appendix 6 of the Protocol. 
7.7.3.1.
Time Period for Detecting Medical Device Incidents

Medical device incidents or malfunctions of the device that result in an incident will 
be detected, documented and reported during all periods of the study in which the 
GSK medical devices are available for use. 

If the investigator learns of any incident at any time after a subject has been 
discharged from the study, and such incident is reasonably related to a GSK medical 
device provided for the study, the investigator will promptly notify GSK.
NOTE: The method of documenting Medical Device Incidents is provided in 
Appendix 5.


2016N275054_04
CONFIDENTIAL
204959
51
7.7.3.2.
Follow-up of Medical Device Incidents

All medical device incidents involving an AE, will be followed until resolution of 
the event, until the condition stabilizes, until the condition is otherwise explained, or 
until the subject is lost to follow-up (as defined in Section 5.5).  This applies to all 
subjects, including those withdrawn prematurely. 

The investigator is responsible for ensuring that follow-up includes any supplemental 
investigations as may be indicated to elucidate as completely as practical the nature 
and/or causality of the incident.

New or updated information will be recorded on the originally completed form with 
all changes signed and dated by the investigator.
7.7.3.3.
Prompt Reporting of Medical Device Incidents to GSK

Medical device incidents will be reported to GSK within 24 hours once the 
investigator determines that the event meets the protocol definition of a medical 
device incident.

Facsimile transmission of the "Medical Device Incident Report Form" is the 
preferred method to transmit this information to the Medical Monitor.

The same individual will be the contact for receipt of medical device reports and 
SAEs.

In the absence of facsimile equipment, notification by telephone is acceptable for 
incidents, with a copy of the "Medical Device Incident Report Form" sent by 
overnight mail. 
7.7.3.4.
Regulatory Reporting Requirements for Medical Device Incidents

The investigator will promptly report all incidents occurring with any GSK medical 
device provided for use in the study in order for GSK to fulfil the legal responsibility 
to notify appropriate regulatory bodies and other entities about certain safety 
information relating to medical devices being used in clinical studies.

The investigator, or responsible person according to local requirements (e.g., the 
head of the medical institution in Japan), will comply with the applicable local 
regulatory requirements relating to the reporting of incidents to the IRB/IEC.
7.7.4.
Physical Exams

A complete physical examination will include, at a minimum, assessment of the 
Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. Height 
and weight will also be measured and recorded at Visit 1.

Investigators should pay special attention to clinical signs related to previous 
serious illnesses.


2016N275054_04
CONFIDENTIAL
204959
52
7.7.5.
Vital Signs

As detailed in the Time and Events Schedule Table (Section 7.1), vital signs will 
be measured in semi-supine position after 5 minutes rest and will include systolic 
and diastolic blood pressure and pulse rate.

Vital signs assessments will be taken before measurement of any ECGs at the 
specified time point.
7.7.6.
Electrocardiogram (ECG)

A single 12-lead ECG will be obtained at each timepoint specified in the Time 
and Events Schedule Table (Section 7.1) during the study using an ECG machine 
that automatically calculates the heart rate and measures PR, QRS, QT, and QTc 
intervals.  

If a routine single ECG demonstrates a prolonged QT interval, obtain two more 
ECGs over a brief period, and then use the averaged QTc values of the three 
ECGs to determine whether the patient should be discontinued from the study.  
Refer to Section 5.5.3 for QTc withdrawal criteria and additional QTc readings 
that may be necessary.

ECG measurements will be made after the subject has rested in the supine position 
for 5 minutes.  The ECG should be obtained after the vital signs assessments and 
followed by other study procedures. 
7.7.7.
Clinical Safety Laboratory Assessments
All protocol required laboratory assessments, as defined in Table 3, must be conducted in 
accordance with the Laboratory Manual, and Protocol Time and Events Schedule.
Laboratory requisition forms must be completed and samples must be clearly labelled 
with the subject number, protocol number, site/centre number, and visit date. Details for 
the preparation and shipment of samples will be provided by the laboratory and are 
detailed in the laboratory manual. Reference ranges for all safety parameters will be 
provided to the site by the laboratory responsible for the assessments.
If additional non-protocol specified laboratory assessments are performed at the 
institution’s local laboratory and result in a change in subject management or are 
considered clinically significant by the investigator (e.g., SAE or AE or dose 
modification) the results must be recorded in the CRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.
Haematology, clinical chemistry, urinalysis and additional parameters to be tested are 
listed in Table 3.


2016N275054_04
CONFIDENTIAL
204959
53
Table 3
Protocol Required Safety Laboratory Assessments
Laboratory 
Assessments
Parameters
Haematology
Platelet Count
RBC Indices:
WBC count with Differential:
RBC Count
MCV
Neutrophils
Hemoglobin
MCH
Lymphocytes
Hematocrit
Monocytes
Eosinophils
Basophils
Clinical 
Chemistry 1
BUN
Potassium
AST (SGOT)
Total and direct 
bilirubin
Creatinine
Sodium
ALT (SGPT)
Total Protein
Glucose 
Calcium
Alkaline phosphatase
Albumin
Routine 
Urinalysis

Specific gravity

pH, glucose, protein, blood and ketones by dipstick

Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
Tests

FSH and estradiol (as needed in women of non-child bearing 
potential only)

Urine hCG Pregnancy test (as needed for women of child bearing 
potential) 2

Parasitic screening (only required in countries with high-risk or for 
subjects who have visited high-risk countries in the past 6 months). 
Sites should use local laboratories.
NOTES :
1.
Details of Liver Chemistry Stopping Criteria and Required Actions and Follow-Up 
Assessments after liver stopping or monitoring event are given in Section 5.5.2 and 
Appendix 4.
2.
Local urine testing will be standard for the protocol unless serum testing is required 
by local regulation or ethics committee.
RBC: Red blood cell; MCV: Mean corpuscular volume; MCH: Mean corpuscular haemoglobin;BUN: Blood urea 
nitrogen; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; FSH: Follicle stimulating hormone
All laboratory tests with values that are considered clinically significantly abnormal 
during participation in the study should be repeated until the values return to normal or 
baseline.  If such values do not return to normal within a period judged reasonable by the 
investigator, the etiology should be identified and the sponsor notified.
7.8.
Asthma Exacerbations
At each study visit the investigator will make an assessment of the occurrence of 
an asthma exacerbation.  Any asthma exacerbation will be recorded on the 
appropriate eCRF page.


2016N275054_04
CONFIDENTIAL
204959
54
An exacerbation of asthma as defined as:
Worsening of asthma which requires use of systemic corticosteroids1and/or 
hospitalization and/or Emergency Department (ED) visits.
1For all subjects, i.v. or oral steroid (e.g., prednisone) for at least 3 days or a single 
intramuscular corticosteroid dose is required. For subjects on maintenance systemic 
corticosteroids, at least double the existing maintenance dose for at least 3 days is 
required.
7.9.
Pharmacodynamic Markers
Blood eosinophil counts will be recorded as part of the standard haematological 
assessments performed at the visits specified in the Time and Events Schedule (Section 
7.1).  
7.10.
Pharmacokinetics
Blood samples for analysis of mepolizumab plasma concentration will be obtained as per 
the Time and Events table (Section 7.1).  Samples obtained at Visits 2, 3, 4 and 5 should 
be drawn prior to dosing.  The date and exact time of collection for each sample will be 
documented in the eCRF.
Details for collection and processing of samples may be found in the SRM.
7.11.
Immunogenicity
Blood samples will be collected for the determination of anti-mepolizumab antibodies, 
prior to dosing, as detailed in the Time and Events Schedule (Section 7.1)
Details for sample collection and processing may be found in the SRM.
7.12.
Genetics
Information regarding genetic research is included in Appendix 7.  IEC/IRB and, where 
required, the applicable regulatory agency must approve the genetic assessments before 
these can be conducted at the site.  The approval(s) must be in writing and will clearly 
specify approval of the genetic assessments (i.e., approval of Appendix 7).  In some 
cases, approval of the genetic assessments can occur after approval is obtained for the 
rest of the study.  If so, then the written approval will clearly indicate approval of the 
genetic assessments is being deferred and the study, except for pharmacogenetics (PGx) 
and genetic assessments, can be initiated.  When genetic assessments will not be 
approved, then the approval for the rest of the study will clearly indicate this and 
therefore, genetic assessments will not be conducted.


2016N275054_04
CONFIDENTIAL
204959
55
8.
DATA MANAGEMENT

For this study subject data will be entered into GSK defined CRFs, transmitted 
electronically to GSK or designee and combined with data provided from other 
sources in a validated data system.  

Management of clinical data will be performed in accordance with applicable 
GSK standards and data cleaning procedures to ensure the integrity of the data, 
e.g., removing errors and inconsistencies in the data.

Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary for Regulatory Activities) and an internal validated 
medication dictionary, GSKDrug.  

CRFs (including queries and audit trails) will be retained by GSK, and copies will 
be sent to the investigator to maintain as the investigator copy.  Subject initials 
will not be collected or transmitted to GSK according to GSK policy.
9.
STATISTICAL CONSIDERATIONS AND DATA 
ANALYSES
9.1.
Hypotheses
The study is designed to descriptively evaluate the mepolizumab liquid drug product in 
autoinjector for self-administration by subjects with severe eosinophilic asthma. 
No formal statistical hypothesis testing is planned.  The number and percentage of 
subjects successfully able to self-administer their mepolizumab dose will be reported
separately for the group of subjects using labelling that includes a pictogram plus 
standard labelling elements or the group using the standard labelling without the 
pictogram, including 95% confidence intervals (CI). No comparison between the labels 
will be performed.
9.2.
Sample Size Considerations
9.2.1.
Sample Size Assumptions
No formal sample size calculations were performed. Assuming a 30% screen failure rate, 
approximately 225 subjects will be screened in order to enrol 158 subjects (attempting at 
least one self-administration of mepolizumab). Assuming a dropout rate of up to 5% 
during the study, 158 enrolled subjects should provide at least 150 subjects with complete 
study data. Approximately 100 subjects will use autoinjectors with labelling that includes 
a pictogram plus standard labelling elements and 50 subjects will use the standard 
labelling without the pictogram.
No sample size re-assessment/adjustment is planned.


2016N275054_04
CONFIDENTIAL
204959
56
9.2.2.
Sample Size Sensitivity
The estimated precision for the proportion of subjects successfully able to self-administer 
their mepolizumab dose is presented below. Sample sizes of both 100 and 50 completed 
subjects are included, corresponding to the number of subjects planned to use the
autoinjectors with labelling that includes a pictogram plus standard labelling elements 
and the standard labelling without the pictogram respectively:-
95% CI
(Exact Method)
Observed Proportion
(%)
N=100
N=50
70
60, 79
55, 82
80
71, 87
66, 90
82
73, 89
69, 91
84
75, 91
71, 93
86
78, 92
73, 94
88
80, 94
76, 95
90
82, 95
78, 97
92
85, 96
81, 98
94
87, 98
83, 99
96
90, 99
86, 100
98
93, 100
89, 100
9.3.
Data Analysis Considerations
Full details of all pre-specified analyses will be described in the Reporting and Analysis 
Plan (RAP).
9.3.1.
Analysis Populations
All Subjects Population
The ‘All Subjects’ population will comprise all enrolled subjects (i.e. attempting at least 
one self-administration of mepolizumab). This population will be used for the evaluation 
of the mepolizumab liquid drug product in autoinjector and for the summaries relating to 
the safety and tolerability of mepolizumab.
PK Population:
The PK population will be defined as all enrolled subjects for whom at least one PK 
sample was obtained and analyzed.  This will be the primary population for assessing PK.
PD Population:
The PD population is defined as all enrolled subjects who also have a baseline PD 
measurement and at least one post-treatment PD measurement. This will be the primary 
population for assessing PD.


2016N275054_04
CONFIDENTIAL
204959
57
9.3.2.
Treatment Comparisons
This is a single arm study. There are no treatment comparisons. All analyses will be 
descriptive.
9.3.3.
Interim Analysis
No interim analysis is planned.
9.4.
Key Elements of Analysis Plan
9.4.1.
Analyses to Evaluate Autoinjector
All analyses to evaluate the autoinjector will be reported separately for subjects using 
autoinjectors with labelling that includes a pictogram plus standard labelling elements or 
subjects using the standard labelling without the pictogram.
Primary Endpoint
The number and percentage of subjects successfully able to self-administer their observed 
third dose at Week 8 will be summarized together with 95% confidence intervals. The 
denominator for the percentage calculation will be the number of subjects attempting an 
injection at Week 8.
Secondary Endpoints
The following will be summarized, including 95% CIs:-

The number and percentage of subjects successfully able to self-administer their 
unobserved second dose at Week 4. The denominator for the percentage 
calculation will be the number of subjects attempting an injection at Week 4.

The number and percentage of subjects successfully able to self-administer their 
observed first dose at Week 0. The denominator for the percentage calculation 
will be the number of subjects attempting an injection at Week 0.

The number and percentage of subjects successfully able to self-administer both 
their unobserved second dose at Week 4 and their observed third dose at Week 8. 
The denominator for the percentage calculation will be the number of subjects
attempting an injection at both Week 4 and Week 8.

The number and percentage of subjects successfully able to self-administer all 
three doses at Week 0, 4 and 8. The denominator for the percentage calculation 
will be the number of subjects attempting all 3 doses at Week 0, 4 and 8.
Data collected on the observer checklist relating to the correct use of the autoinjector and 
any device related issues preventing the full dose being administered will be summarized 
at each visit. 


2016N275054_04
CONFIDENTIAL
204959
58
The root cause evaluation of each unsuccessful injection via the Autoinjector (Pen) 
Error/Failure Reporting Form, including any observations noted by GSK Device 
Engineering, will be summarized separately by GSK Device Engineering for inclusion 
into the study report.
Device usability/functionality assessed at the end of the study will be summarized. 
9.4.2.
Safety Analyses
AEs will be coded using the MedDRA coding dictionary and summarized by preferred 
term. Separate summaries will be provided for all AEs, IP-related AEs, SAEs, events of 
special interest (including systemic reactions and local injection site reactions) and for 
AEs leading to permanent discontinuation of study treatment.  All laboratory parameters 
for clinical chemistry and hematology will be summarized and tabulated.
Exacerbations will be summarized and listed.
Each ECG parameter at every assessed time point will be summarized using summary 
statistics.  Summary statistics of QT interval corrected for heart rate according to 
Fridericia’s formula (QTcF) and QT interval corrected for heart rate according to Bazett’s 
formula (QTcB) as well as change from baseline value will be presented by visit.
Summary statistics of pulse rate and systolic and diastolic blood pressure will be 
presented by visit.
Pain VAS scores and categorical pain assessments will be summarized by visit and time 
post injection (immediately following, 1- and 24-hours post injection).
Immunogenicity will be summarized using appropriate descriptive statistics.
9.4.3.
Pharmacodynamic Analyses
Ratio to baseline (Visit 2) in blood eosinophil count will be summarized by visit, using 
summary statistics appropriate for log-normal data, overall, by previous mepolizumab use 
(i.e. not receiving mepolizumab treatment at Visit 1 or receiving 100 mg SC 
mepolizumab administered for the treatment of severe eosinophilic asthma every 4 weeks 
for at least 12 weeks prior to Visit 1) and by injection site. Values below the lower limit 
of quantification will be imputed as half the lower limit of quantification.
9.4.4.
Pharmacokinetic Analyses
Pharmacokinetic analysis will be the responsibility of the Clinical Pharmacology 
Modeling & Simulation department within GSK. 
PK concentrations will be presented in graphical and/or tabular form and will be 
summarized descriptively overall, by previous mepolizumab use (i.e. not receiving 
mepolizumab treatment at Visit 1 or receiving 100 mg SC mepolizumab administered for 
the treatment of severe eosinophilic asthma every 4 weeks for at least 12 weeks prior to 
Visit 1) and by injection site.


2016N275054_04
CONFIDENTIAL
204959
59
10.
STUDY GOVERNANCE CONSIDERATIONS
10.1.
Posting of Information on Publicly Available Clinical Trial 
Registers
Study information from this protocol will be posted on publicly available clinical trial 
registers before enrolment of subjects begins.
10.2.
Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, GSK will obtain favourable opinion/approval from the 
appropriate regulatory agency to conduct the study in accordance with ICH Good Clinical 
Practice (GCP) and applicable country-specific regulatory requirements.
The study will be conducted in accordance with all applicable regulatory requirements, 
and with GSK policy.
The study will also be conducted in accordance with International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP), all applicable subject privacy 
requirements, and the guiding principles of the current version of the Declaration of 
Helsinki.  This includes, but is not limited to, the following:

IRB/IEC review and favorable opinion/approval of the study protocol and 
amendments as applicable

Obtaining signed informed consent

Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to IRB/IEC)

GSK will provide full details of the above procedures, either verbally, in writing, 
or both.

Signed informed consent must be obtained for each subject prior to participation 
in the study

The IEC/IRB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  

Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrently submitted for 
approval unless regulation requires separate submission.  

Approval of the optional assessments may occur after approval is granted for the 
clinical protocol where required by regulatory authorities.  In this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study, with the exception of the optional 
assessments, can be initiated.


2016N275054_04
CONFIDENTIAL
204959
60
10.3.
Quality Control (Study Monitoring)

In accordance with applicable regulations including GCP, and GSK procedures, 
GSK monitors will contact the site prior to the start of the study to review with the 
site staff the protocol, study requirements, and their responsibilities to satisfy 
regulatory, ethical, and GSK requirements.  

When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eCRF 
will serve as the source document.
GSK will monitor the study and site activity to verify that the:

Data are authentic, accurate, and complete.

Safety and rights of subjects are being protected.

Study is conducted in accordance with the currently approved protocol and any 
other study agreements, GCP, and all applicable regulatory requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents.
10.4.
Quality Assurance

To ensure compliance with GCP and all applicable regulatory requirements, GSK 
may conduct a quality assurance assessment and/or audit of the site records, and 
the regulatory agencies may conduct a regulatory inspection at any time during or 
after completion of the study. 

In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the study, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any findings/issues identified.
10.5.
Study and Site Closure

Upon completion or premature discontinuation of the study, the GSK monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and GSK Standard 
Operating Procedures.

GSK reserves the right to temporarily suspend or prematurely discontinue this 
study at any time for reasons including, but not limited to, safety or ethical issues 
or severe non-compliance. For multicenter studies, this can occur at one or more 
or at all sites.  

If GSK determines such action is needed, GSK will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, GSK will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.


2016N275054_04
CONFIDENTIAL
204959
61

If the study is suspended or prematurely discontinued for safety reasons, GSK will 
promptly inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study. GSK will also promptly 
inform the relevant regulatory authorities of the suspension or premature 
discontinuation of the study and the reason(s) for the action.  

If required by applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the IRB/IEC promptly and provide the 
reason for the suspension or premature discontinuation.
10.6.
Records Retention

Following closure of the study, the investigator or the head of the medical 
institution (where applicable) must maintain all site study records (except for 
those required by local regulations to be maintained elsewhere), in a safe and 
secure location.  

The records must be maintained to allow easy and timely retrieval, when needed 
(e.g., for a GSK audit or regulatory inspection) and must be available for review 
in conjunction with assessment of the facility, supporting systems, and relevant 
site staff.  

Where permitted by local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard copy (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  

The investigator must ensure that all reproductions are legible and are a true and 
accurate copy of the original and meet accessibility and retrieval standards, 
including re-generating a hard copy, if required.  Furthermore, the investigator 
must ensure there is an acceptable back-up of these reproductions and that an 
acceptable quality control process exists for making these reproductions.

GSK will inform the investigator of the time period for retaining these records to 
comply with all applicable regulatory requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
any institutional requirements or local laws or regulations, GSK 
standards/procedures, and/or institutional requirements.  

The investigator must notify GSK of any changes in the archival arrangements, 
including, but not limited to, archival at an off-site facility or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site.
10.7.
Provision of Study Results to Investigators, Posting of 
Information on Publically Available Clinical Trials Registers 
and Publication
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 


2016N275054_04
CONFIDENTIAL
204959
62
opportunity to review the complete study results at a GSK site or other mutually-
agreeable location.
GSK will also provide the investigator with the full summary of the study results.  The 
investigator is encouraged to share the summary results with the study subjects, as 
appropriate.
The procedures and timing for public disclosure of the results summary and for 
development of a manuscript for publication will be in accordance with GSK Policy.
A manuscript will be progressed for publication in the scientific literature if the results 
provide important scientific or medical knowledge.


2016N275054_04
CONFIDENTIAL
204959
63
11.
REFERENCES
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral 
Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med
2014;371(13):1189-1197.
Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma 
(GINA) 2015. Available from: http://www.ginasthma.org/.
Haldar P, Brightling CE, Hargadon B, Gupta, S, Monteiro W, Sousa A, et al. 
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 
2009;360:973-984.
Investigator Brochure (IB) GSK Document Number CM2003/00010/12, Date 05 NOV 
2016.
Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini, E et al. 
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 
2009;360:985-993.
National heart, lung and blood institute (NIH) 2007. Expert panel report 3: Guidelines 
for the diagnosis and management of asthma. National asthma education and prevention 
program. Available at: http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-
guidelines/full-report
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. 
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med
2014;371(13):1198-1207.
Pavord ID, Korn S, Howarth P, Bleeker ER, Buhl R, Keene ON et al. Mepolizumab for
severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled 
trial. Lancet 2012;380:651–659.
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson Jr FN, Bock AS, Branum A et 
al. Second symposium on the definition and management of anaphylaxis: summary 
report—Second National Institute of Allergy and Infectious Disease/Food Allergy and 
Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-397.


2016N275054_04
CONFIDENTIAL
204959
64
12.
APPENDICES
12.1.
Appendix 1: Abbreviations and Trademarks
Abbreviations
ACQ
Asthma Control Questionnaire
ADA
Anti-drug antibody
AE
Adverse Event
ALT
Alanine aminotransferase
AST
Aspartate aminotrasferase
BUN
Blood urea nitrogen
CI
Confidence Interval
CONSORT
Consolidated Standard of Reporting Trials
COPD
Chronic obstructive pulmonary disease
CRF
Case report form
CS
Corticosteroid
Ctrough
Trough concentration at the end of the dosing interval
CV
Cardiovascular
DNA
Deoxyribonucleic acid
ECG
Electrocardiogram
eCRF
Electronic Case Report Form
ED
Emergency Department
EGPA
Eosinophilic granulomatosis with polyangiitis
EMEA
European Medicines Agency
EU
European Union
FAAN
Food Allergy and Anaphylaxis Network
FDA
Food and Drug Administration
FEV1
Forced expiratory volume in 1 second
FP
Fluticasone Propionate
FRP
Females of Reproductive Potential
FSH
Follicle stimulating hormone
G
Gauge
g
gram
GCP
Good Clinical Practice
GCSP
Global Clinical Safety and Pharmacovigilance
GINA
Global Initiative for Asthma
GSK
GlaxoSmithKline
hCG
Human chorionic gonadotropin
HES
Hypereosinophilic Syndrome
hIL
Human interleukin
HIV
Human immunodeficiency virus
HRT
Hormone replacement therapy
IB
Investigator’s Brochure
ICF
Informed consent form
ICH
International Conference on Harmonisation


2016N275054_04
CONFIDENTIAL
204959
65
ICS
Inhaled corticosteroids
IEC
Independent Ethics Committee
IFU
Instructions for Use
IgG
Immunoglobulin
IL
Interleukin
IM
Intramuscular
IP
Investigational Product
IRB
Institutional Review Board
IV
Intravenously
kg
Kilogram
LABA
Lon-acting beta-2-agonist
LTRA
Leukotriene receptor antagonist
mAb
Monoclonal antibody
mcg
Microgram
MCH
Mean corpuscular hemoglobin
MCV
Mean corpuscular volume
MedDRA
Medical Dictionary for Regulatory Activities
mg
Milligram
mL
Milliliter
mm Hg
Milliliter of mercury
MSDS
Material Safety Data Sheet
N/A
Not applicable
NAb
Neutralising antibody
NIAID
National Institute of Allergy and Infectious Disease
NIH
National Heart Lung and Blood Institute
OCS
Oral corticosteroids
PCSA
Placebo-controlled severe asthma
PD
Pharmacodynamic
PEF
Peak expiratory flow
PGx
Pharmacogenetics
PK
Pharmacokinetic
QTc
QI interval corrected for heart rate
QTcB
QT interval corrected for heart rate by Bazett’s formula
QTcF
QT interval corrected for heart rate by Fridericia’s formula
R&D
Research & Development
RAP
Reporting and Analysis plan
RBC
Red blood cell
RNA
Ribonucleic acid
SAE
Serious Adverse Event
SC
Subcutaneous(ly)
SGRQ
St George’s Respiratory Questionnaire 
SRM
Study reference manual
UK
United Kingdom
ULN
Upper limit of normal
US
United States
V
Visit


2016N275054_04
CONFIDENTIAL
204959
66
VAS
Visual Analogue Scale
WFI
Water for injection
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companies
Trademarks not owned by the 
GlaxoSmithKline group of companies
NUCALA
SAS
Xolair (omalizumab)
Ypsomed AG


2016N275054_04
CONFIDENTIAL
204959
67
12.2.
Appendix 2: Anaphylaxis Criteria
Joint NIAID/FAAN Second Symposium on Anaphylaxis [Sampson, 2006]. The criteria 
do not make a distinction based on underlying mechanism. These criteria are summarized 
as follows:
1) Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-
tongue-uvula), and at least one of the following:
a) Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, 
reduced peak expiratory flow [PEF], hypoxemia) 
b) Reduced blood pressure (BP) or associated symptoms of end-organ 
dysfunction (e.g., hypotonia [collapse], syncope, incontinence)
2) Two or more of the following that occur rapidly after exposure to a likely allergen 
for that patient (minutes to several hours):
a) Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, 
swollen lips-tongue-uvula)
b) Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, 
reduced PEF, hypoxemia)
c) Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope, 
incontinence)
d) Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting)
3) Reduced BP after exposure to known allergen for that patient (minutes to several 
hours):
a) Infants and children: low systolic BP (age specific) or greater than 30% 
decrease in systolic BP
b) Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from 
that person’s baseline
References
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson Jr FN, Bock AS, Branum A et 
al. Second symposium on the definition and management of anaphylaxis: summary 
report—Second National Institute of Allergy and Infectious Disease/Food Allergy and 
Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-397.


2016N275054_04
CONFIDENTIAL
204959
68
12.3.
Appendix 3: Modified List of Highly Effective Methods for 
Avoiding Pregnancy in FRP and Collection of Pregnancy 
Information
12.3.1.
Definition of post menopausal female
Post menopausal female is defined as:

Females 60 years of age or older
Menopause is the phase associated with complete cessation of menstrual cycles and 
implies the loss of reproductive potential by ovarian failure. This typically occurs 
around 50 years of age, although it may occur earlier or later. A practical definition 
accepts menopause after 1 year without menses with an appropriate clinical profile, 
e.g., age appropriate, >45 years, in the absence of hormone replacement therapy 
(HRT) or medical suppression of the menstrual cycle (e.g., leuprolide treatment).

In questionable cases for women < 60 years of age, a blood sample with simultaneous 
follicle stimulating hormone and estradiol falling into the central laboratory’s 
postmenopausal reference range is confirmatory (these levels need to be adjusted for 
specific laboratories/assays) [Kronenberg, 2008; Strauss, 2004].

Females under 60 years of age, who are on HRT and wish to continue, and whose 
menopausal status is in doubt, are required to use a highly effective method to avoid 
pregnancy, as outlined in the protocol. Otherwise, they must discontinue HRT to 
allow confirmation of post-menopausal status prior to study enrolment. For most 
forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and 
the blood draw; this interval depends on the type and dosage of HRT. Following 
confirmation of their post-menopausal status, they can resume use of HRT during the 
study without use of a highly effective method to avoid pregnancy. If laboratory 
values for FSH and estradiol are drawn and the results do not confirm menopause on 
a potential subject that otherwise met the specifications for being post-menopausal 
defined above without question, the subject may still enrol in the study as a FNRP if 
approved by the GSK Medical Monitor and the safety physician.
12.3.2.
Modified List of Highly Effective Methods for Avoiding Pregnancy 
in Females of Reproductive Potential (FRP)
The list does not apply to FRP with same sex partners or for subjects who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifestyle. Periodic abstinence (e.g. calendar, 
ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable 
methods of contraception.
1.
Contraceptive subdermal implant
2.
Intrauterine device or intrauterine system
3.
Combined estrogen and progestogen oral contraceptive [Hatcher, 2011])
4.
Injectable progestogen [Hatcher, 2011]


2016N275054_04
CONFIDENTIAL
204959
69
5.
Contraceptive vaginal ring [Hatcher, 2011]
6.
Percutaneous contraceptive patches [Hatcher, 2011]
7.
Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry into the study, and this male is the sole partner for that subject 
[Hatcher, 2011]. The documentation on male sterility can come from the site 
personnel’s: review of subject’s medical records, medical examination and/or semen 
analysis, or medical history interview provided by her or her partner.
These allowed methods of contraception are only effective when used consistently, 
correctly and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properly use these methods of contraception.
12.3.3.
Collection of Pregnancy Information

Investigator will collect pregnancy information on any female subject, who becomes 
pregnant while participating in this study

Information will be recorded on the appropriate form and submitted to GSK within 2 
weeks of learning of a subject's pregnancy.

Subject will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to GSK.  Generally, follow-up will not be required for longer than 6 to 8 
weeks beyond the estimated delivery date. 

Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.

While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.

A spontaneous abortion is always considered to be an SAE and will be reported as 
such.  

Any SAE occurring as a result of a post-study pregnancy which is considered 
reasonably related to the study treatment by the investigator, will be reported to GSK 
as described in Appendix 6. While the investigator is not obligated to actively seek 
this information in former study participants, he or she may learn of an SAE through 
spontaneous reporting.
Any female subject who becomes pregnant while participating will be withdrawn 
from the study.


2016N275054_04
CONFIDENTIAL
204959
70
12.3.4.
References
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, Policar MS, 
editors. Contraceptive Technology. 20th edition. Atlanta, Georgia: Ardent Media, Inc., 
2011: 50. Table 3-2.
Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams Textbook of 
Endocrinology, 11th edition. Philadelphia: Saunders, 2008.
Strauss JF, Barbieri RL, editors. Yen and Jaffe’s Reproductive Endocrinology. 5th 
edition, Philadelphia, Elsevier/Saunders, 2004.


2016N275054_04
CONFIDENTIAL
204959
71
12.4.
Appendix 4: Liver Safety Required Actions and Follow up 
Assessments
12.4.1.
Liver chemistry stopping criteria and required follow up 
assessments
Liver Chemistry Stopping Criteria - Liver Stopping Event
ALT-absolute
ALT 8xULN
ALT Increase
ALT 5xULN but <8xULN  persists for 2 weeks
ALT 3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2
ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) 
INR2
ALT 3xULN and INR>1.5, if INR measured
Cannot 
Monitor
ALT 5xULN but <8xULN and cannot be monitored weekly for 2 weeks
ALT 3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3
ALT  3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stopping Event
Actions
Follow Up Assessments

Immediately discontinue study treatment

Report the event to GSK within 24 hours

Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2

Perform liver event follow up assessments 

Monitor the subject until liver chemistries 
resolve , stabilize, or return to within baseline 
(see MONITORING below)

Do not restart/rechallenge subject with 
study treatment.  Permanently discontinue 
study treatment and may continue subject in 
the study for any protocol specified follow up 
assessments

Viral hepatitis serology4

Only in those with underlying chronic 
hepatitis B at study entry (identified by 
positive hepatitis B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.

Blood sample for pharmacokinetic (PK) 
analysis, obtained within 4 weeks after last 
dose6

Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).

Fractionate bilirubin, if total 
bilirubin2xULN

Obtain complete blood count with 
differential to assess eosinophilia. Note: 
the mechanism of action of mepolizumab 
leads to lowering of eosinophils.


2016N275054_04
CONFIDENTIAL
204959
72
MONITORING:
For bilirubin or INR criteria:

Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24 
hrs

Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within baseline

A specialist or hepatology consultation is 
recommended
For All other criteria:

Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72 hrs 

Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within baseline

Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form

Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal 
remedies, other over the counter 
medications.

Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:

Anti-nuclear antibody, anti-smooth muscle 
antibody, Type 1 anti-liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).

Serum acetaminophen adduct HPLC 
assay (quantifies potential acetaminophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [James, 2009]). NOTE: 
not required in China

Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1.
Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN and bilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury. 
2.
All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3.
New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   
4.
Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5.
If hepatitis delta antibody assay cannot be performed,, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) [Le Gal, 2005].
6.
PK sample may not be required for subjects known to be receiving placebo or non-GSK comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 


2016N275054_04
CONFIDENTIAL
204959
73
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are in 
the SRM.
12.4.2.
Liver chemistry increased monitoring criteria with continued 
therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria
Actions
ALT 5xULN and <8xULN and bilirubin 
<2xULN without symptoms believed to 
be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 2 weeks.
OR
ALT 3xULN and <5xULN and bilirubin 
<2xULN without symptoms believed to 
be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 4 weeks.

Notify the GSK medical monitor within 24 hours of 
learning of the abnormality to discuss subject 
safety. 

Subject can continue study treatment

Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 

If at any time subject meets the liver chemistry 
stopping criteria, proceed as described above

If ALT decreases from ALT 5xULN and <8xULN to 
≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly. 

If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by Consensus Real-Time PCR Indicates 
Different Patterns of Virological Response to Interferon Therapy in Chronically Infected 
Patients.  J Clin Microbiol. 2005;43(5):2363–2369. 


2016N275054_04
CONFIDENTIAL
204959
74
12.5.
Appendix 5: Definition of and Procedures for Documenting 
Medical Device Incidents
12.5.1.
Definitions of a Medical Device Incident
The detection and documentation procedures described in this protocol apply to all GSK 
medical devices provided for use in the study (see Section 6.2 for the list of GSK medical 
devices).
Medical Device Incident Definition:

Incident – Any malfunction or deterioration in the characteristics and/or performance 
of a device, as well as any inadequacy in the labeling or the instructions for use 
which, directly or indirectly, might lead to or might have led to the death of a 
patient/user/other persons or to a serious deterioration in their state of health.

Not all incidents lead to death or serious deterioration in health.  The non-occurrence 
of such a result might have been due to other fortunate circumstances or to the 
intervention of health care personnel.
It is sufficient that:

an incident associated with a device happened and

the incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health.
A serious deterioration in state of health can include:

life-threatening illness

permanent impairment of body function or permanent damage to a body 
structure

a condition necessitating medical or surgical intervention to prevent one of the 
above 

fetal distress, fetal death or any congenital abnormality or birth defects
Examples of incidents

a patient, user, care giver or professional is injured as a result of a medical device 
failure or its misuse

a patient’s treatment is interrupted or compromised by a medical device failure

misdiagnosis due to medical device failure leads to inappropriate treatment

a patient’s health deteriorates due to medical device failure


2016N275054_04
CONFIDENTIAL
204959
75
12.5.2.
Documenting Medical Device Incidents
Medical Device Incident Documenting:

Any medical device incident occurring during the study will be documented in the 
subject’s medical records, in accordance with the investigator’s normal clinical 
practice, and on the appropriate form.

For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE 
CRF page will be completed as described in Appendix 6.

The form will be completed as thoroughly as possible and signed by the investigator 
before transmittal to GSK.

It is very important that the investigator provides his/her assessment of causality to 
the medical device provided by GSK at the time of the initial report, and describes 
any corrective or remedial actions taken to prevent recurrence of the incident.

A remedial action is any action other than routine maintenance or servicing of a 
device where such action is necessary to prevent recurrence of an incident. This 
includes any amendment to the design to prevent recurrence.


2016N275054_04
CONFIDENTIAL
204959
76
12.6.
Appendix 6: Definition of and Procedures for Recording, 
Evaluating, Follow-Up and Reporting of Adverse Events
12.6.1.
Definition of Adverse Events
Adverse Event Definition:

An AE is any untoward medical occurrence in a patient or clinical investigation 
subject, temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.

NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a medicinal product.
Events meeting AE definition include:

Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically 
significant in the medical and scientific judgement of the investigator.

Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.

New conditions detected or diagnosed after study treatment administration even 
though it may have been present prior to the start of the study.

Signs, symptoms, or the clinical sequelae of a suspected interaction.

Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self-
harming intent.  This should be reported regardless of sequelae).

The signs and symptoms and/or clinical sequelae resulting from lack of efficacy will 
be reported if they fulfil the definition of an AE or SAE.  Also, "lack of efficacy" or 
"failure of expected pharmacological action" also constitutes an AE or SAE.
Events NOT meeting definition of an AE include:

Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the subject’s condition.

The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s
condition.


2016N275054_04
CONFIDENTIAL
204959
77

Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is an AE.

Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).

Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.6.2.
Definition of Serious Adverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.
Results in death
b.
Is life-threatening
NOTE:
The term 'life-threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.
c.
Requires hospitalization or prolongation of existing hospitalization
NOTE:

In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician’s 
office or out-patient setting.  Complications that occur during hospitalization are 
AEs.  If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious.  When in doubt as to whether “hospitalization” occurred or was 
necessary, the AE should be considered serious.

Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.
Results in disability/incapacity
NOTE:

The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.

This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 


2016N275054_04
CONFIDENTIAL
204959
78
and accidental trauma (e.g. sprained ankle) which may interfere or prevent everyday 
life functions but do not constitute a substantial disruption
e.
Is a congenital anomaly/birth defect
f.
Other situations:

Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize 
the subject or may require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition.  These should also be considered 
serious.

Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse
g.
Is associated with liver injury and impaired liver function defined as:

ALT 3xULN and total bilirubin* 2xULN (>35% direct), or

ALT 3xULN and INR** >1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary bilirubin via dipstick.  If fractionation is unavailable and ALT 3xULN 
and total bilirubin 2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
12.6.3.
Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:

Myocardial infarction/unstable angina

Congestive heart failure

Arrhythmias

Valvulopathy

Pulmonary hypertension

Cerebrovascular events/stroke and transient ischemic attack

Peripheral arterial thromboembolism


2016N275054_04
CONFIDENTIAL
204959
79

Deep venous thrombosis/pulmonary embolism

Revascularization
12.6.4.
Recording of AEs and SAEs
AEs and SAE Recording:

When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory, and diagnostics reports) 
relative to the event.

The investigator will then record all relevant information regarding an AE/SAE in 
the CRF

It is not acceptable for the investigator to send photocopies of the subject’s medical 
records to GSK in lieu of completion of the GSK, AE/SAE CRF page.

There may be instances when copies of medical records for certain cases are 
requested by GSK.  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records prior to 
submission of to GSK.

The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/symptoms.
12.6.5.
Evaluating AEs and SAEs
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and will assign it to one of the following categories:

Mild:  An event that is easily tolerated by the subject, causing minimal discomfort 
and not interfering with everyday activities.

Moderate:  An event that is sufficiently discomforting to interfere with normal 
everyday activities

Severe:  An event that prevents normal everyday activities. - an AE that is assessed 
as severe will not be confused with an SAE. Severity is a category utilized for rating 
the intensity of an event; and both AEs and SAEs can be assessed as severe.

An event is defined as ‘serious’ when it meets at least one of the pre-defined 
outcomes as described in the definition of an SAE.


2016N275054_04
CONFIDENTIAL
204959
80
Assessment of Causality

The investigator is obligated to assess the relationship between study treatment and 
the occurrence of each AE/SAE.

A "reasonable possibility" is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.

The investigator will use clinical judgment to determine the relationship.

Alternative causes, such as natural history of the underlying diseases, concomitant 
therapy, other risk factors, and the temporal relationship of the event to the study 
treatment will be considered and investigated.

The investigator will also consult the Investigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.

For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.

There may be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to GSK.  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to GSK.

The investigator may change his/her opinion of causality in light of follow-up 
information, amending the SAE data collection tool accordingly.

The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
Follow-up of AEs and SAEs

The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may be indicated or as requested by GSK to 
elucidate as fully as possible the nature and/or causality of the AE or SAE.

The investigator is obligated to assist.  This may include additional laboratory tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.

If a subject dies during participation in the study or during a recognized follow-up 
period, the investigator will provide GSK with a copy of any post-mortem findings, 
including histopathology.

New or updated information will be recorded in the originally completed CRF.

The investigator will submit any updated SAE data to GSK within the designated 
reporting time frames.


2016N275054_04
CONFIDENTIAL
204959
81
12.6.6.
Reporting of SAEs to GSK
SAE reporting to GSK via electronic data collection tool

Primary mechanism for reporting SAEs to GSK will be the electronic data collection 
tool

If the electronic system is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor

Site will enter the serious adverse event data into the electronic system as soon as it 
becomes available.

The investigator will be required to confirm review of the SAE causality by ticking 
the ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.

After the study is completed at a given site, the electronic data collection tool (e.g., 
InForm system) will be taken off-line to prevent the entry of new data or changes to 
existing data

If a site receives a report of a new SAE from a study subject or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by telephone.

Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact Information page.
SAE reporting to GSK via paper CRF

Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Medical Monitor

In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptable, with a copy of the SAE data collection tool sent by 
overnight mail

Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.

Contacts for SAE receipt can be found at this beginning of the protocol on the 
Sponsor/Medical Monitor Contact Information page.


2016N275054_04
CONFIDENTIAL
204959
82
12.7.
Appendix 7: Genetic Research
Genetics – Background
Naturally occurring genetic variation may contribute to inter-individual variability in 
response to medicines, as well as an individual's risk of developing specific diseases. 
Genetic factors associated with disease characteristics may also be associated with 
response to therapy, and could help to explain some clinical study outcomes. For 
example, genetic variants associated with age-related macular degeneration (AMD) are 
reported to account for much of the risk for the condition [Gorin, 2012] with certain 
variants reported to influence treatment response [Chen, 2012]. Thus, knowledge of the 
genetic etiology of disease may better inform understanding of disease and the 
development of medicines. Additionally, genetic variability may impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacodynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficacy and/or safety) observed in a clinical study.
Genetic Research Objectives and Analyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 

Response to medicine, including mepolizumab or any concomitant medicines;

Asthma susceptibility, severity, and progression and related conditions
Genetic data may be generated while the study is underway or following completion of 
the study.  Genetic evaluations may include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic analyses will utilize data collected in the study and will be limited to 
understanding the objectives highlighted above.  Analyses may be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analysis methods will be used. A detailed 
description of any planned analyses will be documented in a Reporting and Analysis Plan 
(RAP) prior to initiation of the analysis. Planned analyses and results of genetic 
investigations will be reported either as part of the clinical RAP and study report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study can participate in genetic research.  Any subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 


2016N275054_04
CONFIDENTIAL
204959
83
identified, may enable future genetic analyses to be conducted to help understand 
variability in disease and medicine response.  

A 2 ml blood sample will be taken for Deoxyribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
enrolled and provided informed consent for genetic research. Instructions for 
collection and shipping of the genetic sample are described in the laboratory 
manual. The DNA from the blood sample may undergo quality control analyses to 
confirm the integrity of the sample. If there are concerns regarding the quality of 
the sample, then the sample may be destroyed. The blood sample is taken on a 
single occasion unless a duplicate sample is required due to an inability to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same study specific number used to 
label other samples and data in the study.   This number can be traced or linked back to 
the subject by the investigator or site staff. Coded samples do not carry personal 
identifiers (such as name or social security number). 
Samples will be stored securely and may be kept for up to 15 years after the last subject 
completes the study, or GSK may destroy the samples sooner.  GSK or those working 
with GSK (for example, other researchers) will only use samples collected from the study 
for the purpose stated in this protocol and in the informed consent form.  Samples may be 
used as part of the development of a companion diagnostic to support the GSK medicinal 
product.
Subjects can request their sample to be destroyed at any time.
Informed Consent
Subjects who do not wish to participate in the genetic research may still participate in the 
study.  Genetic informed consent must be obtained prior to any blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study for any reason other than being lost to follow-up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already 
collected:

Continue to participate in the genetic research in which case the genetic DNA 
sample is retained

Discontinue participation in the genetic research and destroy the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for any 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified by GSK and maintain the documentation in 
the site study records. 


2016N275054_04
CONFIDENTIAL
204959
84
Genotype data may be generated during the study or after completion of the study and 
may be analyzed during the study or stored for future analysis. 

If a subject withdraws consent for genetic research and genotype data has not been 
analyzed, it will not be analyzed or used for future research.  

Genetic data that has been analyzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate. 
Screen Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry criteria for participation in the study, then the investigator should 
instruct the subject that their genetic sample will be destroyed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance a sample destruction form will not be available to 
include in the site files.
Provision of Study Results and Confidentiality of Subject’s Genetic Data
GSK may summarize the genetic research results in the clinical study report, or 
separately and may publish the results in scientific journals. 
GSK may share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. GSK does not inform the subject, 
family members, insurers, or employers of individual genotyping results that are not 
known to be relevant to the subject’s medical care at the time of the study, unless 
required by law. This is due to the fact that the information generated from genetic 
studies is generally preliminary in nature, and therefore the significance and scientific 
validity of the results are undetermined.  Further, data generated in a research laboratory 
may not meet regulatory requirements for inclusion in clinical care.
References
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age-Related Macular 
Degeneration (AMD) Susceptibility Gene CFH and Treatment Response of AMD: A 
Meta-Analysis. PloS ONE 2012; 7: e42464
Gorin MB. Genetic insights into age-related macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467-486.


2016N275054_04
CONFIDENTIAL
204959
85
12.8.
Appendix 8 - Country Specific Requirements
No country-specific requirements exist.


2016N275054_04
CONFIDENTIAL
204959
86
12.9.
Appendix 9: Protocol Changes
12.9.1.
Protocol Amendment 02
Scope:
This amendment applies to all sites.
Protocol Changes specified in Amendment No.2 are summarised below.
Strike through text refers to deleted text and underlined refers to added text.
Section 1 Protocol Synopsis - Overall Design
Rationale for change: To explain why each autoinjector will be labelled in one of two 
different formats.
Added Text:
Due to differences in the labelling requirements among regulatory authorities around the 
world, two different labelling approaches will be included in this global study:  labelling 
that includes a pictogram plus standard labelling elements, or a standard labelling without 
the pictogram.  The pictogram plus standard labelling elements is intended to satisfy 
requirements of the US Food and Drug Administration; while the standard labelling 
(without pictogram) is intended to satisfy requirements of Regulatory Agencies outside of 
the United States.  English speaking subjects outside of the US can contribute to the 
cohort used to assess the US label.  All subjects at a given clinical trial site will utilise the 
same format of device label for all injections throughout the study.  The assessment of 
injection success will be reported separately according to the format of labelling used.
Section 1 Protocol Synopsis – Type and Number of Subjects
Rationale for change: To allow subjects who have a requirement for high dose ICS but 
who may not have received continuous high dose ICS to be enrolled and increase subject 
numbers to account for the two different labelling formats.
Revised Text:
Male or female subjects aged 12 years or older with severe eosinophilic asthma. Subjects 
must either have been receiving mepolizumab administered SC for the treatment of 
severe eosinophilic asthma every 4 weeks for at least 12 weeks prior to Visit 1 or, if not 
previously using mepolizumab must be using, or have a requirement for, high dose 
inhaled corticosteroids plus an additional controller with a history of 1 or more 
exacerbations requiring systemic corticosteroids in the 12 months prior to Visit 1.
Approximately 150 225 subjects will be screened to achieve 105 158 enrolled subjects 
with the aim of achieving 100 150 completed/evaluable subjects. Approximately 100 
subjects will use autoinjectors with labelling that includes a pictogram plus standard 
labelling elements and 50 subjects will use the standard labelling without the pictogram.


2016N275054_04
CONFIDENTIAL
204959
87
Section 1 Protocol Synopsis – Sample Size Calculations and Statistical Analyses
Rationale for change: To increase the number of subjects to account for the two 
different label formats.
Revised Text:
No formal sample size calculations were performed. Assuming a 30% dropout screen 
failure rate during screening, approximately 150 225 subjects will be screened in order to 
enrol 105 158 subjects (attempting at least one self-administration of mepolizumab). 
Assuming a dropout rate of up to 5% during the study, 105 158 enrolled subjects should 
provide at least 100 150 subjects with complete study data.
The number and percentage of subjects successfully able to self-administer their doses 
will be reported presented separately for the group of subjects using labelling that 
includes a pictogram plus standard labelling elements or the group using the standard 
labelling without the pictogram, together with including 95% confidence intervals.  No 
hypothesis testing will be performed.
Section 2.1 Study Rationale
Rationale for change: To indicate that the purpose of the study is to assess real world 
use of the autoinjector and hence the population is meant intended to broadly 
representative of subjects who may use the autoinjector. 
Added Text:
Thus, the primary objective of this study is to characterise the degree of appropriate use 
of the autoinjector by a group of subjects representative (i.e., similar age, dexterity and 
cognitive abilities, degree of training or experience with an autoinjector) of patients, 
likely to use the autoinjector as a self-injected medicine. A separate study (Study 205667) 
will characterise the appropriate use of the safety syringe.
Section 3 Objectives and Endpoints
Rationale for change: To remove incidence of asthma exacerbations as a safety endpoint 
and reclassify it as an ‘other’ endpoint as assessment as asthma exacerbations are not 
considered a safety endpoint. To remove ‘Investigator’ from ‘Evaluation of user/device 
errors’ as this may also be performed by a designee.


2016N275054_04
CONFIDENTIAL
204959
88
Revised Text:
Objectives
Endpoints
Primary

To assess the use of the combination 
product, mepolizumab liquid drug 
product in autoinjector for the 
subcutaneous self-administration of 
mepolizumab by subjects with severe 
eosinophilic asthma

Proportion of subjects successfully able 
to self-administer their observed third 
dose at Week 8
Secondary

To assess the use of mepolizumab 
liquid drug product in autoinjector 
outside the clinic setting

Proportion of subjects successfully 
able to self-administer their 
unobserved second dose outside the 
clinic setting at Week 4


2016N275054_04
CONFIDENTIAL
204959
89
Objectives
Endpoints
Other

To assess the use of mepolizumab 
liquid drug product in autoinjector both 
inside and outside of the clinic setting

To evaluate autoinjector use & 
functionality

To evaluate any autoinjector injection 
errors/failures related to use or device 
performance

To characterise the subject experience 
of using the mepolizumab liquid drug 
product in autoinjector

To assess mepolizumab plasma trough 
concentrations following the SC 
administration of mepolizumab liquid 
drug product in autoinjector

To assess the pharmacodynamic effect 
following the SC administration of 
mepolizumab liquid drug product in 
autoinjector

To assess the frequency of asthma 
exacerbations

Proportion of subjects successfully able 
to self-administer their observed first 
dose at Week 0

Proportion of subjects successfully able 
to self-administer both their unobserved 
second dose and observed third dose at 
Weeks 4 and 8

Proportion of subjects successfully able 
to self-administer all three doses at 
Weeks 0, 4 and 8

Device usability/functionality
questionnaire completed at the End of 
Study/Early Withdrawal Visit

Investigator Evaluation of user/device 
errors

Root cause analysis of each 
unsuccessful injection

Subject Exit Interviews completed over 
the telephone after the End of 
Study/Early Withdrawal Visit

Mepolizumab plasma trough 
concentrations (Ctrough) at Weeks 4, 8 
and 12

Ratio to baseline of blood eosinophils 
at  Weeks 4, 8 and 12

Incidence of asthma exacerbations


2016N275054_04
CONFIDENTIAL
204959
90
Objectives
Endpoints
Safety
To evaluate the safety and tolerability of 
mepolizumab liquid drug product in 
autoinjector

Incidence and frequency of Adverse 
Events / Serious Adverse Events 
including systemic reactions and 
injection site reactions

Clinically significant change in 
haematological and/or clinical 
chemistry parameters

Incidence of asthma exacerbations

Vital signs

12-lead electrocardiogram (ECG)

Incidence of immunogenicity

Level of self-reported pain immediately 
following,1- and 24-hours following 
each injection (patient diary)
Section 4.1 Overall Study Design
Rationale for change: To indicate that two different formats will be used for the labels 
on the autoinjector depending on the country in which it is to be used.
Added Text:
Each autoinjector will have labelling that includes a pictogram plus standard labelling 
elements, or a standard labelling without the pictogram dependant on the country in 
which it is being used.
Rationale for change: To clarify that a designee may complete the Observer checklist.
Revised Text:
Observations about the injection will be recorded by the investigator or designee for the 
doses administered in the clinic using an observer checklist.
All injections will be assessed by the investigator for success based on:

Direct observation of the self-administration using the investigator Observer 
Checklist if the mepolizumab dose was administered in the clinic, and inspection 
of the autoinjector


2016N275054_04
CONFIDENTIAL
204959
91

Subject/caregiver completed checklist and inspection by the investigator of the 
returned autoinjector if the mepolizumab dose was administered outside the clinic
A self-administered injection is considered successful if the following criteria are met: 

Use of a correct injection site (abdomen/thigh or upper arm [caregiver only])

Full dose administration: subject pushes the autoinjector all the way down and 
holds until either the second click, or the plunger stops moving and the inspection 
window is filled with the yellow indicator or pushes the autoinjector all the way 
down and holds for a total of 15 seconds

No observations are made with respect to the autoinjector, following inspection 
by the investigator, which indicates the full dose has not been dispensed
If the above criteria are met, the investigator or designee will confirm the injection was 
successfully delivered.
Rationale for change: To amend text to indicate that all autoinjectors will need to be 
returned to GSK for inspection.
Revised text:
All devices associated with an unsuccessful injection, will be evaluated by Device 
Engineering at GlaxoSmithKline (GSK), post-use, to assess overall performance and 
robustness of the device.
Section 4.3 Type and Number of Subjects
Rationale for change: To increase subject numbers to account for the two different 
labelling formats.
Revised Text:
Approximately 150 225 subjects with severe eosinophilic asthma will be screened in 
order to achieve 105 158 enrolled subjects (attempting at least one self-administration of 
mepolizumab) and 100 150 subjects with complete study data. Approximately 100 
subjects will use autoinjectors with labelling that includes a pictogram plus standard 
labelling elements and 50 subjects will use the standard labelling without the pictogram.
Section 4.4 Design Justification
Rationale for change: To explain that the study is designed to assess the real world use 
of the autoinjector rather than the efficacy of mepolizumab, hence why subjects not on 
mepolizumab may be enrolled based on a requirement for high dose ICS to prevent 
exacerbations if not receiving continuous high dose ICS.


2016N275054_04
CONFIDENTIAL
204959
92
Revised Text:
An open-label, repeat-dose, single arm, multi-centre study design is deemed appropriate 
to evaluate self-administration of mepolizumab liquid drug product in autoinjector in 
subjects with severe eosinophilic asthma. The primary purpose, and resultant study 
design is to assess the appropriate use of the autoinjector in a real world use setting.  
Participants are intended to be broadly representative of patients and caregivers (i.e., 
similar age, dexterity and cognitive abilities, degree of training or experience with an 
autoinjector) who may use the autoinjector, either for the treatment of severe eosinophilic 
asthma or, potentially, other approved indications. In addition, safety outcomes, 
immunogenicity, pharmacokinetics and pharmacodynamics will be also be characterised 
in this study. 
A population of subjects with severe eosinophilic asthma either currently receiving or not 
currently receiving commercially available mepolizumab SC at study entry (Visit 1) was 
selected to reflect the intended population in “real world” use conditions. Subjects not 
currently receiving mepolizumab will have a history of ≥1 exacerbation requiring 
treatment with systemic corticosteroids in the previous 12 months while will be required 
to have severe eosinophilic asthma and while using, or having a requirement for, high 
dose inhaled corticosteroids (ICS) plus a second controller. with a history of ≥1 
exacerbations requiring treatment with systemic corticosteroids in the previous 12 
months. 
Rationale for change: To explain why two different labelling formats for the 
autoinjector are being used.
Added Text:
Due to differences in the labelling requirements among regulatory authorities around the 
world, two different labelling approaches will be included in this global study:  labelling 
that includes a pictogram plus standard labelling elements, or a standard labelling without 
the pictogram.  The pictogram plus standard labelling elements is intended to satisfy 
requirements of the US Food and Drug Administration; while the standard labelling 
(without pictogram) is intended to satisfy requirements of Regulatory Agencies outside of 
the United States.  English speaking subjects outside of the US can contribute to the 
cohort used to assess the US label.  All subjects at a given clinical trial site will utilise the 
same format of device label for all injections throughout the study.  The assessment of 
injection success will be reported separately according to the format of labelling used.
Rationale for change: To clarify the wording around observation of the injection at Visit 
2
Amended Text:
The standardised training provided in this study will be representative of the instruction 
and training materials that will be given once the device is commercially available for 
use. Subjects will be observed self-administering liquid drug product from the 
autoinjector instructed to use the autoinjector at the clinic immediately after being 
trained in its use at Visit 2 (Week 0). and thereafter Subjects will self-administer at 4-


2016N275054_04
CONFIDENTIAL
204959
93
weekly intervals, either at the clinic or outside of the clinic (Time and Events Table, 
Section 7.1).
Section 4.6.2 Benefit Assessment
Revised Text:
The primary purpose of this study is to assess the appropriate use of the autoinjector in a 
real world use setting.  Participants are intended to be broadly representative of patients 
and caregivers (i.e., similar age, dexterity and cognitive abilities, degree of training or 
experience with an autoinjector) who may use the autoinjector, either for the treatment of 
severe eosinophilic asthma or, potentially, other approved indications. Efficacy is not 
being assessed in this study  as the efficacy of mepolizumab in severe eosinophilic 
asthma has previously been demonstrated in prior studies Data from earlier studies
[Haldar, 2009; Nair, 2009; Pavord, 2012;] attest to the clinical utility of mepolizumab in 
the treatment of severe eosinophilic asthma which was confirmed in the Phase III studies 
MEA115575 and MEA115588[ Bel, 2014; Ortega, 2014].  The autoinjector is intended to
provides a more convenient mode of delivery from previous mepolizumab administration 
and potentially provides gives patients an option to self-administer mepolizumab at 
home.
Section 5.1 Inclusion criterion 5
Rationale for change: To allow subjects who may not have received continuous high 
dose ICS to be enrolled provided that it can be demonstrated that they have need to for 
high dose ICS to prevent exacerbations or financial or tolerance issues have prevented 
them receiving continuous high dose ICS.
Revised text: 
5. Inhaled Corticosteroid: A well-documented requirement for regular treatment with 
high dose inhaled corticosteroid (ICS) in the 12 months prior to Visit 1 with or 
without maintenance oral corticosteroids (OCS).

For subjects 18 years old:

ICS dose must be ≥880 mcg/day fluticasone propionate (FP) (ex-
actuator) or equivalent daily.

For ICS/long-acting-beta-2-agonist (LABA) combination 
preparations, the high strength approved maintenance dose in the local 
country will meet this ICS criterion.
For subjects 12 to 17 years old:

ICS dose must be ≥440 mcg/day FP (ex-actuator) or equivalent daily.

For ICS/LABA combination preparations, the mid-strength approved 
maintenance dose in the local country will meet this ICS criterion.
(Subjects will be permitted to be enrolled without continuous high dose ICS providing 
the subject was receiving continuous ICS and the Investigator attests that the subject 


2016N275054_04
CONFIDENTIAL
204959
94
should have been treated with high dose ICS to mitigate the risk of exacerbations but 
financial or tolerance issues prevented the use of high-dose ICS. Such subjects should 
be discussed with GSK Medical Monitor prior to enrolment)
Section 5.3 Continuation to Treatment Criteria
Rationale for change: To reflect increase in subject numbers
Revised text:
At Visit 2, those subjects who continue to meet the inclusion/exclusion criteria and who 
meet the continuation to treatment criteria will commence the study treatment phase until 
the target of approximately 105 158 enrolled subjects is reached.  
Section 6.2 Medical Devices
Rationale for change: To indicate that the labelling will differ depending on the 
geographical region in which the device is to be used.
Revised text:
The devices used in the study are representative of the devices and regionally appropriate 
device product labelling planned to be marketed for the product.
Section 6.5 Packaging and Labelling
Rationale for change: To describe the two different formats that will be used to label the 
autoinjector.
Added text:
The autoinjector will either be labelled with a pictogram plus standard labelling elements 
or standard labelling without the pictogram.
Section 6.7 Training Session
Rationale for change: To remove reference to a practice injection by injecting into a 
foam pad. 
Revised text:
The subject/caregiver will then perform a supervised practice injection using a 
demonstration device and injecting into a foam pad.  Finally, The first actual injection 
will then be supervised observed by site personnel and may include feedback to the 
subject as needed.
Section 6.8.1 Self-Administration at the Clinic
Rationale for change: To clarify that a designee may complete the Observer checklist


2016N275054_04
CONFIDENTIAL
204959
95
Revised Text:
Observations about the injection will be recorded by the investigator or designee using a 
checklist for the doses administered in the clinic.
Section 6.11.1 Permitted Medications and Non-Drug Therapies
Rationale for change: To allow subjects who may not have received continuous high 
dose ICS to be enrolled provided that it can be demonstrated that they have need for high 
dose ICS to prevent exacerbations but financial or tolerance issues have prevented them 
receiving continuous high dose ICS.
Revised text:
For subjects who have not previously received mepolizumab, subjects must have a 
well-documented requirement for regular treatment with high dose inhaled corticosteroid 
(ICS) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids 
(OCS).

Subjects 18 years old:

ICS dose must be ≥880 mcg/day fluticasone propionate (FP) (ex-
actuator) or equivalent daily.

For ICS/LABA combination preparations, the highest strength 
approved maintenance dose in the local country will meet this ICS 
criterion.
Subjects 12 to 17 years old:

ICS dose must be ≥440 mcg/day FP (ex-actuator) or equivalent daily.

For ICS/LABA combination preparations, the mid-strength approved 
maintenance dose in the local country will meet this ICS criterion.
(Subjects will be permitted to be enrolled without continuous high dose ICS providing 
the subject was receiving continuous ICS and the Investigator attests that the subject 
should have been treated with high dose ICS to mitigate the risk of exacerbations but 
financial or tolerance issues prevented the use of high-dose ICS. Such subjects should 
be discussed with GSK Medical Monitor prior to enrolment)
Section 7.1 Time and Events Table
Rationale for change: Asthma exacerbations previously omitted as an assessment during 
the study:
Added text:
Physical/Clinical:
Vital signsi
X
Xd
Xd
Xd
X
12-lead ECG
X
X
Physical examination
X
X
Weight
X


2016N275054_04
CONFIDENTIAL
204959
96
Physical/Clinical:
Concomitant Medication
X
X
X
X
X
X
Asthma Exacerbations
X
X
X
X
X
Serious Adverse Eventsj,k,l
X
X
X
X
X
X
Adverse Eventsj,k,l
X
X
X
X
Section 7.3 Assessment of Autoinjector Use
Rationale for change: To indicate that a designee may inspect the device after each 
injection.
Revised Text:
In addition, the investigator or designee will be asked to inspect the autoinjector, 
following each injection, to confirm that the yellow indicator fills the inspection window 
and the needle guard has locked into place (checked by pressing the needle guard against 
a firm surface), as well as noting any additional observations which indicate the full dose 
has not been dispensed.
Rationale for change: To amend text to indicate that all autoinjectors will need to be 
returned to GSK for inspection.
Revised text:
All devices associated with an unsuccessful injection, will be evaluated by Device 
Engineering, post-use, to assess overall performance and robustness of the device.
Section 7.8 Asthma Exacerbations
Rationale for change: Definition of asthma exacerbation omitted previously including
details of how exacerbations should be recorded.
Added Text:
At each study visit the investigator will make an assessment of the occurrence of an 
asthma exacerbation.  Any asthma exacerbation will be recorded on the appropriate eCRF 
page.
An exacerbation of asthma as defined as:
Worsening of asthma which requires use of systemic corticosteroids1and/or 
hospitalization and/or Emergency Department (ED) visits.
1For all subjects, i.v. or oral steroid (e.g., prednisone) for at least 3 days or a single 
intramuscular corticosteroid dose is required. For subjects on maintenance systemic 
corticosteroids, at least double the existing maintenance dose for at least 3 days is 
required.


2016N275054_04
CONFIDENTIAL
204959
97
Section 9.1 Hypotheses
Rationale for change: To amend the text to indicate that the results will be reported 
separately for the two different formats being used for the labels
Revised text:
No formal statistical hypothesis testing is planned.  The number and percentage of 
subjects successfully able to self-administer their mepolizumab dose will be reported
presented No formal statistical hypothesis testing is planned.  The number and percentage 
of subjects successfully able to self-administer their mepolizumab dose will be reported 
separately for the group of subjects using labelling that includes a pictogram plus 
standard labelling elements or the group using the standard labelling without the 
pictogram, including 95% confidence intervals (CI). No comparison between the labels 
will be performed.
Section 9.2.1 Sample Size Assumptions
Rationale for change: To increase the number of subjects to account for the two 
different label formats.
Revised text:
No formal sample size calculations were performed. Assuming a 30% dropout screen 
failure rate during screening, approximately 150 225 subjects will be screened in order to 
enrol 105 158 subjects (attempting at least one self-administration of mepolizumab). 
Assuming a dropout rate of up to 5% during the study, 105 158 enrolled subjects should 
provide at least 100 150 subjects with complete study data. Approximately 100 subjects 
will use autoinjectors with labelling that includes a pictogram plus standard labelling 
elements and 50 subjects will use the standard labelling without the pictogram.
Section 9.2.2 Sample Size Sensitivity
Rationale for change: To amend the table to include the estimated precision both for the 
100 subjects and 50 subjects according to the label used. 
Revised text:
The estimated precision for the proportion of subjects successfully able to self-administer 
their mepolizumab dose is presented below. assuming 100 completed subjects Sample 
sizes of both 100 and 50 completed subjects are included, corresponding to the number of 
subjects planned to use the autoinjectors with labelling that includes a pictogram plus 
standard labelling elements and the standard labelling without the pictogram 
respectively:-


2016N275054_04
CONFIDENTIAL
204959
98
95% CI
(Exact Method)
Observed Proportion
(%)
N=100
N=50
70
60, 79
55, 82
80
71, 87
66, 90
82
73, 89
69, 91
84
75, 91
71, 93
86
78, 92
73, 94
88
80, 94
76, 95
90
82, 95
78, 97
92
85, 96
81, 98
94
87, 98
83, 99
96
90, 99
86, 100
98
93, 100
89, 100
Section 9.4.1 Analyses to Evaluate Autoinjector
Rationale for change: To indicate that the results will be reported separately according 
to the format of the label being used.
Added text:
All analyses to evaluate the autoinjector will be reported separately for subjects using 
autoinjectors with labelling that includes a pictogram plus standard labelling elements or 
subjects using the standard labelling without the pictogram.


2016N275054_04
CONFIDENTIAL
204959
99
12.9.2.
Protocol Amendment 01
Scope:
This amendment applies to all sites.
Protocol Changes specified in Amendment No.1 are summarised below.
Strike through text refers to deleted text and underlined refers to added text.
Protocol Changes
Section 1 Protocol Synopsis - Objective(s)/Endpoints
Rationale for change: To present the primary endpoint in a tabular format and include 
the secondary endpoint, as per GSK protocol template standard.
Revised text:
The primary endpoint is the proportion of subjects successfully able to self-administer 
their observed third dose using the safety syringe at the clinic at Week 8.
The primary and secondary objectives and associated endpoints are outlined below:
Objectives
Endpoints
Primary

To assess the use of the combination 
product, mepolizumab liquid drug 
product in autoinjector for the 
subcutaneous self-administration of 
mepolizumab by subjects with severe 
eosinophilic asthma

Proportion of subjects successfully able 
to self-administer their observed third 
dose at Week 8
Secondary

To assess the use of mepolizumab 
liquid drug product in autoinjector 
outside the clinic setting

Proportion of subjects successfully 
able to self-administer their 
unobserved second dose outside the 
clinic setting at Week 4
Section 4.1 Overall Design 
Rationale for change: To refine the criteria for a successful injection following a use-
related risk review


2016N275054_04
CONFIDENTIAL
204959
100
Revised text: 

Autoinjector positioned with the yellow needle guard flat on the skin and pushed 
all the way down until a full dose is administered (for a full dose to be 
administered, the subject must either wait for the second click, the plunger to stop 
moving, the inspection window to be filled with the yellow indicator or hold the 
autoinjector down for a total of 15 seconds)

Full dose administration: subject pushes the autoinjector all the way down and 
holds until either the second click, or the plunger stops moving and the inspection 
window is filled with the yellow indicator or pushes the autoinjector all the way 
down and holds for a total of 15 seconds
Section 5.1 Inclusion Criterion No. 9/ Exclusion Criterion No. 15
Rationale for change: Included additional text to Inclusion Criterion 9 to allow 
Exclusion Criterion 15 to be removed:
Revised text:
9. Gender: Male or Female
Females: 
A female subject is eligible to participate if she is not pregnant (as confirmed by a 
negative urine human chorionic gonadotrophin (hCG) test), planning to become pregnant 
during the time of study participation (and up to 16 weeks after the last dose), not 
lactating, and at least one of the following conditions applies:
15.  Pregnancy: Subjects who are pregnant or breastfeeding. Patients should not be 
enrolled if they plan to become pregnant during the time of study participation (and up to 
16 weeks after the last dose).
Section 5.1 Exclusion Criterion No. 7
Rationale for change: To allow Bazett’s to be used as the correction formula for heart 
rate when measuring the QT interval consistent with text elsewhere in the protocol.
Revised Text:
7.  ECG Assessment: QT interval corrected for heart rate by either Fridericia’s or 
Bazett’s formula QTc(F)/QTc(B) ≥450msec or QTc(F)/QTc(B) ≥480 msec for subjects 
with Bundle Branch Block at Visit 1.
Section 7.3 Assessment of Autoinjector Use
Rational for change: To refine the criteria for a successful injection following a use-
related risk review


2016N275054_04
CONFIDENTIAL
204959
101
Revised text:
At Visit 2 (Week 0), and at Visit 4 (Week 8), the investigator or designee will observe, 
using a checklist based on the autoinjector IFU, the ability of the subject/caregiver to 
(self)-administer the injection. The Observer Checklist (see SRM) will be used to 
determine if each step, according to the IFU, was completed easily, with some difficulty 
or not completed/intervention required.
Failure to perform one of the critical steps, i.e., correct choice of injection site, 
autoinjector positioned with the yellow needle guard flat on the skin and pushed all the 
way down until and a full dose is administered (for a full dose to be administered,
determined by the subject must pushing the autoinjector all the way down and holding 
until either wait for the second click, or the plunger to stops moving, and the inspection 
window to be is filled with the yellow indicator or hold by the autoinjector being pushed 
all the way down and held for a total of 15 seconds) will be deemed to be a failure to 
successfully administer the injection.
Section 10.7 Provision of Study Results to Investigators
Rationale for change: Delete text related to randomization codes as study is open-label 
and randomization codes will not be used.
Revised text: 
GSK will provide the investigator with the randomization codes for their site only after 
completion of the full statistical analysis.
Section 11 References
Rationale for change: References not cited in the document.
Revised text:
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology. 19th edition. New York: Ardent Media, 2007(a): 24. Table 3-
2.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology. 19th edition. New York: Ardent Media, 2007(b): 28.
Section 12.3.4 Appendix 3 
Rationale for change: References not cited in document
Revised text:
CHMP, 2005 - EMA - Guideline on Adjuvants in Vaccines for Human Use, 
(CHMP/VEG/134716/2004), January 2005.


2016N275054_04
CONFIDENTIAL
204959
102
Cole LA, Khanlian SA, Sutton JM, Davies S, Rayburn WF. Accuracy of home pregnancy 
tests at the time of missed menses. Am J Ob Gyn 2004(190):100-5.
EMA/CHMP/ICH/449035/2009: General principles to address virus and vector shedding. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/
WC500002680.pdf Accessed 28 Nov 2014.
EMEA/CHMP/GTWP/125459/2006: Guideline on the Nonclinical Studies Required 
Before First Clinical Use of Gene Therapy Medicinal Products [2008]
FDA CBER Guidance for industry, “Considerations for Developmental Toxicity Studies 
for Preventive and Therapeutic Vaccines for Infectious Disease Indications. U.S. FDA; 
Feb. 2006. 
FDA Medical Devices Safety Alerts and Notices, “Blood human chorionic gonadotropin 
(hCG) assays: What laboratorians should know about false-positive results”, 
http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/TipsandArticlesonDeviceS
afety/ucm109390.htm, accessed 17 Nov 2014.
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use. ICH Harmonized Tripartite Guideline. Detection of 
Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility. Parent 
Guideline dated 24 June 1993 (Addendum dated 9 November 2000 incorporated in 
November 2005. ICH S5 (R2)
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use.  ICH Harmonized Tripartite Guideline. Nonclinical 
Evaluation for Anticancer Pharmaceuticals. ICH S9. 2009.
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use. ICH Harmonized Tripartite Guideline. Nonclinical 
Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for 
Pharmaceuticals. ICH M3 (R2). 2009.
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals For Human Use. ICH Harmonized Tripartite Guideline. Preclinical 
Safety Evaluation of Biotechnology-Derived Pharmaceuticals. ICH S6 and Addendum 
ICH S6 (R1). 2011.
U.S. Dept of Health and Human Services, FDA, Center For Biologics Evaluation and 
Research: Guidance for Human Somatic Cell Therapy and Gene Therapy [1998]
WHO, 2013 - WHO - Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants 
and Adjuvanted Vaccines, 2013
World Health Organization. WHO/CONRAD Technical Consultation on Nonoxynol-9.
World Health Organization; Department of Reproductive Health and Research; Geneva; 
9-10 October 2001. Summary Report. 2001. WHO/RHR/03.8.

SAP_001.pdf: 
CONFIDENTIAL
The GlaxoSmithKline group of companies
204959
1
Division
:
Worldwide Development
Information Type
:
Reporting and Analysis Plan (RAP)
Title
:
Reporting and Analysis Plan for Study 204959: An 
open-label, single arm, repeat dose, multi-centre study to 
evaluate the use of an autoinjector for the subcutaneous 
administration of mepolizumab in subjects with severe 
eosinophilic asthma.
Compound Number
:
SB-240563
Effective Date 
:
30-NOV-2017
Description :

The purpose of this RAP is to describe the planned analyses and associated data 
displays to be included in the Clinical Study Report for Protocol 204959.

This RAP defines the content of the final Statistical Analysis Complete (SAC) 
deliverable
RAP Author(s):
Approver
Date
Approval Method
Statistics Leader, Clinical Statistics
16-NOV-2017
eSignature
Copyright 2017 the GlaxoSmithKline (GSK) group of companies. All rights reserved.  
Unauthorised copying or use of this information is prohibited.
PPD


CONFIDENTIAL
The GlaxoSmithKline group of companies
204959
2
RAP Team Approvals:
Approver
Date
Approval Method
Director, Clinical Pharmacology
17-NOV-2017
eSignature
Product Physician Lead
30-NOV-2017
email
Clinical Investigational Lead
17-NOV-2017
eSignature
Global Clinical Safety and Pharmacovigilance
16-NOV-2017
eSignature
Clinical Operations
21-NOV-2017
eSignature
Data Quality Lead
16-NOV-2017
eSignature
Programmer/Analyst, Clinical Programming
22-NOV-2017
eSignature
Medical Writer
14-NOV-2017
email
Clinical Statistics and Clinical Programming Line Approvals:
Approver
Date
Approval Method
Director, Clinical Programming 
14-NOV-2017
email
Director, Clinical Statistics
16-NOV-2017
eSignature
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD


CONFIDENTIAL
204959
3
TABLE OF CONTENTS
PAGE
1.
INTRODUCTION......................................................................................................5
2.
SUMMARY OF KEY PROTOCOL INFORMATION ..................................................5
2.1.
Changes to the Protocol Defined Statistical Analysis Plan............................5
2.2.
Study Objective(s) and Endpoint(s)...............................................................5
2.3.
Study Design ................................................................................................7
2.4.
Statistical Hypotheses...................................................................................8
3.
PLANNED ANALYSIS..............................................................................................9
3.1.
Interim Analyses ...........................................................................................9
3.2.
Final Analyses ..............................................................................................9
4.
ANALYSIS POPULATIONS ...................................................................................10
4.1.
Protocol Deviations.....................................................................................10
5.
CONSIDERATIONS FOR DATA ANALYSES AND DATA HANDLING 
CONVENTIONS.....................................................................................................11
5.1.
Methods for Handling Centres ....................................................................11
5.2.
Multiple Comparisons and Multiplicity .........................................................11
5.3.
Handling of Missing Data............................................................................11
5.4.
Data Display Standards ..............................................................................12
5.4.1.
Study Treatment Descriptors .......................................................12
5.4.2.
Autoinjector Label Descriptors .....................................................12
5.4.3.
Sub-group Display Descriptors ....................................................12
5.5.
Other Considerations for Data Analysis and Data Handling 
Conventions................................................................................................13
6.
STUDY POPULATION ANALYSES .......................................................................14
7.
ANALYSES TO EVALUATE AUTOINJECTOR ......................................................15
7.1.
Primary Analysis.........................................................................................15
7.2.
Secondary Analyses ...................................................................................15
8.
PHARMACOKINETIC ANALYSES.........................................................................17
9.
BLOOD EOSINOPHILS..........................................................................................18
10. EXACERBATIONS.................................................................................................18
11. SAFETY ANALYSES .............................................................................................19
11.1.
Adverse Event Analyses.............................................................................19
11.1.1.
Adverse Events of Special Interest ..............................................19
11.2.
Clinical Laboratory Analyses.......................................................................19
11.3.
Other Safety Analyses ................................................................................20
11.3.1.
Injection Pain Assessment...........................................................20
12. IMMUNOGENICITY ANALYSES............................................................................20
12.1.
Overview of Immunogenicity Analyses........................................................20


CONFIDENTIAL
204959
4
13. REFERENCES.......................................................................................................21
14. APPENDICES........................................................................................................22
14.1.
Appendix 1: Schedule of Activities ..............................................................23
14.1.1.
Protocol Defined Time & Events ..................................................24
14.2.
Appendix 2: Study Phases and Treatment Emergent Adverse 
Events ........................................................................................................27
14.2.1.
Treatment Phases .......................................................................27
14.2.1.1.
Treatment Phases for Adverse Events .......................27
14.2.1.2.
Treatment Phases for Exacerbations..........................27
14.3.
Appendix 3: Data Handling Conventions.....................................................28
14.3.1.
Baseline Definition & Derivations .................................................28
14.3.1.1.
Baseline Definitions....................................................28
14.3.1.2.
Derivations and Handling of Missing Baseline 
Data ...........................................................................28
14.3.2.
Reporting Process & Standards...................................................28
14.4.
Appendix 4: Derived and Transformed Data ...............................................31
14.4.1.
General........................................................................................31
14.4.2.
Study Population..........................................................................31
14.4.3.
Evaluation of Autoinjector ............................................................32
14.4.4.
Safety ..........................................................................................32
14.5.
Appendix 5: Reporting Standards for Missing Data.....................................33
14.5.1.
Premature Withdrawals................................................................33
14.5.2.
Handling of Missing Data.............................................................33
14.5.3.
Handling of Missing Dates ...........................................................34
14.5.4.
Handling of Missing Time Point for Assessment of 
Injection Pain...............................................................................34
14.6.
Appendix 6: Values of Potential Clinical Importance ...................................35
14.6.1.
Laboratory Values of Potential Clinical Concern ..........................35
14.7.
Appendix 7: Abbreviations & Trade Marks ..................................................36
14.7.1.
Abbreviations...............................................................................36
14.7.2.
Trademarks .................................................................................37
14.8.
Appendix 8: List of Data Displays ...............................................................38
14.8.1.
Study Population Tables..............................................................39
14.8.2.
Evaluation of Autoinjector ............................................................41
14.8.3.
Pharmacokinetic Analyses...........................................................44
14.8.4.
Pharmacodynamic Analyses........................................................46
14.8.5.
Exacerbations..............................................................................48
14.8.6.
Safety Analyses...........................................................................49
14.8.7.
Immunogenicity............................................................................56
14.8.8.
ICH and Other Listings.................................................................57
14.9.
Appendix 9: Example Mock Shells for Data Displays ..................................63


CONFIDENTIAL
204959
5
1.
INTRODUCTION
The purpose of this RAP is to describe the analyses to be included in the Clinical Study 
Report (CSR) for Protocol 204959:
Protocol Revision Chronology:
2016N275054_01
18-AUG-2016
Original
2016N275054_03
13-OCT-2016
Amendment No. 1: Updated to refine the criteria for a 
successful injection, and amend exclusion criteria 7 and 
15.
2016N275054_04
15-FEB-2017
Amendment No. 2: Updated to include a change to the 
labelling of the autoinjector in some geographical 
regions, and amend inclusion criteria 5.
All subjects in this study were recruited after the effective date of Protocol 
Amendment 2.
2.
SUMMARY OF KEY PROTOCOL INFORMATION
2.1.
Changes to the Protocol Defined Statistical Analysis Plan
An additional analysis population was defined for reporting screen failures and inclusion 
exclusion criteria deviations. This population is described in Section 4.
There are no other changes to the protocol defined statistical analysis plan.
2.2.
Study Objective(s) and Endpoint(s)
Objectives
Endpoints
Primary Objectives
Primary Endpoint

To assess the use of the 
combination product, mepolizumab 
liquid drug product in autoinjector, 
for the subcutaneous 
self-administration of mepolizumab 
by subjects with severe 
eosinophilic asthma.

Proportion of subjects successfully able to self-
administer their observed third dose at Week 8.
Secondary Objectives
Secondary Endpoints

To assess the use of mepolizumab
liquid drug product in autoinjector
outside the clinic setting.

Proportion of subjects successfully able to 
self-administer their unobserved second dose 
outside the clinic setting at Week 4
Other Objectives
Other Endpoints

To assess the use of mepolizumab
liquid drug product in autoinjector
both inside and outside of the clinic
setting.

Proportion of subjects successfully able to 
self-administer their observed first dose at Week 0

Proportion of subjects successfully able to 
self-administer both their unobserved second dose 


CONFIDENTIAL
204959
6
Objectives
Endpoints
and observed third observed dose at Weeks 4 and 8

Proportion of subjects successfully able to 
self-administer all three doses at Weeks 0, 4 and 8

To evaluate autoinjector use &
functionality.

Device usability/functionality questionnaire 
completed at the End of Study/Early Withdrawal Visit

To evaluate any autoinjector
injection errors/failures related to 
use or device performance.

Investigator evaluation of user/device errors

Root cause analysis of each unsuccessful injection

To characterise the subject 
experience of using the 
mepolizumab liquid drug product in 
autoinjector.

Subject Exit Interviews completed over the telephone 
after the End of Study/Early Withdrawal Visit

To assess mepolizumab plasma 
trough concentrations (Ctrough) 
following the SC administration of 
mepolizumab liquid drug product in 
autoinjector.

Mepolizumab plasma trough concentrations (Ctrough)
at Weeks 4, 8 and 12

To assess the pharmacodynamic
(PD) effect following the SC 
administration of mepolizumab 
liquid drug product in autoinjector.

Ratio to baseline of blood eosinophils at Weeks 4, 8 
and 12

To assess the frequency of asthma 
exacerbations.

Incidence of asthma exacerbations, expressed as 
the number of subjects with at least one 
exacerbation
Safety Objectives
Safety Endpoints

To evaluate the safety and 
tolerability of mepolizumab liquid 
drug product in autoinjector.

Incidence and frequency of Adverse Events (AEs) / 
Serious Adverse Events (SAEs) including systemic 
reactions and local injection site reactions

Clinically significant change in haematological and/or 
clinical chemistry parameters

Vital signs

12-lead electrocardiogram (ECG)

Incidence of immunogenicity

Level of self-reported pain immediately following,1-
and 24-hours following each injection (patient diary)


CONFIDENTIAL
204959
7
2.3.
Study Design
Overview of Study Design and Key Features
Design Features

12-week treatment period, open-label, single arm, repeat-dose, 
multi-centre study in subjects with severe eosinophilic asthma.

Subjects (or their caregiver, if applicable) will be trained to 
administer mepolizumab liquid drug product in autoinjector prior to 
the first dose (Visit 2).

Each autoinjector will have labelling that includes a pictogram plus 
standard labelling elements, or a standard labelling without the 
pictogram dependant on the country in which it is being used.

Mepolizumab will be self-administered (by subject or caregiver, if 
appropriate) under observation in the clinic for first dose (Visit 2) 
and third dose (Visit 4). The second dose of mepolizumab will be 
self-administered (by subject or caregiver, if appropriate) at home 
without observation following Visit 3.

All injections will be assessed by the investigator for success based 
on 
o
Direct observation of the self-administration if the dose was 
administered in the clinic, and inspection of the autoinjector.
o
Subject/caregiver completed checklist if the dose was 
administered outside the clinic, and inspection of the 
returned autoinjector.
Main Subject Entry 
Criteria

Subjects aged 12 or older with physician diagnosis of asthma for 2 
years.
Either

Subjects receiving 100mg subcutaneous (SC) mepolizumab for the 
treatment of severe eosinophilic asthma every 4 weeks for at least 
12 weeks prior to the study.


CONFIDENTIAL
204959
8
Overview of Study Design and Key Features
or

Subjects not receiving mepolizumab treatment at Visit 1 meeting
additional criteria of asthma of eosinophilic phenotype requiring 
regular treatment with high dose inhaled corticosteroids (ICS)1 in the 
12 months prior to Visit 1, current treatment with an additional 
controller medication besides ICS for at least 3 months, and with 
one or more exacerbations in the 12 months prior to Visit 1. 
1Subjects are permitted to be enrolled without continuous high dose 
ICS, following discussion with the GSK Medical Monitor, providing the 
subject was receiving continuous ICS and the Investigator attests that 
the subject should have been treated with high dose ICS but this was 
precluded by financial or tolerance issues. 
Dosing

100 mg mepolizumab SC every 4 weeks (3 administrations) in thigh, 
abdomen or upper arm (caregiver only).
Treatment 
Assignment

All subjects will receive the same treatment.

Autoinjector labelling will differ dependent on the country: subjects
in the US, UK and Australia will use an autoinjector with a pictogram 
plus standard labelling elements, subjects in all other countries will 
use an autoinjector with standard labelling elements only.
Interim Analysis

No interim analysis is planned.
Time and events

See Appendix 1: Time & Events.
2.4.
Statistical Hypotheses
The study is designed to descriptively evaluate the successful use of the mepolizumab 
liquid drug product in autoinjector for self-administration by subjects with severe 
eosinophilic asthma.
No formal statistical hypothesis testing is planned. Separate summaries of successful use 
will be provided for the group of subjects using labelling that includes a pictogram plus 
standard labelling elements, and the group of subjects using the standard labelling 
without the pictogram. The number and percentage of subjects successfully able to self-
administer each mepolizumab dose will be reported, including 95% confidence intervals 
(CI). No comparison between the labels will be performed.


CONFIDENTIAL
204959
9
3.
PLANNED ANALYSIS
3.1.
Interim Analyses
No interim analysis is planned.
3.2.
Final Analyses
The final planned analyses will be performed after the completion of the following steps:
1.
All subjects have completed the study as defined in the protocol.
2.
All required database cleaning activities have been completed and final database 
release and database freeze (DBF) has been declared by Data Management.


CONFIDENTIAL
204959
10
4.
ANALYSIS POPULATIONS
Population
Definition / Criteria
Analyses Evaluated
All Subjects 
Enrolled (ASE)

All subjects for whom a record exists in the 
data base.

Pre-screen and 
screen failures
All Subjects 
(Safety)

All enrolled subjects attempting at least one 
self-administration of mepolizumab.

Endpoints relating to 
autoinjector use and 
functionality, 
including primary 
endpoint

Study Population

Safety
Pharmacokinetic
(PK)

All enrolled subjects attempting at least one 
self-administration of mepolizumab for whom 
a PK sample was obtained and analysed.

PK
Pharmacodynamic
(PD)

All enrolled subjects attempting at least one 
self-administration of mepolizumab who had 
a baseline PD measurement and at least one 
post-treatment PD measurement.

PD
NOTES : 

Please refer to Appendix 8: List of Data Displays which details the population to be used for each display being 
generated.
4.1.
Protocol Deviations

Protocol deviations will be tracked by the study team throughout the conduct of the 
study in accordance with the Protocol Deviation Management Plan (PDMP).
o
Data will be reviewed prior to DBF to ensure all important deviations are captured 
and categorised on the protocol deviations dataset. 
o
This dataset will be the basis for the summaries and listings of protocol 
deviations.

Important protocol deviations (including deviations related to study 
inclusion/exclusion criteria, conduct of the trial, subject management or subject 
assessment) will be summarised and listed.

A separate summary and listing of all inclusion/exclusion criteria deviations will also 
be provided. This summary will be based on data as recorded on the 
inclusion/exclusion page of the electronic case report form (eCRF).


CONFIDENTIAL
204959
11
5.
CONSIDERATIONS FOR DATA ANALYSES AND DATA
HANDLING CONVENTIONS
5.1.
Methods for Handling Centres
In this multi-centre global study, enrolment will be presented by investigative site within
country.
Each autoinjector will have labelling that includes a pictogram plus standard labelling 
elements, or a standard labelling without the pictogram. Centres in the US, UK and 
Australia will use labelling that includes a pictogram plus standard labelling elements, 
while centres in Canada, Germany, Netherlands, Russia and Sweden will use standard 
labelling without the pictogram.  Separate summaries of successful use will be provided 
for the group of subjects using labelling that includes a pictogram plus standard labelling 
elements, and the group of subjects using the standard labelling without the pictogram.
5.2.
Multiple Comparisons and Multiplicity
No formal hypothesis will be tested in the study. Each endpoint will be considered 
separately and no adjustment for multiplicity will be made.
5.3.
Handling of Missing Data
In general, analysis will be performed on all available data and no imputation will be 
performed for missing data. However, if there are withdrawals from study treatment due 
to issues pertaining to the use of the autoinjector, sensitivity analysis of the primary 
endpoint will be performed. Missing injection success assessments for subjects
withdrawing from study treatment due to issues with the autoinjector will be included in 
the analysis as injection failures i.e. as unsuccessful attempts to self-administer 
mepolizumab. Injection success assessments classed as “not attempted” on the eCRF for 
subjects withdrawing from study treatment due to issues with the autoinjector will also be 
included in this analysis as injection failures.


CONFIDENTIAL
204959
12
5.4.
Data Display Standards
5.4.1.
Study Treatment Descriptors
RandAll NG 
Data Displays for Reporting 
Description
Description
Order
Not applicable
Liquid Autoinjector
1
5.4.2.
Autoinjector Label Descriptors
Analyses to evaluate the autoinjector will be reported separately for the group of subjects 
using autoinjectors with labelling that includes a pictogram plus standard labelling 
elements, and the group of subjects using the standard labelling without the pictogram.
Listings of autoinjector evaluation data will include the following label descriptions:
Reporting Group Descriptions – Autoinjector Label
RandAll NG 
Country
Data Displays for Reporting 
Code
Description
Description
Order
Not applicable
Australia, UK, US
Standard Label + Pictogram
1
Canada, Germany, 
Netherlands, 
Russia, Sweden 
Standard Label
2
5.4.3.
Sub-group Display Descriptors
Data Displays for Reporting
Subgroup Descriptor
Category
Order
Baseline Mepolizumab Use
No
1
Yes
2
Injection Site
Abdomen
1
Upper Arm
2
Thigh
3


CONFIDENTIAL
204959
13
5.5.
Other Considerations for Data Analysis and Data Handling 
Conventions
Table 1 provides an overview of the appendices within the RAP for outlining other 
general considerations for data analyses and data handling conventions. 
Table 1
Overview of Appendices
Section
Component
Section 14.1
Appendix 1: Schedule of Activities
Protocol Defined Time & Events
Section 14.2
Appendix 2: Study Phases and Treatment Emergent Adverse Events

Treatment Phases for Adverse Events

Treatment Phases for Exacerbations
Section 14.3
Appendix 3: Data Display Standards & Handling Conventions

Baseline Definition & Derivations

Reporting Process & Standards
Section 14.4
Appendix 4: Derived and Transformed Data

General

Study Population

Evaluation of Autoinjector

Safety
Section 14.5
Appendix 5: Reporting Standards for Missing Data

Premature Withdrawals

Handling of Missing Data

Handling of Missing and Partial Dates
Section 14.6
Appendix 6: Values of Potential Clinical Importance


CONFIDENTIAL
204959
14
6.
STUDY POPULATION ANALYSES
The study population analyses will be based on the “All Subjects (Safety)” population, 
unless otherwise specified.
Study population analyses including analyses of subject’s disposition, protocol 
deviations, demographic and baseline characteristics, concomitant medications and
exposure will be based on GSK Core Data Standards.  Details of the planned displays are 
presented in Appendix 8: List of Data Displays.


CONFIDENTIAL
204959
15
7.
ANALYSES TO EVALUATE AUTOINJECTOR

All analyses will be based on the “All Subjects (Safety)” population.

All analyses to evaluate the autoinjector will be reported separately for the group of 
subjects using autoinjectors with labelling that includes a pictogram plus standard 
labelling elements, and the group of subjects using the standard labelling without the 
pictogram. No comparison between the labels will be performed.
7.1.
Primary Analysis
The primary endpoint is the proportion of subjects successfully able to self-administer 
their observed third dose at Week 8. 

The number and percentage of subjects successfully able to self-administer their 
observed third dose at Week 8 will be summarized together with 95% CI. 

The denominator for the percentage calculation will be the number of subjects 
attempting an injection at Week 8.

CI for the percentages will be generated using the Exact (Clopper-Pearson) method 
for binomial proportions.

No formal statistical analysis will be conducted and no comparison between labels 
will be performed.

If a subject has more than one attempt to self-administer study treatment at Week 8, 
the first attempt will be included in the primary analysis. The best attempt will also be 
summarised as a supportive analysis. A separate listing of injection success for 
subjects who had more than one attempt to self-administer mepolizumab will be 
provided.

If there are withdrawals from study treatment due to issues pertaining to the use of the 
autoinjector, a sensitivity analysis of the primary endpoint will be performed. Missing 
injection success assessments for subjects withdrawing from study treatment due to 
issues with the autoinjector will be included in the analysis as injection failures i.e. as 
unsuccessful attempts to self-administer mepolizumab. Injection success assessments 
classed as “not attempted” on the eCRF for subjects withdrawing from study 
treatment due to issues with the autoinjector will also be included in this analysis as 
injection failures.
Full details of data displays being presented in Appendix 8: List of Data Displays.
7.2.
Secondary Analyses
The following endpoints will be summarised in the same way as the primary endpoint 
(Section 7.1).


CONFIDENTIAL
204959
16

The number and percentage of subjects successfully able to self-administer their 
unobserved second dose at Week 4. The denominator for the percentage calculation 
will be the number of subjects attempting an injection at Week 4.

The number and percentage of subjects successfully able to self-administer their 
observed first dose at Week 0. The denominator for the percentage calculation will be 
the number of subjects attempting an injection at Week 0.

The number and percentage of subjects successfully able to self-administer both their 
unobserved second dose at Week 4 and their observed third dose at Week 8. The 
denominator for the percentage calculation will be the number of subjects attempting 
an injection at both Week 4 and Week 8.

The number and percentage of subjects successfully able to self-administer all three 
doses at Week 0, 4 and 8. The denominator for the percentage calculation will be the 
number of subjects attempting all three doses at Week 0, 4 and 8.
Data collected on the observer checklist for in-clinic injections and subject completed
checklists for home injections will be summarised. The investigator assessment of 
user/device errors will be summarised by visit. Device usability/functionality assessed by 
the subject at the end of the study will also be summarised.
Full details of data displays being presented in Appendix 8: List of Data Displays.


CONFIDENTIAL
204959
17
8.
PHARMACOKINETIC ANALYSES

The PK analyses will be based on the “PK” population.

Linear and semi-logarithmic individual mepolizumab plasma concentration-time 
profiles will be produced for each subject. Time will be relative to the first dose of 
study treatment. Individual mepolizumab plasma concentration-time profile plots 
grouped by baseline mepolizumab use and by baseline mepolizumab use and 
injection site (performed only for the subset of subjects using the same injection site 
throughout the study) will also be produced.

Mepolizumab plasma concentrations will be listed and summarised by nominal time
and by nominal time and baseline mepolizumab use. Mean (SD) and median profiles 
by nominal time and baseline mepolizumab use will be plotted.

Summaries of mepolizumab plasma concentration-time data will also be produced by 
baseline mepolizumab use and injection site, and mean (SD) and median 
concentration-time profiles by baseline mepolizumab use and injection site will be 
plotted. These summaries will be performed only for the subset of subjects using the 
same injection site throughout the study.

Refer to Appendix 3: Data Handling Conventions, Section 14.3.2 Reporting Process 
& Standards.
Full details of the data displays to be presented are given in Appendix 8: List of Data 
Displays.


CONFIDENTIAL
204959
18
9.
BLOOD EOSINOPHILS

Blood eosinophil analyses will be based on the “Pharmacodynamic” population.

Blood eosinophil values will be loge-transformed prior to summarising. 
Non-detectable values of 0 GI/L, will be replaced by half of the lowest observed 
detectable (non-zero) value in the study data set, prior to log transformation.

Blood eosinophil values will be summarised by visit, and by visit and baseline 
mepolizumab use.

Blood eosinophil values will also be summarised by visit, baseline mepolizumab use 
and injection site. These summaries will be performed only for the subset of subjects 
using the same injection site throughout the study.

Absolute and ratio to baseline blood eosinophils will be listed.
Full details of data displays to be presented are given in Appendix 8: List of Data 
Displays.
10.
EXACERBATIONS
Analyses of exacerbations will be based on the “All Subjects (Safety)” population. The 
number and percentage of subjects with at least one on-treatment exacerbation will be 
summarised. On-treatment exacerbations are defined in Section 14.2.1.2. All 
exacerbation data will be listed.


CONFIDENTIAL
204959
19
11.
SAFETY ANALYSES
Analysis of safety data will be based on the ‘All Subjects (Safety)” population.
11.1.
Adverse Event Analyses
Adverse event analyses including the analysis of AEs, SAEs and other significant AEs 
will be based on GSK Core Data Standards. The details of the planned displays are 
provided in Appendix 8: List of Data Displays.
11.1.1.
Adverse Events of Special Interest
Adverse events of special interest (AESIs) are AEs associated with the identified and 
potential risks of mepolizumab. AESIs reported by the investigator as anaphylaxis 
reactions, systemic reactions (further categorised by the investigator as either allergic 
[type I hypersensitivity] or other systemic reactions) and local injection site reactions are 
collected via targeted eCRF within the study.
AESIs of opportunistic infections, malignancies, serious cardiac, vascular and 
thromboembolic (CVT) events and serious ischemic events will be identified from a list 
of relevant preferred terms maintained within a project level reference dataset created 
based on the MedDRA dictionary available at the time of DBF for this study. Further 
details of how relevant preferred terms are identified are given in the Program Safety 
Analysis Plan (PSAP).
Separate summary tables showing the number and percent of subjects with each type of 
AESI, broken down by preferred term will be created.
For each type of AESI a profile summary table will be produced containing information 
including, but not limited to, the number of occurrences of the event, event 
characteristics, time to onset, intensity, outcome and action taken.
Separate listings of AESIs identified by the investigator as anaphylaxis, allergic (type I 
hypersensitivity), other systemic reactions and local injection site reactions will be 
produced, as well as listings of opportunistic infections, malignancies, serious CVT 
events and serious ischemic events.
11.2.
Clinical Laboratory Analyses
Laboratory evaluations including the analyses of Chemistry laboratory tests, 
Haematology laboratory tests and liver function tests will be based on GSK Core Data 
Standards. The details of the planned displays are provided in Appendix 8: List of Data 
Displays.
A scatter plot of maximum ALT vs baseline ALT, and maximum ALT vs total bilirubin 
will be produced. In addition, if any liver stopping or liver monitoring events occur 
during the study, summaries of liver monitoring/stopping event reporting and 
hepatobiliary laboratory abnormalities will be produced.


CONFIDENTIAL
204959
20
11.3.
Other Safety Analyses
The analyses of non-laboratory safety test results including ECGs and vital signs will be 
based on GSK Core Data Standards, unless otherwise specified. The details of the 
planned displays are presented in Appendix 8: List of Data Displays.
11.3.1.
Injection Pain Assessment
Injection pain assessed immediately after the injection and at 1 and 24 hours 
post-injection, will be summarised by visit and time point. Summary statistics of the 
Visual Analogue Scale (VAS) score for injection pain will be presented. Categorical 
summaries of pain description (sharp/stinging, dull/aching, burning, other), pain relative 
to expectation (greater than expected, less than expected, as expected) and acceptability 
of pain will also be summarised. All injection pain data will be listed.
12.
IMMUNOGENICITY ANALYSES
12.1.
Overview of Immunogenicity Analyses
For the immunogenicity assessment, two types of anti-drug antibody (ADA) assays will 
be performed, a binding antibody assay and a neutralising antibody assay.
For the binding assay, there will be a three tiered analysis: screening, confirmation and 
titration. The screening assay produces a result of positive or negative relative to a 
screening cut point. Positive samples continue with the confirmation assay, which also 
produces a result of positive or negative relative to a confirmation cut point. For positive 
confirmation samples, a titre value will also be obtained to quantify the degree of binding 
in a titration assay and the sample will be tested with the neutralising assay, which also 
reports results as positive or negative.
The binding ADA results at Week 0 and Week 12/Early withdrawal will be summarised 
by visit. Summary statistics for the titre result at Week 12/Early Withdrawal will also be 
presented. Summaries will also be produced by visit and baseline mepolizumab use.
A summary of adverse events by Week 12/Early Withdrawal binding ADA result will be 
produced.
A summary of liquid treatment emergent positive confirmatory binding ADA assays in 
the subset of subjects who did not have a positive confirmatory binding ADA assay prior 
to the first dose of liquid study treatment at Week 0 will also be presented. 
Neutralising antibody assay results will be summarised by visit, and by visit and baseline 
mepolizumab use.
Immunogenicity data will be listed for subjects with at least one positive screening 
binding assay.


CONFIDENTIAL
204959
21
13.
REFERENCES
GlaxoSmithKline Document Number 2016N275054_04 Study ID 204959. An open-
label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for 
the subcutaneous administration of mepolizumab in subjects with severe eosinophilic 
asthma (Study 204959). Report Date 15-FEB-2017. 


CONFIDENTIAL
204959
22
14.
APPENDICES
Section
Appendix
RAP Section 5 : General Considerations for Data Analyses & Data Handling Conventions
Section 14.1
Appendix 1: Schedule of Activities

Protocol Defined Time & Events
Section 14.2
Appendix 2: Study Phases and Treatment Emergent Adverse Events

Treatment Phases for Adverse Events

Treatment Phases for Exacerbations
Section 14.3
Appendix 3: Data Handling Conventions

Baseline Definition & Derivations

Reporting Process & Standards
Section 14.4
Appendix 4: Derived and Transformed Data

General

Study Population

Evaluation of Autoinjector

Safety
Section 14.5
Appendix 5: Reporting Standards for Missing Data

Premature Withdrawals

Handling of Missing Data

Handling of Missing Dates
Section 14.6
Appendix 6: Values of Potential Clinical Importance
Other RAP Appendices
Section 14.7
Appendix 7: Abbreviations & Trade Marks
Section 14.8
Appendix 8: List of Data Displays
Section 14.9
Appendix 9: Example Mock Shells for Data Displays


CONFIDENTIAL
204959
23
14.1.
Appendix 1: Schedule of Activities


CONFIDENTIAL
204959
24
14.1.1.
Protocol Defined Time & Events
Pre-screening Week -6 
to Week -5a 
Screening Week -4 
to Week -1 
Week 0 
(Day 1) 
Week 4 
(7 days) 
Week 8 
(7 days) 
End of Study/ Early Withdrawalb
Week 12 (7 days)
Visit number 
V0 
V1 
V2 
V3 
V4 
V5 
Informed consent 
X 
Demography/child bearing status assessment 
X 
Medical history 
X 
Asthma and Exacerbation history 
X 
Asthma Therapy history 
X 
Smoking history 
X 
Parasitic screeningc
X 
Prior needle use / self-administration assessment 
X 
Inclusion/Exclusion criteria 
X 
Training session 
Xd
Autoinjector self-administration in clinic 
X 
X 
Autoinjector self-administration outside of clinic 
Xe, f
Laboratory: 
Urine pregnancy test 
X 
Xd
Xd
Xd
X 
Haematology (including eosinophils)g / Clinical 
Chemistry 
X 
Xd
Xd
Xd
Xd
Urinalysis 
X 
Immunogenicity 
Xd
Xd
PK 
Xd
Xd
Xd
Xd
Pharmacogeneticsh
X 
Physical/Clinical: 
Vital signsi
X 
Xd
Xd
Xd
X 
12-lead ECG 
X 
X 
Physical examination 
X 
X 
Weight 
X 


CONFIDENTIAL
204959
25
Pre-screening Week -6 
to Week -5a 
Screening Week -4 
to Week -1 
Week 0 
(Day 1) 
Week 4 
(7 days) 
Week 8 
(7 days) 
End of Study/ Early Withdrawalb
Week 12 (7 days)
Visit number 
V0 
V1 
V2 
V3 
V4 
V5 
Concomitant Medication 
X 
X 
X 
X 
X 
X 
Asthma Exacerbations
X
X
X
X
X
Serious Adverse Eventsj,k,l
X 
X 
X 
X 
X 
X 
Adverse Eventsj,k,l
X 
X 
X 
X 
Dispense patient diary 
Xm
X 
X 
Return/review patient diary 
X 
X 
Xn
Dispense autoinjector for self-administration 
outside of clinic 
X
Return/ inspect autoinjector following self-
administration outside of clinic 
X 
Xn,o
Subject completed pain assessment diary (0, 1-
and 24hours post dose) 
X 
Xf
X 
Autoinjector observer assessment checklist 
X 
X 
Subject/caregiver completed autoinjector
checklist 
Xf
Assessment of injection success 
X 
Xp
Device usability/functionality questionnaire 
X 
Exit Interviewq
(X) 
a. Pre-screening Visit (V0) can occur on the same day as the Screening Visit (V1) but must be completed prior to initiating any Visit 1 procedures; The Pre-screening Visit can be 
conducted up to a maximum of 2 weeks prior to the Screening Visit. 
b. The Early Withdrawal Visit will occur 4 weeks (7 days) after last dose of mepolizumab for any subject who withdraws prior to Week 12 
c. Parasitic screening is only required in countries with high-risk or for subjects who have visited high-risk countries in the past 6 months. Sites should use local laboratories. 
d. Perform prior to mepolizumab administration during the study and prior to restarting pre-study mepolizumab treatment on study completion/early withdrawal. 
e. Subjects will be instructed to contact clinical study staff at any time if they have concerns or questions regarding self-administration.  They will have the option of returning to the 
clinical site for further training or assistance with self-administration.  Requirement for additional training or assistance will be documented. 
f. Self-administration of mepolizumab using the autoinjector should occur within 24 hours following the clinic visit. 
g. Includes measurement of eosinophil levels for pharmacodynamic analysis at Visits 2, 3, 4 and 5 (Week 0, 4, 8 and 12)
h. Pharmacogenetic sample may be drawn any time after the respective informed consent form is signed and the subject is enrolled. 
i. Vital signs include temperature, sitting blood pressure, respiratory rate and pulse. 


CONFIDENTIAL
204959
26
j. Any SAEs assessed as related to study participation (e.g., study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK 
concomitant medication, will be recorded from the time a subject consents to participate in the study up to and including any follow up contact. All other AEs/SAEs are recorded from 
the start of study treatment until the End of Study / Early Withdrawal visit. 
k. Injection site reactions (e.g., induration, erythema, edema, rash, pruritus, pain) are to be recorded on both AE and SAE CRF forms. 
l. Information on systemic reactions and events that meet the anaphylaxis criteria is collected on both AE and SAE CRF forms. 
m. Patient diary should be dispensed prior to administration of injection 
n. For any subject who withdraws prior to Week 12 (V5), patient diary and study drug for self-administration outside of clinic will be returned at the Early Withdrawal visit (if applicable). 
o. Assessment to be completed at the Early Withdrawal visit only if the dose of mepolizumab immediately prior to withdrawal was administered outside of the clinic. 
p. Includes both the injection outside the clinic from Week 4 (V3) and the injection in clinic at Week 8 (V4)
q. In a subset of subjects only. Completed over the telephone after the End of Study/Early Withdrawal Visit


CONFIDENTIAL
204959
27
14.2.
Appendix 2: Study Phases and Treatment Emergent 
Adverse Events
14.2.1.
Treatment Phases
Assessments and events will be classified according to the time of occurrence relative to 
the first dose of study treatment.
14.2.1.1.
Treatment Phases for Adverse Events
Treatment State
Definition
Pre-Treatment

AE start date < First dose of study treatment1
On-Treatment

First dose of study treatment1 ≤ AE start date ≤ Last dose of study treatment + 
28 days

Any AE with missing start date will be assumed to be “On-Treatment”.

Any AE with partial start date will be assumed to be “On-Treatment” unless 
there is evidence to the contrary (e.g. month/year of onset is present and is 
earlier than the month/year of the first dose of study treatment).
Post-Treatment

AE start date > Last dose of study treatment + 28 days
1Note: the first dose of study treatment will be defined as the earliest dosing date/time entered into the eCRF,
regardless of whether self-administration of the injection was successful i.e. full dose administered for this dosing 
occasion.
14.2.1.2.
Treatment Phases for Exacerbations
Treatment State
Definition
Pre-Treatment

Exacerbation onset date < First dose of study treatment1
On-Treatment

First dose of study treatment1 ≤ exacerbation onset date ≤ Last dose of study 
treatment + 28 days

Any exacerbation with missing onset date will be assumed to be “On-
Treatment”.

Any exacerbation with partial onset date will be assumed to be “On-Treatment” 
unless there is evidence to the contrary (e.g. month/year of onset is present 
and is earlier than the month/year of the first dose of study treatment).
Post-Treatment

Exacerbation onset date > Last dose of study treatment + 28 days
1Note: the first dose of study treatment will be defined as the earliest dosing date/time entered into the eCRF,
regardless of whether self-administration of the injection was successful i.e. full dose administered for this dosing 
occasion.


CONFIDENTIAL
204959
28
14.3.
Appendix 3: Data Handling Conventions
14.3.1.
Baseline Definition & Derivations
14.3.1.1.
Baseline Definitions

Baseline will be defined for all subjects in the ‘All Subjects (Safety)’ population.

The baseline values for each assessment will be the latest available assessment prior 
to administration of mepolizumab at Visit 2.
14.3.1.2.
Derivations and Handling of Missing Baseline Data
Definition
Reporting Details
Change from Baseline
= Post-Dose Visit Value – Baseline
% Change from Baseline
= 100 x [(Post-Dose Visit Value – Baseline) / Baseline]
Ratio to Baseline
= Visit Value / Baseline
NOTES :

Unless otherwise specified, the baseline definitions specified in Section 14.3.1.1 will be used for derivations for 
endpoints / parameters and indicated on summaries and listings.

Unless otherwise stated, if baseline data is missing no derivation will be performed and will be set to missing.
14.3.2.
Reporting Process & Standards
Reporting Process
Software

The currently supported versions of SAS software will be used.
Reporting Area
HARP Server
: uk1salx00175
HARP Area
: sb240563/mid204959
Analysis Datasets 

Analysis Data Model (ADaM) datasets will be created according to Clinical Data Interchange 
Standards Consortium (CDISC) standards.

For creation of ADaM datasets (ADCM/ADAE), the same version of dictionary datasets will be 
implemented for conversion from System Independent (SI) to Study Data Tabulation Model 
(SDTM).
Generation of RTF Files

Rich text format (RTF) files will be generated for the final reporting effort.
Reporting Standards
General

The current GSK Integrated Data Standards Library (IDSL) will be applied for reporting, unless 
otherwise stated:
o
4.03 to 4.23: General Principles
o
5.01 to 5.08: Principles Related to Data Listings
o
6.01 to 6.11: Principles Related to Summary Tables


CONFIDENTIAL
204959
29
Reporting Standards
o
7.01 to 7.13: Principles Related to Graphics 
o
Safety and study population displays will be based on the core IDSL templates for these 
data types.
Formats

The reported precision (decimal places [DPs]) will follow the IDSL statistical principles but may 
be adjusted to a clinically interpretable number of DPs.
Planned and Actual Time

Reporting for tables, figures and formal statistical analyses:

Planned time relative to dosing will be used in figures, summaries, statistical analyses and 
calculation of any derived parameters, unless otherwise stated.

The impact of any major deviation from the planned assessment times and/or scheduled 
visit days on the analyses and interpretation of the results will be assessed as appropriate.

Reporting for Data Listings: 

Planned and actual time relative to study drug dosing will be shown in listings (Refer to 
IDSL Statistical Principle 5.05.1).

Unscheduled or unplanned readings will be presented within the subject’s listings. 

Visits outside the protocol defined time-windows (i.e. recorded as protocol deviations) will 
be included in listings.
Unscheduled Visits

Data recorded at an unscheduled visit will be re-assigned in the ADaM data sets to the closest 
nominal visit at which collection of data was scheduled, unless information already exists at 
that visit. Unscheduled data re-assigned to a scheduled visit will be reported in summary tables 
and figures. Unscheduled data that is not re-assigned to a scheduled visit will not be included 
in summary tables or figures by scheduled visit, with the exception of any unscheduled 
assessments of injection success which may be included in the summary of “best attempt” 
investigator assessment of self-administration of study treatment if appropriate – see Section 
7.1. Unscheduled data that is not re-assigned to a scheduled visit will be considered in the 
derivation of baseline or highest/worst case post-baseline result for the summary tables.

Data from all unscheduled visits will be included in listings and individual subject figures.
Early Withdrawal Visits

Data recorded at the early withdrawal visit will be re-assigned in the ADaM data sets to the 
next scheduled visit, unless information already exists at that visit. Early withdrawal data re-
assigned to a scheduled visit will be reported at that visit in summary tables and figures. Early 
withdrawal visit data that is not re-assigned to a scheduled visit will not be included in summary 
tables or figures by scheduled visit. However early withdrawal data that is not re-assigned to a 
scheduled visit will be considered in the derivation of highest/worst case post-baseline result 
for the summary tables.

Data from all early withdrawal visits will be included in listings and individual subject figures.
Descriptive Summary Statistics
Continuous Data
Refer to IDSL Statistical Principle 6.06.1
Categorical Data
N, n, frequency, %
Reporting of Pharmacokinetic Concentration Data
Descriptive 
Refer to IDSL Statistical Principle 6.06.1


CONFIDENTIAL
204959
30
Reporting Standards
Summary Statistics
Assign zero to non-quantifiable (NQ) values (Refer to GUI_51487 for further 
details)
Graphical Displays

Refer to IDSL Statistical Principals 7.01 to 7.13.


CONFIDENTIAL
204959
31
14.4.
Appendix 4: Derived and Transformed Data
14.4.1.
General
Multiple Measurements at One Time Point

May arise when unscheduled visits are re-assigned to a nominal visit (see Section 14.3.2). If 
there is data at the nominal visit, the nominal visit data will be used in the summary tables and 
figures, with the exception of any unscheduled assessments of injection success which may be 
included in the summary of “best attempt” investigator assessment of self-administration of 
study treatment if appropriate – see Section 7.1. All assessments will be listed.

Subjects having both High and Low values for Normal Ranges at any post-baseline visits for 
safety parameters will be counted in both the High and Low categories of “Any visit post-
baseline” row of related summary tables. This will also be applicable to relevant Potential 
Clinical Importance (PCI) summary tables.
Study Day

Calculated as the number of days from the earliest dosing date/time entered into the eCRF,
regardless of whether self-administration of the injection was successful i.e. full dose 
administered for this dosing occasion.

Ref Date = Missing           → Study Day = Missing 

Ref Date < Visit 2 Date     → Study Day = Ref Date – Visit 2 Date    

Ref Data ≥ Visit 2 Date     → Study Day = Ref Date – (Visit 2 Date) + 1    
14.4.2.
Study Population
Demographics
Age

GSK standard IDSL algorithms will be used for calculating age where birth day and month will 
be imputed ‘30th June’.

Birth date will be presented in listings as ‘YYYY’.

Age will be calculated relative to the date of the screening visit (Visit 1).
Body Mass Index (BMI)

Calculated as Weight (kg) / [Height (m)2]
Disease Duration

Calculated in years as Number of Years + (Number of Months)/12
Extent of Exposure

Number of months of exposure to liquid mepolizumab during this study will be calculated based 
on the formula: 
Duration of Exposure (Months) = (Date of Last Dose of Study Treatment – Date of First 
Dose of Study Treatment + 29) × 12/365.25

The first dose of study treatment will be defined as the earliest dosing date/time entered into the 
eCRF, regardless of whether self-administration of the injection was successful i.e. full dose 
administered for this dosing occasion.


CONFIDENTIAL
204959
32
14.4.3.
Evaluation of Autoinjector
Time from removal of autoinjector from storage to injection

Calculated in minutes as Time of Injection – Time Autoinjector Removed from Storage
14.4.4.
Safety
Adverse Events
Drug Related AEs
AEs with relationship marked ‘YES’ or relationship missing.
AEs Leading to Permanent Discontinuation from Study Treatment or Withdrawal from the Study 
AEs with action marked “Study treatment withdrawn” or withdrawn from study status marked “YES”, 
or a response to either of these questions is missing.
AE Time Since First Dose (Days)

If AE start date < Date of first dose of study treatment then 
Time since first dose  = AE start date - Date of first dose of study treatment

If AE start date ≥ Date of first dose of study treatment then 
Time since first dose = AE start date – Date of first dose of study treatment +1

Missing if AE start date or date of first dose of study treatment is missing.
AE Duration (Days)

AE end date – AE start date + 1

Missing if AE start date or end date is missing.
AESIs

See Section 11.1.1


CONFIDENTIAL
204959
33
14.5.
Appendix 5: Reporting Standards for Missing Data
14.5.1.
Premature Withdrawals
Element
Reporting Detail
General

Subject study completion is defined as completion of the End of Study (Week 
12) visit.

Withdrawn subjects will not be replaced in the study.

All available data from subjects who were withdrawn from the study will be listed 
and all available planned data will be included in summary tables and figures, 
unless otherwise specified.
Pre-Screen 
and Screen 
Failures

A subject will be assigned a subject number at the time when the informed 
consent form (ICF) is signed. 

A subject who is assigned a subject number but does not have any screening 
procedures at Visit 1 will be considered a pre-screen failure.

A subject who completes at least one Visit 1 procedure but does not attempt to 
self-administer a dose of mepolizumab will be considered a screen failure.
14.5.2.
Handling of Missing Data
Element
Reporting Detail
General

In general, analysis will be performed on all available data and no imputation will 
be performed for missing data. However, if there are withdrawals from the study 
due to issues pertaining to the use of the autoinjector, a sensitivity analysis of 
the primary analysis will be performed. Missing or “not attempted” injection 
success assessments following these withdrawals will be imputed as injection 
failures i.e. unsuccessful attempts to self-administer mepolizumab in this 
sensitivity analysis.

Missing data occurs when any requested data is not provided, leading to blank 
fields on the collection instrument. These data will be indicated by the use of a 
“blank” in subject listing displays, unless all data for a specific visit are missing in 
which case the data is excluded from the listing. 

Data below the limit of quantification (BLQ) is not missing data and must be 
displayed as such and included in all listings and summaries.
Outliers

Any subjects excluded from the summaries and/or statistical analyses because 
their values are considered outliers will be documented along with the reason for 
exclusion in the CSR.


CONFIDENTIAL
204959
34
14.5.3.
Handling of Missing Dates
Element
Reporting Detail
General

Missing dates will be indicated by the use of a “blank” in subject listing
displays.
AEs

No partial dates will be recorded in this study for AEs or SAEs

Missing start or end dates will remain missing, with no imputation applied. 
Consequently, time to onset and duration of such events will be missing. AEs
with completely missing start dates will be considered to start on-treatment 
(worst case).
14.5.4.
Handling of Missing Time Point for Assessment of Injection Pain
Element
Reporting Detail
Pain Diary

Missing nominal time point description (Injection, 1 hour or 24 hours) in the pain 
diary data may occur if the time of injection is corrected during data cleaning and 
subsequent pain diary assessments fall out of the eDiary defined time window 
for the pain assessment.

Pain diary assessments with missing nominal timepoint will be assigned to the 
closest nominal timepoint, unless data already exists at that timepoint, and will 
be included in summary tables.


CONFIDENTIAL
204959
35
14.6.
Appendix 6: Values of Potential Clinical Importance
14.6.1.
Laboratory Values of Potential Clinical Concern
Haematology
Laboratory Parameter
Units
Age 
Category
Clinical Concern Range
Low Flag (< x)
High Flag (>x)
Hematocrit 
Ratio of 1
12+
0.201 
0.599 
Haemoglobin 
G/L
12+
71
199
Platelet Count 
GI/L
1+
31 
1499 
White Blood Cell Count (WBC)
GI/L
12+
1.1
Clinical Chemistry
Laboratory Parameter
Units
Age
Category
Clinical Concern Range
Low Flag (< x)
High Flag (>x)
ALT
U/L
3-12
>143 (and Total 
Bilirubin >43)
U/L
13+
>239 (and Total 
Bilirubin >43)
Calcium
mmol/L
3+
1.50
3.24
Glucose
mmol/L
1+
2.2
27.8
Phosphorus, Inorg
mmol/L
3+
0.32
Potassium
mmol/L
3+
2.8
6.5
Sodium
mmol/L
0+
120
160
Possible Hy’s Law Cases
Laboratory Parameter
Units
Category
Clinical Concern Range
ALT, Bilirubin
ALT ≥ 3xULN and Bilirubin ≥ 2xULN 
(>35% direct) 
ALT, INR
ALT ≥ 3xULN and INR > 1.5 
NOTES:

ULN = Upper Limit of Normal.


CONFIDENTIAL
204959
36
14.7.
Appendix 7: Abbreviations & Trade Marks
14.7.1.
Abbreviations
Abbreviation
Description
ADA
Anti-drug Antibody
ADaM
Analysis Data Model
AE
Adverse Event
AESI
Adverse Events of Special Interest
A&R
Analysis and Reporting 
ASE
All Subjects Enrolled
BLQ
Below the Limit of Quantification
CDISC
Clinical Data Interchange Standards Consortium
CI
Confidence Interval
CRF
Case Record Form
CSR
Clinical Study Report
Ctrough
Concentration at the end of the dosing interval
CVT
Cardiac, Vascular and Thromboembolic
DBF
Database Freeze
DOB
Date of Birth
DP
Decimal Places
ECG
Electrocardiogram
eCRF
Electronic Case Record Form
GSK
GlaxoSmithKline
ICH
International Conference on Harmonisation
ICS
Inhaled Corticosteroid
IDSL
Integrated Data Standards Library
LLQ
Lower Limit of Quantification
NQ
Non-quantifiable
PCI
Potential Clinical Importance 
PD
Pharmacodynamic
PDMP
Protocol Deviation Management Plan
PK
Pharmacokinetic
PSAP
Program Safety Analysis Plan
RAP
Reporting & Analysis Plan
RTF
Rich Text Format
SAC
Statistical Analysis Complete
SAE
Serious Adverse Event
SC
Subcutaneous
SD
Standard Deviation
SDTM
Study Data Tabulation Model
SI
System Independent
ULN
Upper Limit of Normal
VAS
Visual Analogue Scale
WBC
White Blood Cell


CONFIDENTIAL
204959
37
14.7.2.
Trademarks
Trademarks of the GlaxoSmithKline 
Group of Companies
Trademarks not owned by the 
GlaxoSmithKline Group of Companies
NONE
SAS


CONFIDENTIAL
204959
38
14.8.
Appendix 8: List of Data Displays


CONFIDENTIAL
204959
39
14.8.1.
Study Population Tables
Study Population - Tables
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
6.1
ASE
TAB_POP1
Summary of Study Populations
SAC
6.2
ASE
ES6
Summary of Screen Failures
Include footnote “Note: 
Inclusion/exclusion criteria include 
protocol defined continuation criteria.”
SAC
6.3
ASE
NS1
Summary of Number of Subjects by Country and Site
“Not Treated” column should be added 
to include subjects who did not receive 
treatment.
SAC
6.4
All Subjects
SD1
Summary of IP Discontinuation
SAC
6.5
All Subjects
ES1
Summary of Subject Disposition
SAC
6.6
All Subjects
DV1
Summary of Important Protocol Deviations
SAC
6.7
All Subjects
EX1
Summary of Exposure to Study Treatment (months)
Categories 1, 2, 3 months
Summary statistics for duration of 
exposure (months)
Include footnote: “Note: For the 
categorical summary, exposure is 
rounded to the nearest whole month.
SAC
6.8
All Subjects
TAB_EX1
Summary of Injection Site by Visit
SAC
6.9
All Subjects
DM1
Summary of Demographic Characteristics
SAC
6.10
All Subjects
DM5
Summary of Race and Racial Combinations
SAC
6.11
ASE
DM11
Summary of Age Ranges
“Not Treated” column should be added 
to include subjects who did not receive 
treatment.
SAC
6.12
All Subjects
TAB_POP2
Summary of Disease Duration
SAC
6.13
All Subjects
TAB_POP3
Summary of Prior Experience with Self-Injection of Medication
SAC


CONFIDENTIAL
204959
40
Study Population - Tables
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
6.14
All Subjects
TAB_POP4
Summary of Baseline Mepolizumab Use
SAC
6.15
All Subjects
TAB_POP5
Summary of Previous Mepolizumab Clinical Trials
SAC
6.16
All Subjects
MH4
Summary of Past Medical Conditions
SAC
6.17
All Subjects
MH4
Summary of Current Medical Conditions
SAC
6.18
All Subjects
FH1
Summary of Family History of Cardiovascular Risk Factors
SAC
6.19
All Subjects
SU1
Summary of Smoking History
Smoking status (current/former/never) 
only
SAC


CONFIDENTIAL
204959
41
14.8.2.
Evaluation of Autoinjector
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Evaluation of Autoinjector - Tables
7.1
All Subjects
TAB_INJ1
Summary of the Proportion of Subjects Successfully Able to 
Self-Administer Injection by Visit – First Attempt
Autoinjector with Standard Label + Pictogram
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, only the first attempt is included in 
this summary.”
SAC
7.2
All Subjects
TAB_INJ1
Summary of the Proportion of Subjects Successfully Able to 
Self-Administer Injection by Visit – First Attempt
Autoinjector with Standard Label
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, only the first attempt is included in 
this summary.”
SAC
7.3
All Subjects
TAB_INJ1
Summary of the Proportion of Subjects Successfully Able to 
Self-Administer Injection by Visit – Best Attempt
Autoinjector with Standard Label + Pictogram
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, the best attempt is included in this 
summary.”
SAC
7.4
All Subjects
TAB_INJ1
Summary of the Proportion of Subjects Successfully Able to 
Self-Administer Injection by Visit – Best Attempt
Autoinjector with Standard Label
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, the best attempt is included in this 
summary.”
SAC
7.5
All Subjects
TAB_INJ2
Summary of Investigator Evaluation of User/Device Errors by 
Visit
Autoinjector with Standard Label + Pictogram
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, only the first attempt is included in 
this summary.”
SAC


CONFIDENTIAL
204959
42
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Evaluation of Autoinjector - Tables
7.6
All Subjects
TAB_INJ2
Summary of Investigator Evaluation of User/Device Errors by 
Visit
Autoinjector with Standard Label
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, only the first attempt is included in 
this summary.”
SAC
7.7
All Subjects
TAB_INJ3
Summary of Observer Checklist for In-Clinic Injections
Autoinjector with Standard Label + Pictogram
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, only the first attempt is included in 
this summary.”
SAC
7.8
All Subjects
TAB_INJ3
Summary of Observer Checklist for In-Clinic Injections
Autoinjector with Standard Label
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, only the first attempt is included in 
this summary.”
SAC
7.9
All Subjects
TAB_INJ4
Summary of Subject Completed Checklist for At-Home Injection 
at Week 4
Autoinjector with Standard Label + Pictogram
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, only the first attempt is included in 
this summary.”
SAC
7.10
All Subjects
TAB_INJ4
Summary of Subject Completed Checklist for At-Home Injection 
at Week 4
Autoinjector with Standard Label
Add footnote: “Note: If a subject has 
more than one attempt to self-
administer study treatment at a single 
visit, only the first attempt is included in 
this summary.”
SAC


CONFIDENTIAL
204959
43
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Evaluation of Autoinjector - Tables
7.11
All Subjects
TAB_INJ5
Summary of Device Usability/Functionality Questionnaire
Autoinjector with Standard Label + Pictogram
Add footnote: “Note: Questionnaire was 
not completed by subjects who took 
part in liquid safety syringe study 
205667.”
SAC
7.12
All Subjects
TAB_INJ5
Summary of Device Usability/Functionality Questionnaire
Autoinjector with Standard Label
Add footnote: “Note: Questionnaire was 
not completed by subjects who took 
part in liquid safety syringe study 
205667.”
SAC
7.13
All Subjects
LIST_INJ1
Listing of Investigator Assessment of Injection Success -
Subjects Requiring More Than One Attempt to Self-Administer 
Mepolizumab at any Visit
Include treatment and label description 
in by-line.
SAC


CONFIDENTIAL
204959
44
14.8.3.
Pharmacokinetic Analyses
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
PK Concentration: Figures
8.1
PK
PK16a
Individual Plasma Mepolizumab Concentration-Time Plots 
(Linear and Semi-Log) by Subject
Subject number and baseline 
mepolizumab use as by-line. Indicate 
the injection site used for each dose 
using different plotting characters.
SAC
8.2
PK
PK26
Individual Plasma Mepolizumab Concentration-Time Plots
(Linear and Semi-Log) by Baseline Mepolizumab Use
Baseline mepolizumab use as a by-line. 
All subjects in the same baseline 
mepolizumab group on the same graph 
(“spaghetti” plot).
Due to the number of subjects, legend 
to identify subjects is not required.
SAC
8.3
PK
PK26
Individual Plasma Mepolizumab Concentration-Time Plots
(Linear and Semi-Log) by Baseline Mepolizumab Use and 
Injection Site – Subjects Using the Same Injection Site 
Throughout the Study
Baseline mepolizumab use and 
injection site as a by-line. All subjects in 
the same baseline mepolizumab group 
and injection site on the same graph 
(“spaghetti” plot).
Include only the subset of subjects 
using the same injection site for all 
doses of study treatment.
Due to the number of subjects, legend 
to identify subjects is not required.
SAC
8.4
PK
PK19
Mean Plasma Mepolizumab Concentration-Time Plots by 
Baseline Mepolizumab Use (Linear and Semi-Log)
Include (N=XX) in legend.
SAC
8.5
PK
PK18
Median Plasma Mepolizumab Concentration-Time Plots by 
Baseline Mepolizumab Use (Linear and Semi-Log)
Include (N=XX) in legend.
SAC


CONFIDENTIAL
204959
45
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
8.6
PK
PK19
Mean Plasma Mepolizumab Concentration-Time Plots by 
Baseline Mepolizumab Use and Injection Site (Linear and Semi-
Log) – Subjects Using the Same Injection Site Throughout the 
Study
Include only the subset of subjects 
using the same injection site for all 
doses of study treatment.
Include (N=XX) in legend.
SAC
8.7
PK
PK18
Median Plasma Mepolizumab Concentration-Time Plots by 
Baseline Mepolizumab Use and Injection Site (Linear and Semi-
Log) – Subjects Using the Same Injection Site Throughout the 
Study
Include only the subset of subjects 
using the same injection site for all
doses of study treatment.
Include (N=XX) in legend.
SAC
8.8
PK
-
Scatter Plot of Individual Plasma Mepolizumab Concentration-
Time Data by Week 12 Binding Antibody Result
Use grey open circles for data points for 
subjects with negative binding antibody.
Use larger filled blue circles for data 
points for subjects with positive binding 
antibody, and annotate data points with 
subject number. 
SAC
Pharmacokinetic – Tables
8.1
PK
PK01
Summary of Plasma Mepolizumab Concentration-Time Data 
SAC
8.2
PK
PK01
Summary of Plasma Mepolizumab Concentration-Time Data by 
Baseline Mepolizumab Use
SAC
8.3
PK
PK01
Summary of Plasma Mepolizumab Concentration-Time Data by 
Baseline Mepolizumab Use and Injection Site – Subjects Using 
the Same Injection Site Throughout the Study
Include only the subset of subjects 
using the same injection site for all 
doses of study treatment.
SAC


CONFIDENTIAL
204959
46
14.8.4.
Pharmacodynamic Analyses
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Pharmacodynamic – Figures
9.1
PD
FIG_PD1
Geometric Mean (95% CI) Absolute Blood Eosinophils by Visit 
and Baseline Mepolizumab Use
Include (N=XX) in legend.
SAC
9.2
PD
FIG_PD1
Geometric Mean (95% CI) Absolute Blood Eosinophils by Visit, 
Baseline Mepolizumab Use and Injection Site – Subjects Using 
the Same Injection Site Throughout the Study
Baseline mepolizumab use as by-line. 
Separate lines on graph corresponding 
to injection sites.
Include only the subset of subjects 
using the same injection site for all 
doses of study treatment.
Include (N=XX) in legend.
SAC
9.3
PD
FIG_PD1
Geometric Mean (95% CI) Ratio to Baseline Blood Eosinophils 
by Visit and Baseline Mepolizumab Use
Include (N=XX) in legend.
SAC
9.4
PD
FIG_PD1
Geometric Mean (95% CI) Ratio to Baseline Blood Eosinophils 
by Visit, Baseline Mepolizumab Use and Injection Site –
Subjects Using the Same Injection Site Throughout the Study
Baseline mepolizumab use as by-line. 
Separate lines on graph corresponding 
to injection sites.
Include only the subset of subjects 
using the same injection site for all 
doses of study treatment.
Include (N=XX) in legend.
SAC


CONFIDENTIAL
204959
47
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
9.5
PD
-
Scatter Plot of Individual Blood Eosinophil-Time Data by Week 
12 Binding Antibody Result
Use grey open circles for data points for 
subjects with negative binding antibody.
Use larger filled blue circles for data 
points for subjects with positive binding 
antibody, and annotate data points with 
subject number. 
SAC
Pharmacodynamic – Tables
9.1
PD
TAB_PD1
Summary of Blood Eosinophils (GI/L) by Visit
SAC
9.2
PD
TAB_PD2
Summary of Ratio to Baseline Blood Eosinophils by Visit
SAC
9.3
PD
TAB_PD3
Summary of Blood Eosinophils by Visit and Baseline 
Mepolizumab Use
SAC
9.4
PD
TAB_PD4
Summary of Ratio to Baseline Blood Eosinophils by Visit and 
Baseline Mepolizumab Use
SAC
9.5
PD
TAB_PD3
Summary of Blood Eosinophils by Visit, Baseline Mepolizumab 
Use and Injection Site– Subjects Using the Same Injection Site 
Throughout the Study
Add baseline mepolizumab use to by 
line, and include injection site in first 
column.
Include only the subset of subjects 
using the same injection site for all 
doses of study treatment.
SAC
9.6
PD
TAB_PD4
Summary of Ratio to Baseline Blood Eosinophils by Visit, 
Baseline Mepolizumab Use and Injection Site– Subjects Using 
the Same Injection Site Throughout the Study
Add baseline mepolizumab use to by 
line, and include injection site in first 
column.
Include only the subset of subjects 
using the same injection site for all 
doses of study treatment.
SAC


CONFIDENTIAL
204959
48
14.8.5.
Exacerbations
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Exacerbations: Tables 
10.1
All Subjects
TAB_EX1
Summary of Number of Subjects with at Least One
On-Treatment Exacerbation
SAC


CONFIDENTIAL
204959
49
14.8.6.
Safety Analyses
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Safety : Figures
Adverse Events 
11.1
All Subjects
LIVER14
Scatter Plot of Maximum vs Baseline for ALT
If there are unscheduled assessments 
add footnote: “Note: Maximum Value 
includes scheduled and unscheduled 
assessments.”
SAC
11.2
All Subjects
LIVER9
Scatter Plot of Maximum Total Bilirubin vs Maximum ALT
If there are unscheduled assessments 
add footnote: “Note: Maximum Value 
includes scheduled and unscheduled 
assessments.”
SAC
Safety : Tables 
Adverse Events
11.1
All Subjects
AE1
Summary of All On-Treatment Adverse Events by System Organ 
Class and Preferred Term
SAC
11.2
All Subjects
AE1
Summary of All Post-Treatment Adverse Events by System 
Organ Class and Preferred Term
SAC
11.3
All Subjects
AE3
Summary of Common (>=3% Incidence) On-Treatment Adverse 
Events by Overall Frequency
SAC
11.4
All Subjects
AE15
Summary of Common (>=3% Incidence) On-Treatment Non-
Serious Adverse Events by System Organ Class and Preferred 
Term (Number of Subjects and Occurrences)
SAC


CONFIDENTIAL
204959
50
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Safety : Figures
11.5
All Subjects
AE5A
Summary of All On-Treatment Adverse Events by Maximum 
Intensity by System Organ Class and Preferred Term
SAC
11.6
All Subjects
AE1
Summary of All Drug-Related Adverse Events by System Organ 
Class and Preferred Term
SAC
11.7
All Subjects
AE5A
Summary of All Drug-Related Adverse Events by Maximum 
Intensity by System Organ Class and Preferred Term
SAC
11.8
All Subjects
AE1
Summary of On-Treatment Adverse Events by Week 12 Binding
Antibody Result
Add in row with n in each binding 
antibody result category.
See Section 12.
SAC
11.9
All Subjects
AE3
Summary of All Adverse Events Leading to Permanent 
Discontinuation from Study Treatment and/or Withdrawal from 
the Study by Overall Frequency
SAC
11.10
All Subjects
AE1
Summary of Adverse Events Reported on the Day of Dosing by 
System Organ Class and Preferred Term
SAC
11.11
All Subjects
AE7
Listing of Subject Numbers for Individual On-Treatment Adverse 
Events
SAC
11.12
All Subjects
AE2
Listing of Relationship of Adverse Event, System Organ 
Classes, Preferred Terms and Verbatim Text
SAC
Serious Adverse Events 
11.13
All Subjects
AE3
Summary of Fatal Serious Adverse Events by Overall Frequency
SAC
11.14
All Subjects
AE3
Summary of Drug-Related Fatal Serious Adverse Events by 
Overall Frequency
SAC


CONFIDENTIAL
204959
51
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Safety : Figures
11.15
All Subjects
AE1
Summary of All On-Treatment Serious Adverse Events by 
System Organ Class and Preferred Term
SAC
11.16
All Subjects
AE16
Summary of All On-Treatment Serious Adverse Events by 
System Organ Class and Preferred Term (Number of Subjects 
and Occurrences)
SAC
11.17
All Subjects
AE1
Summary of All Post-Treatment Serious Adverse Events by 
System Organ Class and Preferred Term
SAC
11.18
All Subjects
AE1
Summary of All Pre-Treatment Serious Adverse Events by 
System Organ Class and Preferred Term
SAC
11.19
All Subjects
AE1
Summary of All Drug-Related Serious Adverse Events by 
System Organ Class and Preferred Term
SAC
Adverse Events of Special Interest
11.20
All Subjects
AE1
Summary of On-Treatment Adverse Events Reported by the 
Investigator as Meeting the Criteria for Anaphylaxis
SAC
11.21
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Reported by 
the Investigator as Meeting the Criteria for Anaphylaxis
SAC
11.22
All Subjects
AE1
Summary of On-Treatment Adverse Events Defined by the 
Investigator as Systemic Reactions - Allergic (Type I 
Hypersensitivity) and Other Systemic
SAC
11.23
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Defined by 
the Investigator as Systemic Reactions - Allergic (Type I 
Hypersensitivity) and Other Systemic
SAC


CONFIDENTIAL
204959
52
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Safety : Figures
11.24
All Subjects
AE1
Summary of On-Treatment Adverse Events Defined by the 
Investigator as Systemic Reactions - Allergic (Type I 
Hypersensitivity)
SAC
11.25
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Defined by 
the Investigator as Systemic Reactions - Allergic (Type I 
Hypersensitivity)
SAC
11.26
All Subjects
AE1
Summary of On-Treatment Adverse Events Defined by the 
Investigator as Systemic Reactions – Other Systemic
SAC
11.27
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Defined by 
the Investigator as Systemic Reactions - Other Systemic
SAC
11.28
All Subjects
AE1
Summary of On-Treatment Adverse Events Defined by the 
Investigator as Local Injection Site Reactions
SAC
11.29
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Defined by 
the Investigator as Local Injection Site Reactions
SAC
11.30
All Subjects
AE1
Summary of On-Treatment Adverse Events Categorised as 
Serious Cardiac, Vascular and Thromboembolic Events
SAC
11.31
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Categorised 
as Serious Cardiac, Vascular and Thromboembolic Events
SAC
11.32
All Subjects
AE1
Summary of On-Treatment Adverse Events Categorised as 
Serious Ischemic Events
SAC
11.33
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Categorised 
as Serious Ischemic Events
SAC


CONFIDENTIAL
204959
53
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Safety : Figures
11.34
All Subjects
AE1
Summary of On-Treatment Adverse Events Categorised as 
Malignancies
SAC
11.35
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Categorised 
as Malignancies
SAC
11.36
All Subjects
AE1
Summary of On-Treatment Adverse Events Categorised as 
Opportunistic Infections
SAC
11.37
All Subjects
TAB_S1
Summary Profile of On-Treatment Adverse Events Categorised 
as Opportunistic Infections
SAC
Laboratory - Haematology
11.38
All Subjects
LB1
Summary of Haematology Changes from Baseline by Visit
Include baseline values
SAC
11.39
All Subjects
LB3
Summary of Haematology Shifts from Baseline Relative to 
Normal Range by Visit
SAC
11.40
All Subjects
LB3
Summary of Haematology Shifts from Baseline Relative to PCI 
Criteria by Visit
SAC
Laboratory – Clinical Chemistry
11.41
All Subjects
LB1
Summary of Clinical Chemistry Changes from Baseline by Visit
Include baseline values
SAC
11.42
All Subjects
LB3
Summary of Clinical Chemistry Shifts from Baseline Relative to 
Normal Range by Visit
SAC
11.43
All Subjects
LB3
Summary of Clinical Chemistry Shifts from Baseline Relative to 
PCI Criteria by Visit
SAC


CONFIDENTIAL
204959
54
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Safety : Figures
ECG
11.43
All Subjects
EG1
Summary of ECG Findings by Visit
SAC
11.45
All Subjects
EG2
Summary of ECG Values by Visit
SAC
11.46
All Subjects
EG2
Summary of Change from Baseline in ECG Values by Visit
Include baseline values
SAC
11.47
All Subjects
TAB_ECG1
Summary of Actual and Change From Baseline QTc(F) Values 
by Category (msec)
If there are unscheduled ECGs, include 
“Maximum Value Post Baseline” as an 
additional timepoint and add footnote: 
“Note: Maximum Value Post-Baseline 
includes scheduled and unscheduled 
assessments.”
SAC
11.48
All Subjects
TAB_ECG1
Summary of Actual and Change From Baseline QTc(B) Values 
by Category (msec)
If there are unscheduled ECGs, include 
“Maximum Value Post Baseline” as an 
additional timepoint and add footnote: 
“Note: Maximum Value Post-Baseline 
includes scheduled and unscheduled 
assessments.”
SAC
11.49
All Subjects
TAB_ECG1
Summary of Actual and Change From Baseline QTc (Correction 
Unspecified) Values by Category (msec)
If there are unscheduled ECGs, include 
“Maximum Value Post Baseline” as an 
additional timepoint and add footnote: 
“Note: Maximum Value Post-Baseline 
includes scheduled and unscheduled 
assessments.”
SAC
Vital Signs
11.50
All Subjects
VS1
Summary of Vital Signs by Visit
SAC


CONFIDENTIAL
204959
55
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Safety : Figures
11.51
All Subjects
VS1
Summary of Change from Baseline in Vital Signs by Visit
Include baseline values
SAC
Injection Pain Assessments
11.52
All Subjects
TAB_S3
Summary of Injection Pain – VAS Scores (mm)
By Visit and time point post-injection 
(injection, 1 hr post, 24 hrs post)
SAC
11.53
All Subjects
TAB_S4
Summary of Injection Pain – Categorical Pain Assessment
By Visit and time point post-injection 
(injection, 1 hr post, 24 hrs post)
SAC


CONFIDENTIAL
204959
56
14.8.7.
Immunogenicity
No.
Population
IDSL / TST ID / 
Example Shell
Title
Programming Notes
Deliverable 
[Priority]
Immunogenicity : Tables 
12.1
All Subjects
TAB_S2
Summary of Binding Antibody by Visit
Positive/Negative at Week 0 and Week 
12/Early Withdrawal. For Week 
12/Early Withdrawal, include min, 
median, max values for titre.
SAC
12.2
All Subjects
TAB_S2
Summary of Binding Antibody by Visit and Baseline 
Mepolizumab Use
Positive/Negative at Week 0 and Week 
12/Early Withdrawal. For Week 
12/Early Withdrawal, include min, 
median, max values for titre.
SAC
12.3
All Subjects
TAB_S2
Summary of Binding Antibody – Subjects Without Positive 
Result at Week 0
Positive/Negative at Week 12/Early 
Withdrawal, include min, median, max 
values for titre.
SAC
12.4
All Subjects
TAB_S2
Summary of Neutralising Antibody by Visit
No titre values available for Neutralising 
antibody.
SAC
12.5
All Subjects
TAB_S2
Summary of Neutralising Antibody by Visit and Baseline 
Mepolizumab Use
No titre values available for Neutralising 
antibody.
SAC


CONFIDENTIAL
204959
57
14.8.8.
ICH and Other Listings
ICH and Other Listings
No.
Population
IDSL / TST ID 
/ Example 
Shell
Title
Programming Notes
Deliverable 
[Priority]
Study Population 
1
ASE
ES7
Listing of Reasons for Screen Failure
Include footnote “Note: 
Inclusion/exclusion criteria include 
protocol defined continuation criteria.”
SAC
2
All Subjects
SP3
Listing of Subjects Excluded from Any Population
SAC
3
All Subjects
SD2
Listing of Reasons for Study Treatment Discontinuation
SAC
4
All Subjects
ES2
Listing of Reasons for Study Withdrawal
SAC
5
All Subjects
DV2
Listing of Important Protocol Deviations
SAC
6
All Subjects
IE3
Listing of Subjects with Inclusion/Exclusion Criteria Deviations
Include any deviations in protocol 
defined continuation criteria.
SAC
7
All Subjects
EX3
Listing of Exposure Data
Include the following additional 
variables: injection site, investigator 
assessment of injection success.
Include treatment and label 
description.
SAC
8
All Subjects
LIST_INJ2
Listing of Person Administering Injection[1] and Time From 
Removal of Autoinjector from Storage to Injection
Include data for all 3 doses.
Footnote: “[1] For the at-home 
injection (week 4), the person 
administering the injection is 
documented by the eDiary as the user 
(caregiver/patient) who logged in to 
complete the at-home injection 
checklist.”
SAC


CONFIDENTIAL
204959
58
ICH and Other Listings
No.
Population
IDSL / TST ID 
/ Example 
Shell
Title
Programming Notes
Deliverable 
[Priority]
9
All Subjects
DM2
Listing of Demographic Characteristics
SAC
10
All Subjects
DM9
Listing of Race
SAC
11
All Subjects
LIST_POP1
Listing of Baseline Mepolizumab Use
SAC
12
All Subjects
LIST_POP2
Listing of Previous Mepolizumab Clinical Trials
SAC
13
All Subjects
MH2
Listing of Medical Conditions
SAC
14
All Subjects
FH5
Listing of Family History
SAC
15
All Subjects
CM3
Listing of Concomitant Medications
Include all data collected on the CRF,
plus study day for start date
Evaluation of Autoinjector
16
All Subjects
LIST_INJ1
Listing of Investigator Assessment of Injection Success
Include treatment and label description 
in by-line.
SAC
17
All Subjects
-
Listing of Observer Checklist for In-Clinic Injections
Include treatment and label description 
in by-line.
Exclude information presented in 
Listing 8.
SAC
18
All Subjects
-
Listing of Subject Completed Checklist for At-Home Injection at 
Week 4
Include treatment and label description 
in by-line.
Exclude information presented in 
Listing 8.
SAC
19
All Subjects
-
Listing of Device Usability/Functionality Questionnaire
Include treatment and label description 
in by-line.
SAC


CONFIDENTIAL
204959
59
ICH and Other Listings
No.
Population
IDSL / TST ID 
/ Example 
Shell
Title
Programming Notes
Deliverable 
[Priority]
PK Concentration
20
PK
PK07
Listing of Plasma Concentration-Time Data
SAC
Exacerbations
21
All Subjects
LIST_EX1
Listing of Exacerbations
SAC
Adverse Events 
22
All Subjects
AE8
Listing of All Adverse Events
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC
23
All Subjects
AE8
Listing of Adverse Events Leading to Withdrawal From Study
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC
24
All Subjects
AE8
Listing of Adverse Events Reported on the Day of Dosing
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC
Serious Adverse Events 
25
All Subjects
AE8
Listing of Fatal Serious Adverse Events
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC


CONFIDENTIAL
204959
60
ICH and Other Listings
No.
Population
IDSL / TST ID 
/ Example 
Shell
Title
Programming Notes
Deliverable 
[Priority]
26
All Subjects
AE8
Listing of Non-Fatal Serious Adverse Events
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC
27
All Subjects
AE14
Listing of Reasons for Considering as a Serious Adverse Event
Include treatment in by-line.
SAC
Adverse Events of Special Interest
28
All Subjects
AE8
Listing of Adverse Events Reported by the Investigator as 
Meeting the Criteria for Anaphylaxis
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Add injection reaction symptoms and 
number of doses prior to event.
Include treatment in by-line.
SAC
29
All Subjects
AE8
Listing of Adverse Events Defined by the Investigator as 
Systemic Reactions - Allergic (Type I Hypersensitivity)
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Add injection reaction symptoms and 
number of doses prior to event.
Include treatment in by-line.
SAC
30
All Subjects
AE8
Listing of Adverse Events Defined by the Investigator as 
Systemic Reactions – Other Systemic
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Add injection reaction symptoms and 
number of doses prior to event.
Include treatment in by-line.
SAC


CONFIDENTIAL
204959
61
ICH and Other Listings
No.
Population
IDSL / TST ID 
/ Example 
Shell
Title
Programming Notes
Deliverable 
[Priority]
31
All Subjects
AE8
Listing of Adverse Events Defined by the Investigator as Local 
Injection Site Reactions
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Add injection reaction symptoms and 
number of doses prior to event.
Include treatment in by-line.
SAC
32
All Subjects
AE8
Listing of Adverse Events Categorised as Serious Cardiac, 
Vascular and Thromboembolic Events
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC
33
All Subjects
AE8
Listing of Adverse Events Categorised as Serious Ischemic
Events
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC
34
All Subjects
AE8
Listing of Adverse Events Categorised as Malignancies
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC
35
All Subjects
AE8
Listing of Adverse Events Categorised as Opportunistic 
Infections
Add phase: Pre-treatment, on-
treatment, post-treatment (see Section 
14.2.1.1).
Include treatment in by-line.
SAC


CONFIDENTIAL
204959
62
ICH and Other Listings
No.
Population
IDSL / TST ID 
/ Example 
Shell
Title
Programming Notes
Deliverable 
[Priority]
Laboratory
36
All Subjects
LB5
Listing of Haematology Data for Subjects with Abnormalities of 
Potential Clinical Concern
Include treatment in by-line.
SAC
37
All Subjects
LB5
Listing of Chemistry Data for Subjects with Abnormalities of 
Potential Clinical Concern
Include treatment in by-line.
SAC
ECG
38
All Subjects
EG3
Listing of ECG Values (Subjects with QTc >500 msec or 
Increase >= 60 msec from Baseline)
Include treatment in by-line.
SAC
Injection Pain
39
All Subjects
LIST_S1
Listing of Injection Pain Assessment
Include treatment in by-line.
SAC
Immunogenicity
40
All Subjects
IMM2
Listing of Immunogenicity Data for Subjects with at Least One 
Positive Screening Binding Assay
Include columns for Screening Binding 
Assay, Confirmation Binding Assay, 
Confirmation Binding Assay Titre,
Transient/Persistent, Neutralising 
Antibody Assay
SAC
PD
41
Pharmacodynamic
LIST_PD1
Listing of Blood Eosinophils
SAC


CONFIDENTIAL
204959
63
14.9.
Appendix 9: Example Mock Shells for Data Displays
Example TAB_POP1
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects Enrolled
Table X
Summary of Study Populations
Population
Liquid Autoinjector
(N=XX)
All Subjects Enrolled
XX
All Subjects (Safety)
XX (XX%)
    Autoinjector with Standard Label + Pictogram
XX (XX%)
    Autoinjector with Standard Label
XX (XX%)
Pharmacokinetic
XX (XX%)
Pharmacodynamic
XX (XX%)
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
64
Example TAB_POP2
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X
Summary of Disease Duration
Liquid Autoinjector
(N=XX)
Duration of Disease (years)
n
XX
>=1 to <5
XX (XX%)
>=5 to <10
XX (XX%)
etc.
XX (XX%)
Mean
XX.X
SD
XX.XX
Median
XX.X
Minimum
XX
Maximum
XX
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
65
Example TAB_EX1
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X
Summary of Injection Site
Visit
Injection Site
Liquid Autoinjector
(N=XX)
WEEK 0
n
XX
Abdomen
XX (XX%)
Upper arm
XX (XX%)
Thigh
XX (XX%)
Other, or intervention required
XX (XX%)
WEEK 4
n
XX
Abdomen
XX (XX%)
Upper arm
XX (XX%)
Thigh
XX (XX%)
Other
XX (XX%)
WEEK 8
n
XX
Abdomen
XX (XX%)
Upper arm
XX (XX%)
Thigh
XX (XX%)
Other, or intervention required
XX (XX%)
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
66
Example TAB_POP3
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X
Summary of Prior Experience with Self-Injection of Medication
Visit
Liquid Autoinjector
(N=XX)
Does the subject have any prior experience with 
self-injection of medication?
n
XX
No
XX (XX%)
Yes
XX (XX%)
Autoinjector (Pen)
XX (XX%)
Prefilled syringe
XX (XX%)
Vial and syringe
XX (XX%)
Other method
XX (XX%)
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
67
Example TAB_POP4
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X
Summary of Baseline Mepolizumab Use
Liquid Autoinjector
(N=XX)
Is the subject currently receiving treatment with mepolizumab?
n
XX
No
XX (XX%)
Yes
XX (XX%)
Blood eosinophil count criteria met [1][2]?
n
No
XX (XX%)
Yes
XX (XX%)
Most recent blood eosinophil count prior to starting mepolizumab 
(cells/uL) [2]
n
XX
Median
XX.X
Minimum
XX
Maximum
XX
[1] Blood eosinophil count immediately before starting mepolizumab that was >= 150 cells/uL or a blood eosinophil count 
that was >= 300 cells/uL in the 12 months prior to starting mepolizumab.
[2] Subjects currently receiving treatment with mepolizumab only.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
68
Example TAB_POP5
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X
Summary of Previous Mepolizumab Clinical Trials
Liquid Autoinjector
(N=XX)
Did the subject participate in a previous mepolizumab trial?
n
XX
No
XX (XX%)
Yes
XX (XX%)
Protocol number
115666
XX (XX%)
204471
XX (XX%)
205667
XX (XX%)


CONFIDENTIAL
204959
69
Example TAB_INJ1
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X
Summary of Proportion of Subjects Successfully Able to Self-Administer Injection by Visit – First Attempt
Autoinjector with Standard Label + Pictogram
                                             Liquid Autoinjector (N = XX)
                                   ---------------------------------------------------
                                   Attempted Injections      Successful Injections [1]   
                                   --------------------      -------------------------
                Visit              n (%)                     n (%)     95% CI
               ----------------------------------------------------------------------
                WEEK 0             XX (XX%)                  XX (XX%)   (XX%, XX%)
                WEEK 4             XX (XX%)                  XX (XX%)   (XX%, XX%)
                WEEK 8             XX (XX%)                  XX (XX%)   (XX%, XX%)
                WEEK 4 and 8      XX (XX%)                  XX (XX%)   (XX%, XX%)
                WEEK 0, 4 and 8    XX (XX%)                  XX (XX%)   (XX%, XX%)
[1] The denominator for the percentage of successful injections is the number of attempted injections.
Note: If a subject has more than one attempt to self-administer study treatment at a single visit, only the first attempt 
is included in this summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
70
Example TAB_INJ2
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X.X
Summary of Investigator Evaluation of User/Device Errors by Visit
Autoinjector with Standard Label + Pictogram
                                                                                          
                                                                                            Liquid Autoinjector
Visit          n                                                                                  (N=XX)
---------------------------------------------------------------------------------------------------------------
WEEK 0         XX   Was the drug successfully  Yes                                           XX (XX%)
                     injected?
                                                No                                            XX (XX%)
                                                Not attempted                                 XX (XX%)
                     User Error                 Any User Error                                XX (XX%)
                                                Ring cap not removed from autoinjector        XX (XX%)
                                                Autoinjector not properly activated on        XX (XX%)
                                                injection site (e.g., gold needle guard not
                                                flush with skin)
                                                Autoinjector used upside down                 XX (XX%)
                                                Autoinjector pulled away before end of        XX (XX%)
                                                injection (i.e., before purple indicator
                                                stopped moving)
                                                Other                                         XX (XX%)
                     Device Error               Any Device Error                              XX (XX%)
                                                Autoinjector leaking                          XX (XX%)
                                                Components missing / broken / cracked         XX (XX%)
                                               Inspection window not clear                   XX (XX%)
                                                Cannot remove ring cap                        XX (XX%)
                                                Bent needle                                   XX (XX%)
                                                Cannot push the gold needle guard down to     XX (XX%)
                                                activate (i.e., force too high)
                                                Autoinjector does not activate (after         XX (XX%)
                                                pressing gold needle guard down)
Note: If a subject has more than one attempt to self-administer study treatment at a single visit, only the first attempt 
is included in this summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM
Programming Note: Continue for Week 4 and 8


CONFIDENTIAL
204959
71
Example TAB_INJ3
Protocol: 204959                                                                                        Page 1 of X
Population: All Subjects (Safety)
Table X.X
Summary of Observer Checklist for In-Clinic Injections
Autoinjector with Standard Label + Pictogram
Visit: WEEK 0
Liquid Autoinjector
(N=XX)
Time from removal of pen from storage to injection (mins)
n
XX
Mean
XX.X
SD
XX.XX
Median
XX.X
Minimum
XX
Maximum
XX
Confirm who will be administering the injection
n
XX
Patient
XX (XX%)
Caregiver
XX (XX%)
Subject/caregiver completed all the training required
n
XX
Yes
XX (XX%)
No
XX (XX%)
Subject/caregiver had instructions for use (IFU) available for review 
during injection (as recommended)
n
XX
Yes
XX (XX%)
No
XX (XX%)
[1] Subject / caregiver completed task easily without repeated reference to the IFU.
[2] Subject / caregiver completed task but with some difficulty or repeated reference to the IFU for assistance.
[3] Subject / caregiver was not able to (or did not) complete task after multiple attempts and reference to the IFU, or 
intervention was required.
Note: If a subject has more than one attempt to self-administer study treatment at a single visit, only the first attempt 
is included in this summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
72
Example TAB_INJ3 (cont.)
Protocol: 204959                                                                                        Page 2 of X
Population: All Subjects (Safety)
Table X.X
Summary of Observer Checklist for In-Clinic Injections
Autoinjector with Standard Label + Pictogram
Visit: WEEK 0
Liquid Autoinjector
(N=XX)
Check that the subject / caregiver looks at the label to check the 
expiration date on the pen prior to use.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
Check that the subject / caregiver looks in the inspection window to 
check the liquid prior to use.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
[1] Subject / caregiver completed task easily without repeated reference to the IFU.
[2] Subject / caregiver completed task but with some difficulty or repeated reference to the IFU for assistance.
[3] Subject / caregiver was not able to (or did not) complete task after multiple attempts and reference to the IFU, or 
intervention was required.
Note: If a subject has more than one attempt to self-administer study treatment at a single visit, only the first attempt 
is included in this summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
73
Example TAB_INJ3 (cont.)
Protocol: 204959                                                                                        Page 3 of X
Population: All Subjects (Safety)
Table X.X
Summary of Observer Checklist for In-Clinic Injections
Autoinjector with Standard Label + Pictogram
Visit: WEEK 0
Liquid Autoinjector
(N=XX)
Check that the subject / caregiver removes the clear needle cap from the 
pen prior to use.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
Check that the subject / caregiver injects within 5 minutes of removing 
the needle cap.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
Check that the subject / caregiver positions the pen straight on the 
injection site with the yellow needle guard flat on the skin.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
[1] Subject / caregiver completed task easily without repeated reference to the IFU.
[2] Subject / caregiver completed task but with some difficulty or repeated reference to the IFU for assistance.
[3] Subject / caregiver was not able to (or did not) complete task after multiple attempts and reference to the IFU, or 
intervention was required.
Note: If a subject has more than one attempt to self-administer study treatment at a single visit, only the first attempt 
is included in this summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
74
Example TAB_INJ3 (cont.)
Protocol: 204959                                                                                        Page 4 of X
Population: All Subjects (Safety)
Table X.X
Summary of Observer Checklist for In-Clinic Injections
Autoinjector with Standard Label + Pictogram
Visit: WEEK 0
Liquid Autoinjector
(N=XX)
Check that the subject / caregiver starts the injection by pushing the 
pen all the way down.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
Check that the subject / caregiver keeps the pen in position and pushes 
all the way down until a full dose is administered.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
[1] Subject / caregiver completed task easily without repeated reference to the IFU.
[2] Subject / caregiver completed task but with some difficulty or repeated reference to the IFU for assistance.
[3] Subject / caregiver was not able to (or did not) complete task after multiple attempts and reference to the IFU, or 
intervention was required.
Note: If a subject has more than one attempt to self-administer study treatment at a single visit, only the first attempt 
is included in this summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM
Programming Note: Continue for Week 8.


CONFIDENTIAL
204959
75
Example TAB_INJ4
Protocol: 204959                                                                                        Page 1 of X
Population: All Subjects (Safety)
Table X.X
Summary of Subject Completed Checklist for At-Home Injection at Week 4
Autoinjector with Standard Label + Pictogram
Liquid Autoinjector
(N=XX)
User who logged in to complete the at-home injection checklist.”
n
XX
Patient
XX (XX%)
Caregiver
XX (XX%)
Time from removal of pen from storage to injection (mins)
n
XX
Mean
XX.X
SD
XX.XX
Median
XX.X
Minimum
XX
Maximum
XX
Did you need to contact the investigator / site prior to the 
injection for additional training?
n
XX
Yes – Telephone
XX (XX%)
Yes – Clinic Visit
XX (XX%)
No
XX (XX%)
Was the pen stored in the fridge at 2-8 degrees C before preparing 
for use?
n
XX
Yes
XX (XX%)
No
XX (XX%)
[1] I was able to complete the task easily without repeated reference to the IFU.
[2] I was able to complete the task but with some difficulty or repeated reference to the IFU for assistance.
[3] I was not able to (or did not) complete task after multiple attempts and reference to the IFU.
Note: If a subject has more than one attempt to self-administer study treatment, only the first attempt is included in this 
summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
76
Example TAB_INJ4 (cont.)
Protocol: 204959                                                                                        Page 2 of X
Population: All Subjects (Safety)
Table X.X
Summary of Subject Completed Checklist for At-Home Injection at Week 4
Autoinjector with Standard Label + Pictogram
Liquid Autoinjector
(N=XX)
Check expiration date on the pen has not passed.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
Look in the inspection window to check that the liquid is clear 
(free from cloudiness or particles) and colorless to slightly yellow 
in color.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
[1] I was able to complete the task easily without repeated reference to the IFU.
[2] I was able to complete the task but with some difficulty or repeated reference to the IFU for assistance.
[3] I was not able to (or did not) complete task after multiple attempts and reference to the IFU.
Note: If a subject has more than one attempt to self-administer study treatment, only the first attempt is included in this 
summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
77
Example TAB_INJ4 (cont.)
Protocol: 204959                                                                                        Page 3 of X
Population: All Subjects (Safety)
Table X.X
Summary of Subject Completed Checklist for At-Home Injection at Week 4
Autoinjector with Standard Label + Pictogram
Liquid Autoinjector
(N=XX)
Remove the clear needle cap from the pen by pulling it straight off.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
Inject within 5 minutes of removing the needle cap.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
Position the pen straight on the injection site with the yellow 
needle guard flat on the skin as show.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
[1] I was able to complete the task easily without repeated reference to the IFU.
[2] I was able to complete the task but with some difficulty or repeated reference to the IFU for assistance.
[3] I was not able to (or did not) complete task after multiple attempts and reference to the IFU.
Note: If a subject has more than one attempt to self-administer study treatment, only the first attempt is included in this 
summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
78
Example TAB_INJ4 (cont.)
Protocol: 204959                                                                                        Page 4 of X
Population: All Subjects (Safety)
Table X.X
Summary of Subject Completed Checklist for At-Home Injection at Week 4
Autoinjector with Standard Label + Pictogram
Liquid Autoinjector
(N=XX)
To start the injection, push the pen all the way down and hold.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
Pen is kept in position and pushed all the way down until a full 
dose is administered.
n
XX
Easily [1]
XX (XX%)
With some difficulty [2]
XX (XX%)
Did not complete [3]
XX (XX%)
[1] I was able to complete the task easily without repeated reference to the IFU.
[2] I was able to complete the task but with some difficulty or repeated reference to the IFU for assistance.
[3] I was not able to (or did not) complete task after multiple attempts and reference to the IFU.
Note: If a subject has more than one attempt to self-administer study treatment, only the first attempt is included in this 
summary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
79
Example TAB_INJ5
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X.X
Summary of Device Usability/Functionality Questionnaire
Autoinjector with Standard Label + Pictogram
Question
Category
Liquid Autoinjector
(N=XX)
How comfortable did you feel with the training you received 
on how to use the autoinjector to administer your Nucala 
(mepolizumab)?
n
XX
Not at all comfortable
XX (XX%)
A little comfortable
XX (XX%)
Moderately comfortable
XX (XX%)
Very comfortable
XX (XX%)
Extremely comfortable
XX (XX%)
At the end of the study, how confident were you about your 
ability to use the autoinjector in the correct way on your 
own when you were not in the doctor’s office?
n
XX
Not at all confident
XX (XX%)
A little confident
XX (XX%)
Moderately confident
XX (XX%)
Very confident
XX (XX%)
Extremely confident
XX (XX%)
Programming Note: Continue for all remaining questions on the questionnaire.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
80
Example TAB_PD1  
Protocol: 204959                                                                                             Page 1 of 1
Population: Pharmacodynamic
Table X
Summary of Blood Eosinophils (GI/L) by Visit
Treatment: Liquid Autoinjector (N=XX)
Visit
n
Geom.
Mean
95% CI
(Lower,Upper)
SD (logs)
Min.
Median
Max.
SCREENING
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 0
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 4
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 8
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 12
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
81
Example TAB_PD2  
Protocol: 204959                                                                                             Page 1 of 1
Population: Pharmacodynamic
Table X
Summary of Ratio to Baseline Blood Eosinophils by Visit
Treatment: Liquid Autoinjector (N=XX)
Visit
n
Geom.
Mean
95% CI
(Lower,Upper)
SD (logs)
Min.
Median
Max.
WEEK 4
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 8
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 12
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
82
Example TAB_PD3  
Protocol: 204959                                                                                             Page 1 of 1
Population: Pharmacodynamic
Table X
Summary of Blood Eosinophils (GI/L) by Visit and Baseline Mepolizumab Use
Treatment: Liquid Autoinjector (N=XX)
Baseline Mepolizumab Use
N
Visit
n
Geom.
Mean
95% CI
(Lower,Upper)
SD (logs)
Min.
Median
Max.
Yes
XX
SCREENING
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 0
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 4
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 8
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 12
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
No
XX
SCREENING
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 0
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 4
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 8
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 12
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
83
Example TAB_PD4  
Protocol: 204959                                                                                             Page 1 of 1
Population: Pharmacodynamic
Table X
Summary of Ratio to Baseline Blood Eosinophils by Visit and Baseline Mepolizumab Use
Treatment: Liquid Autoinjector (N=XX)
Baseline Mepolizumab Use
N
Visit
n
Geom.
Mean
95% CI
(Lower,Upper)
SD (logs)
Min.
Median
Max.
Yes
XX
WEEK 4
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 8
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 12
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
No
XX
WEEK 4
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 8
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
WEEK 12
XX
xxxx.xx
(xxxx.xx,xxxx.xx)
xx.xxx
xx.x
xxxx.xx
xx.x
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
84
Example TAB_S1  
Protocol: 204959                                                                                             Page 1 of 3
Population: All Subjects (Safety)
Table X.X
Summary Profile of On-Treatment Adverse Events Defined by the Investigator as Allergic (Type I Hypersensitivity) Reactions
Liquid Autoinjector
(N=XX)
1
All Events
>= 1 event [1]
1 event
2 events
3 events
>=4 events
xx/xx (x%)
xx (x%)
xx (x%)
xx (x%)
xx (x%)
2
Serious Events
>= 1 event [1]
xx/xx (x%)
3
Events considered related to investigational product
>= 1 event [1]
xx/xx (x%)
3.5
Events reported on the day of dosing
xx/xx (x%)
>= 1 event [1]
4
Intensity [1]
Mild
Moderate
Severe
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
5
Outcome [1]
Recovered/Resolving
Recovering/Resolving
Not recovered/Not Resolved
Recovered/Resolved with sequelae
Fatal 
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
[1] Information presented as number of events / number (%) subjects with at least one event.  Subjects may be counted in 
more than one row. 
[2] Cardiac History=Yes includes all subjects with any past medical condition under Cardiac Disorders.
[3] Unable to categorise time since last dose as event time not reported.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
85
Example TAB_S1 (Cont.)  
Protocol: 204959                                                                                             Page 2 of 3
Population: All Subjects (Safety)
Table X.X
Summary Profile of On-Treatment Adverse Events Defined by the Investigator as Allergic (Type I Hypersensitivity) Reactions
Liquid Autoinjector
(N=XX)
6
Action Taken [1]
Study treatment withdrawn 
Dose reduced
Dose increased
Dose not changed
Dose interrupted/delayed 
Not applicable
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
7
Cardiac History [1][2]
Yes  
No 
xx/xx (x%)
xx/xx (x%)
8
Anaphylaxis Criteria Met
Anaphylactic Criterion 1
Anaphylactic Criterion 2
Anaphylactic Criterion 3
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
9
No. doses prior to event [1]
1
2
3
etc.
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
10
No. doses prior to first event
1
2
3
etc.
xx (x%)
xx (x%)
xx (x%)
[1] Information presented as number of events / number (%) subjects with at least one event.  Subjects may be counted in 
more than one row. 
[2] Cardiac History=Yes includes all subjects with any past medical condition under Cardiac Disorders.
[3] Unable to categorise time since last dose as event time not reported.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
86
Example TAB_S1 (Cont.)  
Protocol: 204959                                                                                             Page 3 of 3
Population: All Subjects (Safety)
Table X.X
Summary Profile of On-Treatment Adverse Events Defined by the Investigator as Allergic (Type I Hypersensitivity) Reactions
Liquid Autoinjector
(N=XX)
11
Time since last dose to event onset [1] 
<=1 hr
1-<6 hrs 
6-<24 hrs
>=24 hrs
Missing [3]
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
12
Time since last dose to first event onset
<=1 hr
1-<6 hrs 
6-<24 hrs
>=24 hrs
Missing [3]
xx (x%)
xx (x%)
xx (x%)
xx (x%)
xx (x%)
13
No. symptoms associated with event [1]
0 symptoms
1 symptom
2-5 symptoms
>5 symptoms
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
14
Symptoms [1]
ABDOMINAL
ANGIOEDEMA
ARTHRALGIA
Etc.
xx/xx (x%)
xx/xx (x%)
xx/xx (x%)
[1] Information presented as number of events / number (%) subjects with at least one event.  Subjects may be counted in 
more than one row. 
[2] Cardiac History=Yes includes all subjects with any past medical condition under Cardiac Disorders.
[3] Unable to categorise time since last dose as event time not reported.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
87
Programming Notes:-
Remove footnotes that are not relevant for the table.
Sections 1 – 6, 9, 10:
Create for all adverse events of special interest
Sections 9 and 10:
For studies longer than 1 year can consider the following categories: 1, 2, 3, 4, 5, 6, 7-12, 13-18, 
19-24, >24
Section 7: 
Only for the following adverse events of special interest
Serious Cardiac, Vascular and Thromboembolic Events
Serious Ischemic Events
Section 8: 
Only for the following adverse events of special interest 
Anaphylaxis
Systemic – Allergic (Type I Hypersensitivity)
Sections 11 – 14: 
Only for the following adverse events of special interest 
Anaphylaxis
Systemic – Allergic (Type I Hypersensitivity) and Other Systemic
Systemic – Allergic (Type I Hypersensitivity)
Systemic – Other Systemic
Local Injection Site Reactions
Section 3.5:
Only for the following adverse events of special interest 
Anaphylaxis
Systemic – Allergic (Type I Hypersensitivity) and Other Systemic
Systemic – Allergic (Type I Hypersensitivity)
Systemic – Other Systemic


CONFIDENTIAL
204959
88
Example TAB_S2  
Protocol: 204959                                                                                             Page 2 of 2
Population: All Subjects (Safety)
Table X
Summary of Binding Antibody Results by Visit
Visit
Assay Result
Liquid Autoinjector
(N=XX)
WEEK 0
n
X
NEGATIVE
X (XX%)
POSITIVE
X (XX%)
WEEK 12/EARLY WITHDRAWAL
n
X
NEGATIVE
X (XX%)
POSITIVE
X (XX%)
  Titre value
Min.
X
Median
X.X
Max.
X
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
89
Example TAB_S3  
Protocol: 204959                                                                                             Page 1 of X
Population: All Subjects (Safety)
Table X
Summary of Injection Pain – VAS Scores (mm)
Treatment: Liquid Autoinjector (N=XX)
Visit
N
Planned Relative Time
n
Mean
SD
Median
Min.
Max.
WEEK 0
XX
INJECTION
XX
X.X
X.XX
X.X
XX
XX
1 HR POST INJECTION
XX
X.X
X.XX
X.X
XX
XX
24 HRS POST INJECTION
XX
X.X
X.XX
X.X
XX
XX
WEEK 4
XX
INJECTION
XX
X.X
X.XX
X.X
XX
XX
1 HR POST INJECTION
XX
X.X
X.XX
X.X
XX
XX
24 HRS POST INJECTION
XX
X.X
X.XX
X.X
XX
XX
WEEK 8
XX
INJECTION
XX
X.X
X.XX
X.X
XX
XX
1 HR POST INJECTION
XX
X.X
X.XX
X.X
XX
XX
24 HRS POST INJECTION
XX
X.X
X.XX
X.X
XX
XX
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
90
Example TAB_S4  
Protocol: 204959                                                                                             Page 1 of X
Population: All Subjects (Safety)
Table X
Summary of Injection Pain – Categorical Pain Assessment
Visit: WEEK 0 (N=XX)
Planned 
Relative Time
Pain Assessment
Category
Liquid Autoinjector
(N=XX)
INJECTION
VAS Score (mm)
n
XX
0
XX (XX%)
>0
XX (XX%)
Description of Pain [1}
n
XX
Sharp/Stinging
XX (XX%)
Dull/aching
XX (XX%)
Burning
XX (XX%)
Other
XX (XX%)
Pain Relative to Expectation
n
XX
Greater than expected
XX (XX%)
Less than expected
XX (XX%)
As expected
XX (XX%)
Pain acceptable?
n
XX
Yes
XX (XX%)
No
XX (XX%)
[1] More than one description may be ticked.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM
Programming Note: continue for planned relative time = 1 HR POST INJECTION, 24 HRS POST INJECTION and Week 4 and 8.


CONFIDENTIAL
204959
91
Example TAB_EX1
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects Enrolled
Table X
Summary of Number of Subjects With at Least One On-Treatment Exacerbation
Population
Liquid Autoinjector
(N=XX)
Number of Subjects With at Least One Exacerbation
XX (XX%)
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
92
Example TAB_ECG1
Protocol: 204959                                                                                        Page 1 of 1
Population: All Subjects (Safety)
Table X
Summary of Actual and Change from Baseline QTc(F) Values by Category (msec)
Population
Liquid Autoinjector
(N=XX)
Baseline
n
XX
<=450
XX (XX%)
>450 - <=480
XX (XX%)
>480 - <=500
XX (XX%)
>500
XX (XX%)
Week 12
n
XX
<=450
XX (XX%)
>450 - <=480
XX (XX%)
>480 - <=500
XX (XX%)
>500
XX (XX%)
Week 12 Change from Baseline
N
XX
<-60
XX (XX%)
>=-60 - <-30
XX (XX%)
>=-30 - <0
XX (XX%)
>=0 - <30
XX (XX%)
>=30 - <60
XX (XX%)
>=60
XX (XX%)
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
93
Example LIST_POP1  
Protocol: 204959                                                                                       Page 1 of 1
Population: All Subjects (Safety)
Table X.X
Listing of Baseline Mepolizumab Use
Treatment: Liquid Autoinjector
Site Id./
Unique 
Subject Id.
Subject Currently Receiving
Treatment with Mepolizumab?
Blood Eosinophil Count 
Criteria Met [1]?
Most Recent Blood Eosinophil Count Prior 
to Starting Mepolizumab (cells/uL)[2]
XXXXXX/
MID204959.XXXXXX
Yes
Yes
300
[1] Blood eosinophil count immediately before starting mepolizumab that was >= 150 cells/uL or a blood eosinophil count 
that was >= 300 cells/uL in the 12 months prior to starting mepolizumab.
[2] Historical value taken prior to starting mepolizumab for subjects currently receiving treatment with mepolizumab only.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
94
Example LIST_POP2  
Protocol: 204959                                                                                       Page 1 of 1
Population: All Subjects (Safety)
Table X.X
Listing of Previous Mepolizumab Clinical Trials
Treatment: Liquid Autoinjector
Site Id./
Unique 
Subject Id.
Did the subject participate 
in a previous mepolizumab 
clinical trial?
Previous Protocol 
Identifier
Previous Subject Number
XXXXXX/
MID204959.XXXXXX
Yes
205667
XXX
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
95
Example LIST_INJ1  
Protocol: 204959                                                                                       Page 1 of 1
Population: All Subjects (Safety)
Table X.X
Listing of Investigator Assessment of Injection Success
Treatment: Liquid Autoinjector, Standard Label + Pictogram
                    Visit/                 Was Self-
Site Id./           In-Clinic            
Administration of
Unique              or Home    Date of     Injection
Subject Id.         Injection  Assessment  Successful?        User Error                    Device Error
XXXXXX/             WEEK 0/   DDMMYYYY    Yes                        
MID204959.XXXXXX    IN-CLINIC
                    WEEK 4/   DDMMYYYY    Yes
                    HOME
                    WEEK 8/   DDMMYYYY    Yes
                    IN-CLINIC
XXXXXX/             WEEK 0/   DDMMYYYY    No                 Incorrect injection site
MID204959.XXXXXX    IN-CLINIC                                 selected - arm
                    UNSCHED/   DDMMYYYY    Yes
                    IN-CLINIC
XXXXXX/             WEEK 0/    DDMMYYYY    No                                               Syringe leaking
MID204959.XXXXXX    IN-CLINIC                                                               Components broken / cracked
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
96
Example LIST_INJ2  
Protocol: 204959                                                                                       Page 1 of 1
Population: All Subjects (Safety)
Table X.X
Listing of Person Administering Injection [1] and Time From Removal of Syringe from Storage to Injection
Treatment: Liquid Autoinjector
Site Id./
Unique 
Subject Id.
Visit
Confirm who will be 
administering the 
injection [1]
Time from removal of 
autoinjector from 
storage to injection 
(mins)
XXXXXX/
MID204959.XXXXXX
WEEK 0
Patient
Yes
WEEK 4
Patient
Yes
WEEK 8
Patient
Yes
XXXXXX/
MID204959.XXXXXX
WEEK 0
Patient
Yes
[1] For the at-home injection (week 4), the person administering the injection is documented by the eDiary as the user 
(caregiver/patient) who logged in to complete the at-home injection checklist.
Note: If a subject has more than on attempt to self-administer study treatment, only information for the first attempt is 
available in the eDiary.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
97
Example LIST_EX1  
Protocol: 204959                                                                                       Page 1 of 1
Population: All Subjects (Safety)
Table X.X
Listing of Exacerbations
Treatment: Liquid Autoinjector
Site                         Date of    Treatment               
Outcome/    CS       Hospitalised?/
Id.     Unique Subject Id.   Onset      Phase          Withdrawn  End Date    Taken [1] ER Visit?      Intubated?
------------------------------------------------------------------------------------------------------------------
  MID204959.XXXXXX     DDMMYYYY  On-Treatment   No       
RESOLVED/   Y        N/              N
                                                            DDMMYYYY             N
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM
[1] CS = Systemic/oral corticosteroids
PPD


CONFIDENTIAL
204959
98
Example LIST_S1  
Protocol: 204959                                                                                       Page 1 of 1
Population: All Subjects (Safety)
Table X.X
Listing of Injection Pain Assessment
Treatment: Liquid Autoinjector
Site Id./
Unique 
Subject Id.
Visit/
Planned 
Relative Time
Date/Time of 
Assessment
Study 
Day
VAS 
Score 
(mm)
Description of pain
Pain Relative 
to Expectation
Was the 
Pain 
Acceptable?
XXXXXX/
MID204959.XXXXXX
WEEK 0/
INJECTION
DDMMYYYY/
HH:MM
1
XX
Sharp/stinging
Greater
Yes
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
99
Example LIST_PD1  
Protocol: 204959                                                                                       Page 1 of 1
Population: Pharmacodynamic
Table X.X
Listing of Blood Eosinophils (units)
Treatment: Liquid Autoinjector
Site Id./
Unique 
Subject Id.
Age (years)/
Sex/
Race
Visit
Date/
Study Day
Result
Change from 
Baseline
Ratio to 
Baseline
Normal Range
NR Flag 
[1]
XXXXXX/
MID204959.XXXXXX
XX/
F/
ASIAN
WEEK 0
YYYY-MM-DD/
1
XX.XX
XX.XX
X.XX
X.XX – X.XX
NORMAL
[1] NR = Normal Range.
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM


CONFIDENTIAL
204959
100
Example FIG_PD1  
Protocol: 204959                                                                                       Page 1 of 1
Population: Pharmacodynamic
Figure X.X
Geometric Mean Ratio to Baseline Blood Eosinophils by Visit and Baseline Mepolizumab Use
userid: /arenv/arprod/compound/study/final/drivers/drivername.sas DDMMMYYYY HH:MM